

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
12 October 2023 (12.10.2023)



(10) International Publication Number  
**WO 2023/194584 A1**

(51) International Patent Classification:

C07K 16/22 (2006.01) A61P 35/00 (2006.01)  
A61K 39/395 (2006.01) A61K 31/7068 (2006.01)

(21) International Application Number:

PCT/EP2023/059271

(22) International Filing Date:

06 April 2023 (06.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2205200.5 08 April 2022 (08.04.2022) GB

(71) Applicant: **UCB BIOPHARMA SRL** [BE/BE]; UCB Biopharma SRL, Allée de la Recherche 60, 1070 Brussels (BE).

(72) Inventors: **DAVIES, Gareth Charles Glyndwr**; c/o IPD, UCB Biopharma UK, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **JONES, Paul**; c/o IPD, UCB Biopharma UK, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **MORTON, Jennifer Patricia**; c/o Cancer Research UK Beatson Institute, Garscube Estate, Switchback Rd, Glasgow G61 1BD (GB).

(74) Agent: **J A KEMP LLP**; 80 Turnmill Street, London Greater London EC1M 5QU (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMBINATION OF A GREMLIN-1 ANTAGONIST WITH A CYTIDINE ANALOGUE OR DEOXYCYTIDINE ANALOGUE

(57) Abstract: The invention relates to an anti-GREMI antagonist for use in a method for the treatment or prevention of a cancer in combination with a proliferation-dependent cytotoxic agent.



**Combination of a gremlin-1 antagonist with a cytidine analogue or deoxycytidine analogue.**

### **Field of the Invention**

The present invention relates to combination therapies for the treatment or prevention of a cancer. In particular, the present invention relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer in combination with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, and related compositions and kits. The present invention also relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of pancreatic cancer in combination with a proliferation-dependent cytotoxic agent, and related compositions and kits. The present invention also relates to methods of predicting whether or not a patient is likely to respond to a combination therapy based on stromal GREM1 overexpression.

### **Background of the invention**

Cancer continues to be a significant and complex global challenge despite technological advances in cancer immunotherapy, gene therapy, data science and precision medicine. Setbacks associated with drug resistance and poor responses to existing therapies highlight the need to develop improved therapies for the treatment and prevention of cancer. Combination therapies that are able to improve the efficacy of existing treatments are also needed.

One such cancer that presents a significant challenge is pancreatic cancer. Pancreatic cancer is a fatal disease with increased incidence in recent years. Environmental risk factors associated with pancreatic cancer include smoking, pancreatitis, alcohol, obesity, infection and diet, meaning that pancreatic cancer is becoming increasingly common in developed countries. Surgical resection (pancreatico-duodenectomy) combined with chemotherapy presents the only long-term potential cure for pancreatic cancer. However, limited screening coupled with lack of symptoms means that patients are typically diagnosed with late stage, advanced disease, limiting the chances of surgical resection. As a result, pancreatic cancer has one of the lowest survival rates of all common

cancers, with a 5-year survival rate of less than 7% and a poor survival rate of 5% over 10 years or more. Over the last 40 years, there has been limited improvement in survival rate, reinforcing the urgent need for new therapeutic treatments for pancreatic cancer. In non-resectable tumours, the standard of care for pancreatic cancer is chemotherapy regimens. However, chemotherapy is associated with side effects and cancer recurrence is common. Late diagnosis combined with poor prognosis and limited treatment strategies for pancreatic cancer necessitate a need for improved therapies. More broadly, there is an urgent need for combination therapies that increase responsiveness and/or reduce side effects to chemotherapeutics for the treatment of cancer.

### **Summary of the invention**

The inventors have surprisingly shown that GREM1 antagonists can be administered advantageously in combination with chemotherapeutic agents for the treatment or prevention of pancreatic cancer. Using the LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx1-Cre (KPC) mouse model of pancreatic cancer, the inventors have demonstrated that a combination therapy comprising an anti-GREM1 antagonist and a chemotherapeutic agent significantly improves survival in these mice compared to vehicle controls. Without being bound by theory, the inventors hypothesise that stromal targeting using an anti-GREM1 antagonist is able to enhance the efficacy of chemotherapy treatment for pancreatic cancer since the stroma itself is able to confer chemoresistance on tumour cells. It is also envisaged by the inventors based on these results that combination therapies comprising GREM1 antagonists and proliferation-dependent cytotoxic agents, such as gemcitabine and other cytidine analogues or deoxycytidine analogues, will be of general utility in the treatment and prevention of cancers. In particular, the inventors envisage that combination therapies comprising GREM1 antagonists and proliferation-dependent cytotoxic agents will be of general utility in the treatment and prevention of cancers characterised by the presence of dormant stem-like cancer cells. The inventors' findings provide for a new approach to the prevention and treatment of cancer, in particular, pancreatic cancer.

Thus, in a first aspect of the present invention there is provided an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer, wherein the method further comprises administering a cytidine analogue or deoxycytidine analogue .

In a further aspect of the present invention there is provided an anti-GREM1 antagonist for use in a method for the treatment or prevention of pancreatic cancer, wherein the method further comprises administering a proliferation-dependent cytotoxic agent.

In another aspect of the present invention there is provided a cytidine analogue or deoxycytidine analogue for use in a method for the treatment or prevention of cancer wherein the method further comprises administering an anti-GREM1 antagonist.

In yet another aspect of the present invention there is provided a method of treating cancer comprising administering a therapeutically effective amount of an anti-GREM1 antagonist in combination with a therapeutically effective amount of a cytidine analogue or deoxycytidine analogue to a subject in need thereof.

In a further aspect of the present invention there is provided a proliferation-dependent cytotoxic agent for use in a method for the treatment or prevention of pancreatic cancer, wherein the method further comprises administering an anti-GREM1 antagonist.

In yet another aspect of the present invention there is provided a method of treating pancreatic cancer comprising administering a therapeutically effective amount of an anti-GREM1 antagonist in combination with a therapeutically effective amount of a proliferation-dependent cytotoxic agent.

In another aspect of the present invention there is provided a composition or kit comprising an anti-GREM1 antagonist and a cytidine analogue or deoxycytidine analogue.

In yet another aspect of the present invention there is provided a composition or kit comprising:

an anti-GREM1 antagonist and a mitotic inhibitor.

In a further aspect of the present invention there is provided a method for determining whether or not a patient having or suspected of having or being at risk of developing cancer is likely to respond to a combination treatment with a GREM1 antagonist and a cytidine analogue or deoxycytidine analogue, which method comprises measuring stromal and/or epithelial expression of GREM1 in the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the combination.

In yet another aspect of the present invention there is provided a method for determining whether or not a patient having or suspected of having or being at risk of developing pancreatic cancer is likely to respond to a combination treatment with a GREM1 antagonist and a proliferation-dependent cytotoxic agent, which method comprises measuring stromal and/or epithelial expression of GREM1 in the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the combination.

#### **Brief description of the Figures**

Figure 1 - Kaplan-Meier analysis showing survival of PDAC patients with gremlin-1 expression above or below median as indicated. Patients with tumours expressing high levels of gremlin 1 have a significantly poorer prognosis compared to those with low expression. Generated from KMplotter.

Figure 2 - Schematic showing (a) breeding strategy and (b) experimental design.

Figure 3 - Graph showing tumour burden, as measured by high-resolution ultrasound, in individual mice on treatment as indicated

Figure 4 - Kaplan-Meier analysis showing survival of Pdx1-Cre; LSL<sup>-KrasG12D/+</sup>; LSL-Trp53R172H/+ (KPC) mice from start of treatment with Ab7326 mIgG1 (n = 7), vehicle (n = 7), Gemcitabine (n = 5) or Ab7326 mIgG1 in combination with gemcitabine (n = 6), as indicated. Mice treated with the combination of Ab7326 mIgG1 and gemcitabine show a significant increase in survival compared with vehicle controls (Log Rank, p=0.04).

#### **Brief description of the Tables**

Table 1 - Table showing grem1 upregulated in KPC tumours, and in all pancreatic mouse models combined, compared with Kras<sup>G12D+</sup> mouse pancreatic duct cells

Table 2 - Table showing dose and schedule of treatments given, number of mice on each treatment (including those censored cases, and median survival in each treatment cohort. Mice treated with the combination of Ab7326 mIgG1 and gemcitabine show a significant increase in median survival compared with vehicle controls

Table 3 - Table showing survival data and censoring for individual mice on treatment as indicated. \* denotes smaller than average tumour at start of treatment.

### **Detailed description of the invention**

It is to be understood that different applications of the disclosed products and methods may be tailored to the specific needs in the art. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.

In addition, as used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “an inhibitor” includes two or more such inhibitors, or reference to “an oligonucleotide” includes two or more such oligonucleotide and the like.

All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.

### **Combination therapy using an anti-GREMI antagonist and a cytidine analogue or deoxycytidine analogue**

The present invention provides an anti-GREMI antagonist in combination with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, for use in a method for the treatment or prevention of cancer. The cancer is typically a cancer having GREMI

overexpression and/or a cancer that can be targeted with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof. The cancer may additionally or alternatively be characterised as comprising dormant cancer cells, such as dormant stem-like cancer cells and/or being a recurring cancer.

The invention further provides a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, for use in a method for the treatment or prevention of cancer wherein the method comprises separate, sequential or simultaneous administration of an anti-GREM1 antagonist.

#### Cytidine analogue or deoxycytidine analogue

The present invention provides a combination therapy using an anti-GREM1 antagonist together with a cytidine analogue or deoxycytidine analogue for the treatment or prevention of a cancer. Cytidine analogues and deoxycytidine analogues are specific nucleoside inhibitors or antimetabolites that exert cytotoxic activity by mimicking endogenous nucleosides and interfering with the synthesis of nucleic acids. Nucleoside inhibitors or antimetabolites include analogues of physiological pyrimidine and purine nucleobases and nucleosides. Cytidine analogues and deoxycytidine analogues, in particular, mimic endogenous cytidine or deoxycytidine. Such compounds may also interfere with DNA methylation or modify the metabolism of physiological nucleosides. The phrase “analogue(s)” refers to (a) compound(s) that display structural or functional similarities to a target/compound of interest. For example, a cytidine analogue or deoxycytidine analogue may possess structural similarities to cytidine or deoxycytidine and/or possess similar chemical and biological properties to cytidine or deoxycytidine.

In the context of treating any cancer, the present invention encompasses the use of any cytidine analogue or deoxycytidine analogue. Exemplary cytidine analogues or deoxycytidine analogues for use in the present invention include gemcitabine (2'-deoxy-2',2'-difluorocytidine; 4-Amino-1-(2-deoxy-2,2-difluoro- $\beta$ -D-erythro-pentofuranosyl)pyrimidin-2(

1*H*)-on; 4-amino-1-[(2*R*,4*R*,5*R*)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one), or a derivative thereof; azacitidine (5-azacytidine; 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1*H*)-one), or a derivative thereof; cytarabine (Ara-*C*/ cytosine 1-[β-D-arabinofuranoside; 4-amino-1-[(2*R*,3*S*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl] pyrimidin-2-one), or a derivative thereof; decitabine (5-aza-2'-deoxycytidine/5-azadeoxycytidine; 4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1*H*)-one; 4-amino-1-[(2*R*,4*S*,5*R*)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, or a derivative thereof; and troxacitabine (Troxytyl/ 4-amino-1-[(2*S*)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one), or a derivative thereof. In a preferred embodiment, the deoxycytidine analogue is gemcitabine.

In some embodiments, the combination therapy provides an anti-GREM1 antagonist together with one or more cytidine analogues or deoxycytidine analogues. In a preferred embodiment, the present invention provides an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer, wherein the method further comprises administering gemcitabine. In one exemplary embodiment, the present invention provides an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer, wherein the method further comprises administering gemcitabine in combination with troxacitabine. In a particularly preferred embodiment, the present invention provides an anti-GREM1 antagonist for use in a method for the treatment or prevention of a pancreatic cancer, wherein the method further comprises administering gemcitabine in combination with troxacitabine.

It is contemplated that a combination therapy comprising a GREM1 antagonist as defined herein and a cytidine analogue or deoxycytidine analogue as described herein, can be used for the treatment or prevention of cancers that are typically targeted with said cytidine analogue or deoxycytidine analogue. The cancer may be a cancer or tumour previously described for treatment with cytidine analogues or deoxycytidine analogues. Such cancers include, but are not limited to, pancreatic cancer, breast cancer, ovarian cancer, non-small cell lung cancer and bladder cancer.

The cancer may be a cancer that is responsive to treatment with a cytidine analogue or deoxycytidine analogue, and/or a cancer that is contemplated for treatment with a



cytidine analogue or deoxycytidine analogue. Alternatively, the cancer may be a cancer that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or deoxycytidine analogue. The cancer may be previously described as being unsuitable for treatment with a cytidine analogue or deoxycytidine analogue. In some instances, the cancer may be initially responsive to treatment a cytidine analogue or deoxycytidine analogue, but develop resistance to treatment with the cytidine analogue or deoxycytidine analogue. Responsiveness may be measured by any means. For example, responsiveness to treatment may be assessed by measuring tumour size before and after treatment using X-ray, CT or MRI scans or by measuring tumour markers. Blood tests to determine organ function may also be used to assess responsiveness to treatment. One exemplary blood marker for monitoring responsiveness in pancreatic cancer is CA19-9. A person skilled in the art knows how to measure responsiveness of a cancer to treatment.

The cancer may additionally or alternatively be characterised as comprising dormant cancer cells, such as dormant stem-like cancer cells and/or being a recurring cancer.

In one especially preferred embodiment, an anti-GREM1 antagonist is administered in combination with a cytidine analogue or deoxycytidine analogue for the treatment of pancreatic cancer. One exemplary pancreatic cancer is an exocrine pancreatic cancer, such as a pancreatic ductal adenocarcinoma.

### Gemcitabine

Gemcitabine (2'-deoxy-2',2'-difluorocytidine/2', 2'-difluoro 2'deoxycytidine) is a chemotherapeutic agent that is typically used to treat pancreatic cancer, breast cancer, ovarian cancer, non-small cell lung cancer, bladder cancer and other solid cancers. Gemcitabine is an antimetabolite. As described above and in more detail below, antimetabolites exert cytotoxic activity by mimicking endogenous nucleosides and interfering with the synthesis of nucleic acids. Gemcitabine is a pyrimidine nucleotide analogue of cytidine. It is able to enter a cell via nucleotide transporters on the cell membrane where it subsequently undergoes a series of phosphorylation reactions to form

gemcitabine diphosphate and gemcitabine triphosphate. Gemcitabine triphosphate competes with endogenous deoxycytidine triphosphate (dCTP) for incorporation into an elongating DNA strand, resulting in masked chain termination, whilst gemcitabine diphosphate inhibits ribonucleotide reductase resulting in reduced dCTP availability.

In the context of the present invention, combination therapies comprising gemcitabine, or a derivative thereof are contemplated. The phrase “a derivative thereof” refers to a compound that exerts similar therapeutic effects and is derived from a similar/precursor compound. Gemcitabine derivatives may include, for example, stereoisomers of gemcitabine, or gemcitabine esters or amides.

The inventors have surprisingly shown that GREM1 antagonists can be administered advantageously in combination with gemcitabine for the treatment or prevention of pancreatic cancer in a KPC mouse model. Without being bound by theory, the inventors’ postulate that anti-GREM1 antagonists are able to drive dormant stem-like cancer cells into a more proliferative state, making them more susceptible to treatment with proliferation-dependent cytotoxic agents, such as gemcitabine or other cytidine or deoxycytidine analogues. The inventors also hypothesise that stromal targeting using an anti-GREM1 antagonist is able to enhance the efficacy of chemotherapy treatment for pancreatic cancer since the stroma itself is able to confer chemoresistance on tumour cells. Thus, it is envisaged that combination therapies comprising GREM1 antagonists and gemcitabine, or a derivative thereof, can be used for the treatment or prevention of a wide range of cancers. It is also envisaged that combination therapies comprising GREM1 antagonists and other cytidine analogues or deoxycytidine analogues, such as those described herein can be used for the treatment or prevention of a wide range of cancers.

In particular, it is contemplated that a combination therapy comprising a GREM1 antagonist as defined herein and gemcitabine, or a derivative thereof, can be used for the treatment or prevention of cancers that are typically targeted with gemcitabine, or a derivative thereof. The cancer may be a cancer or tumour previously described for treatment with gemcitabine, or a derivative thereof. Such cancers include, but are not limited to, pancreatic cancer, breast cancer, ovarian cancer, non-small cell lung cancer and bladder cancer.

The cancer may be a cancer that is responsive to treatment with gemcitabine, or a derivative thereof, and/or a cancer that is contemplated for treatment with gemcitabine or a derivative thereof. Alternatively, the cancer may be a cancer that is poorly responsive, non-responsive or refractory to treatment with gemcitabine or a derivative thereof. The cancer may be previously described as being unsuitable for treatment with gemcitabine or a derivative thereof. In some instances, the cancer may be initially responsive to treatment with gemcitabine or a derivative thereof, but develop resistance to gemcitabine treatment. Responsiveness may be measured by any means. For example, responsiveness to treatment may be assessed by measuring tumour size before and after treatment using X-ray, CT or MRI scans or by measuring tumour markers. Blood tests to determine organ function may also be used to assess responsiveness to treatment. One exemplary blood marker for monitoring responsiveness in pancreatic cancer is CA19-9. A person skilled in the art knows how to measure responsiveness of a cancer to treatment.

The cancer may additionally or alternatively be characterised as comprising dormant cancer cells, such as dormant stem-like cancer cells and/or being a recurring cancer.

In one especially preferred embodiment, an anti-GREM1 antagonist is administered in combination with gemcitabine or a derivative thereof for the treatment of pancreatic cancer. One exemplary pancreatic cancer is an exocrine pancreatic cancer, such as a pancreatic ductal adenocarcinoma.

### Cancer

In the context of a combination therapy comprising an anti-GREM1 antagonist and a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, the cancer may be any cancer or tumour. In particular, in the context of a combination therapy comprising an anti-GREM1 antagonist and a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, the cancer may be any cancer or tumour having a stroma, typically a desmoplastic stroma. The cancer may be any cancer or tumour which is GREM1-initiated. The cancer may be any cancer where

stromal and/or epithelial GREM1 overexpression is observed. The cancer or tumour may have stromal GREM1 overexpression and no epithelial GREM1 overexpression. The cancer or tumour may have epithelial GREM1 overexpression and no stromal GREM1 overexpression. In preferred embodiments, the cancer or tumour has an overexpression of GREM1 in the desmoplastic stroma. The cancer or tumour may be any cancer or tumour suitable for targeting with a GREM1 antagonist and/or a cytidine analogue or deoxycytidine analogue, including any cancer or tumour known in the art to be suitable for targeting with such agent(s), and any cancer or tumour known in the art to be suitable for treatment with such agent(s). For example, the cancer or tumour may be any cancer or tumour suitable for targeting with gemcitabine (2'-deoxy-2',2'-difluorocytidine), or a derivative thereof. The cancer or tumour may be any cancer or tumour suitable for targeting with azacitidine (5-azacytidine), or a derivative thereof. The cancer or tumour may be any cancer or tumour suitable for targeting with cytarabine (Ara-C/ cytosine 1-[beta]-D-arabinofuranoside), or a derivative thereof. The cancer or tumour may be any cancer or tumour suitable for targeting with decitabine ((5-aza-2'-deoxycytidine/5-azadeoxycytidine), or a derivative thereof. The cancer or tumour may be any cancer or tumour suitable for targeting with a troxacitabine (Troxytyl/ 4-amino-1-[(2S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one), or a derivative thereof. The cancer or tumour may be a solid tumour. The solid tumour may have a desmoplastic stroma.

Anti-GREM1 antagonists have been previously shown to be effective for treatment of a range of cancers in WO 2019/243801 filed on 18 June 2019, the disclosure of which is incorporated herein by reference in its entirety. Particularly preferred cancers that may be treated include colorectal cancer, multiple myeloma, pancreatic cancer, bladder cancer, breast cancer, lung cancer, stomach cancer, duodenal cancer, oesophageal cancer, head and neck cancer, prostate cancer, glioma, endometrial cancer, ovarian cancer, liver cancer, spleen cancer, bone-resident cancer, and osteosarcoma. The cancer that may be treated may be intestinal cancer, colon cancer, or rectal cancer. The cancer to be treated may be a disseminated cancer, for example a metastatic cancer. A disseminated cancer should be understood as one that has spread from its initial site of origin within the body. For

example, a disseminated cancer could be one that originated in the bone marrow, colon, prostate, or breast tissue of a patient but has spread to *e.g.* the patient's liver or lung.

The combination therapy comprising a GREM1 antagonist and a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof may also be used to prevent the dissemination of a cancer. For example, a combination therapy comprising a GREM1 antagonist and gemcitabine, or a derivative thereof, may be used to prevent the dissemination of cancer. A combination therapy comprising a GREM1 antagonist and azacitidine, or a derivative thereof, may be used to prevent the dissemination of a cancer. A combination therapy comprising a GREM1 antagonist and cytarabine, or a derivative thereof, may be used to prevent the dissemination of a cancer. A combination therapy comprising a GREM1 antagonist and decitabine, or a derivative thereof, may be used to prevent the dissemination of a cancer. A combination therapy comprising a GREM1 antagonist and troxacitabine, or a derivative thereof, may be used to prevent the dissemination of a cancer.

The combination therapy comprising a GREM1 antagonist and a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof may be used to prevent polyposis associated with a cancer. For example, a combination therapy comprising a GREM1 antagonist and gemcitabine, or a derivative thereof, may be used to prevent polyposis associated with a cancer. A combination therapy comprising a GREM1 antagonist and azacitidine, or a derivative thereof, may be used to prevent polyposis associated with a cancer. A combination therapy comprising a GREM1 antagonist and cytarabine, or a derivative thereof, may be used to prevent polyposis associated with a cancer. A combination therapy comprising a GREM1 antagonist and decitabine, or a derivative thereof, may be used to prevent polyposis associated with a cancer. A combination therapy comprising a GREM1 antagonist and troxacitabine, or a derivative thereof, may be used to prevent polyposis associated with a cancer.

Grading systems are used in cancer biology and medicine to categorize cancer cells with respect to their lack of cellular differentiation. This reflects the extent to which the cancer cells differ in morphology from healthy cells found in the tissue from which the cancer cell originated. The grading system can be used to provide an indication of how

quickly a particular cancer might be expected to grow. Typically used grades of cancer are Grades (G) X and 1 to 4. GX indicates that the cancer grade cannot be assessed. G1 (low grade) cancer cells have a similar morphology to normal, healthy, cells (*i.e.* they are well differentiated) and would be expected to grow slowly, and are less likely to spread. G2 (intermediate grade) cancer cells are moderately differentiated, *i.e.* they appear more abnormal and would be expected to grow slightly faster than G1 cells. G3 (high grade) cancer cells have a very different morphology compared to normal cells (*i.e.* they are poorly differentiated) and would be expected to grow faster than G1 and G2 cells. G4 (high grade) cancer cells are undifferentiated (also referred to as anaplastic) and would be expected to have the highest capacity for proliferation.

Cancer grading is different to cancer staging, which gives an indication of how a cancer might spread. A common cancer staging system has five stages, namely Stage 0: cancer cells *in situ* (*i.e.* located in their normal tissue); Stage I: cancers are localized to one part of the body; Stage II: cancers are locally advanced; Stage III: cancers are also locally advanced (whether a cancer is designated as Stage II or Stage III can depend on the specific type of cancer); and Stage IV: cancers have often metastasized, or spread to other organs or throughout the body.

A person skilled in the art knows how to determine the grade and/or stage of a cancer. In one embodiment, the invention relates to use of an anti-GREM1 antagonist for the treatment and/or prevention of an established cancer. In one embodiment, the cancer is an established cancer. An established cancer may be a high grade cancer, for example a G3 or a G4 cancer. An established cancer may be a cancer that is Stage II or above. An established cancer may be a Stage III or a stage IV cancer. In one embodiment, the established cancer is a Stage IV cancer that has metastasized. In one embodiment, the established cancer is an established pancreatic cancer.

In addition to specifically exemplified applications in the treatment and prevention of pancreatic cancer, the inventors envisage that the therapeutic efficacy of GREM1 antagonists in combination with gemcitabine and other cytidine analogues or deoxycytidine analogues, as illustrated in the Examples will also be applicable to treatment of other cancers having corresponding features as described herein.

In particular, it is envisaged that combinations comprising GREM1 antagonists will be useful in preventing or treating cancers in which there is stromal and/or epithelial GREM1 overexpression, and this overexpression contributes to malignant cell growth. Such cancers include pancreatic cancer, bladder cancer, lung cancer, stomach cancer, duodenal cancer, oesophageal cancer, head and neck cancer, glioma, endometrial cancer, liver cancer, spleen cancer, bone-resident cancer, and osteosarcoma.

Antagonists of the present invention are used in treating or preventing cancer in combination with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof. Other cytidine analogues or deoxycytidine analogues contemplated for use in the present invention are described herein and include azacitidine, or a derivative thereof; cytarabine, or a derivative thereof; decitabine, or a derivative thereof; or troxacitabine, or a derivative thereof. Antagonists of the present invention are also used in treating or preventing pancreatic cancer in combination with a proliferation-dependent cytotoxic agent.

Prevention of cancer may include preventing the subject from ever being diagnosed with cancer or deferring the onset of cancer. Prevention of cancer may also include prevention of relapse or recurrence of cancer in a subject who has been previously diagnosed with cancer. Prevention of cancer may additionally include increasing the survival of a subject who has not been diagnosed with cancer or who has been previously diagnosed with cancer.

Treatment of cancer may ameliorate one or more symptoms of, induce or prolong remission from, or delay relapse or recurrence of the cancer. Treatment may cure, alleviate or partially arrest the cancer. It may result in a decrease in severity of disease symptoms, or an increase in frequency or duration of symptom-free periods. Treatment of cancer may also include preventing a cancer (*e.g.* an established cancer) from spreading from its initial site within a patient's body to one or more secondary sites within the patient's body. Thus, treatment of cancer may include prevention of the dissemination or the metastasis of an existing cancer. Treatment of pancreatic cancer may result in a reduction in primary tumour size, for example as assayed by CT or endoscopic ultrasound. Such a reduction may facilitate Whipple procedure (pancreaticoduodenectomy) for the removal of tumours

from the head of the pancreas. The inventors' have demonstrated that treatment with an anti-GREM1 antagonist in combination with gemcitabine can increase survival in a KPC mouse model. Thus, treatment of pancreatic cancer with gemcitabine or another cytidine analogue or deoxycytidine analogue according to the invention may also improve patient survival.

### Pancreatic cancer

The invention is preferably directed to the treatment or prevention of pancreatic cancer. As described in more detail in the Examples, the present inventors have confirmed GREM1 overexpression in human pancreatic ductal adenocarcinoma samples, and demonstrated that high expression of *Grem1* mRNA is significantly associated with poor prognosis (Figure 1). Moreover, the present inventors have demonstrated that a combination therapy comprising an anti-GREM1 antagonist and gemcitabine increased survival in a KPC mouse model.

Accordingly, in one embodiment, the pancreatic cancer is a pancreatic cancer that is characterised by having overexpression of GREM1. In another embodiment, the pancreatic cancer may be characterised as having exocrine tumours or neuroendocrine tumours. Pancreatic neuroendocrine cancers (also known as islet cell tumours) develop in the endocrine gland of the pancreas. An especially preferred form of pancreatic cancer is an exocrine pancreatic cancer, such as pancreatic ductal adenocarcinoma, which develops in the lining in the ducts of the pancreas and accounts for 90% of all pancreatic carcinomas (Feldmann *et al.* J Hepatobiliary Pancreat Surg. 2007; 14(3): 224-32). Other exocrine pancreatic cancers include squamous cell carcinomas, which form in pancreatic ducts; adenosquamous carcinomas; signet ring cell carcinomas; and colloid carcinomas, which typically develop from intraductal papillary mucinous neoplasms. Late diagnosis combined with poor prognosis and limited treatment strategies for pancreatic cancer necessitate a need for improved therapies.

A preferred type of pancreatic cancer for treatment may be resistant to one or more known anti-cancer agents (such as chemotherapeutic agents). The pancreatic cancer may



be a disseminated pancreatic cancer. The pancreatic cancer may be metastatic pancreatic cancer. Metastatic cancer should be understood as one that has spread from its initial site of origin within the body. Thus, metastatic pancreatic cancer refers to a cancer that starts in the pancreas and spreads to other organs, such as the lungs, liver, bones and brain. The pancreatic cancer may also be recurrent pancreatic cancer. In other words, the pancreatic cancer to be treated by the methods of the present invention includes pancreatic cancer that has returned after months or even years after earlier treatment, such as chemotherapy, radiotherapy or curative surgery. A preferred type of pancreatic cancer for treatment may be resistant to one or more known anti-cancer agents (such as chemotherapeutic agents), as described further below.

In some aspects, the pancreatic cancer may be a pancreatic cancer that is responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof. The pancreatic cancer may alternatively be a pancreatic cancer that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. The pancreatic cancer may be previously considered unsuitable for treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. In some instances, the pancreatic cancer may be initially responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, but develop resistance to treatment with the cytidine analogue or deoxycytidine analogue, such as gemcitabine treatment.

For example, in some aspects, the pancreatic cancer may be a pancreatic cancer that is responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The pancreatic cancer may alternatively be a pancreatic cancer that is poorly responsive, non-responsive or refractory to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The pancreatic cancer may be previously considered unsuitable for treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. In some instances, the pancreatic cancer may be initially responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof,

but develop resistance to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof.

### Lung cancer

In a further aspect, the present invention relates to the treatment or prevention of lung cancer. The lung cancer is most preferably non-small cell lung cancer (NSCLC). The NSCLC may be advanced NSCLC, such as Stage III or IV NSCLC. The NSCLC may be a squamous cell carcinoma, adenocarcinoma or large cell carcinoma. The cancer may be small cell lung cancer. The lung cancer may be unresectable. The lung cancer may be a primary lung cancer or any secondary cancer that has spread to the lung such as a breast or pancreatic cancer. The lung cancer may be a disseminated lung cancer. The lung cancer may be a metastatic lung cancer. The lung cancer may be a lung cancer that is characterised by having overexpression of GREM1. The lung cancer may be a recurrent lung cancer. In other words, the lung cancer to be treated by the methods of the present invention includes lung cancer that has returned after months or even years after earlier treatment, such as chemotherapy, radiotherapy or curative surgery. A preferred type of lung cancer for treatment may be resistant to one or more known anti-cancer agents (such as chemotherapeutic agents), as described further below.

In some aspects, the lung cancer, such as the NSCLC, may be a lung cancer that is responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof. The lung cancer, such as the NSCLC, may alternatively be a lung cancer that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. The lung cancer, such as the NSCLC, may be previously considered unsuitable for treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. In some instances, the lung cancer, such as the NSCLC, may be initially responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, but develop

resistance to treatment with the cytidine analogue or deoxycytidine analogue, such as gemcitabine treatment.

For example, in some aspects, the lung cancer may be a lung cancer that is responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The lung cancer may alternatively be a lung cancer that is poorly responsive, non-responsive or refractory to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The lung cancer may be previously considered unsuitable for treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. In some instances, the lung cancer may be initially responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof, but develop resistance to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof.

#### Bladder cancer

In a further aspect, the present invention relates to the treatment or prevention of bladder cancer. The bladder cancer may be transitional cell (urothelial) bladder cancer. The bladder cancer may arise from the epithelial lining of the urinary bladder. The bladder cancer may be non-muscle invasive bladder cancer. The bladder cancer may be squamous cell bladder cancer. The bladder cancer may be an adenocarcinoma. The bladder cancer may be a high grade T1 tumour that has grown from the bladder lining into the lamina propria. The bladder cancer may be a superficial cancer or an invasive bladder cancer. The bladder cancer may be a recurrent bladder cancer. The term recurrent bladder cancer as used herein refers to a bladder cancer that has recurred following treatment, such as surgical treatment.

The present invention further provides for treatment and prevention of bladder cancer by administering an anti-GREM1 antagonist in combination with gemcitabine, or a derivative thereof. The bladder cancer may be a disseminated bladder cancer. The

bladder cancer may be a metastatic bladder cancer. The bladder cancer may be metastatic bladder cancer of the lung. The bladder cancer may be metastatic bladder cancer of the liver. The bladder cancer may be metastatic bladder cancer of the bone. The bladder cancer may be a bladder cancer that is characterised by having overexpression of GREM1. The bladder cancer may also be recurrent bladder cancer. In other words, the bladder cancer to be treated by the methods of the present invention includes bladder cancer that has returned after months or even years after earlier treatment, such as chemotherapy, radiotherapy or curative surgery. A preferred type of bladder cancer for treatment may be resistant to one or more known anti-cancer agents (such as chemotherapeutic agents), as described further below.

In some aspects, the bladder cancer may be a bladder cancer that is responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof. The bladder cancer may alternatively be a bladder cancer that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. The bladder cancer may be previously considered unsuitable for treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. In some instances, the bladder cancer may be initially responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, but develop resistance to treatment with the cytidine analogue or deoxycytidine analogue, such as gemcitabine treatment.

For example, in some aspects, the bladder cancer may be a bladder cancer that is responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The bladder cancer may alternatively be a bladder cancer that is poorly responsive, non-responsive or refractory to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The bladder cancer may be previously considered unsuitable for treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. In some instances, the bladder cancer may be initially responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof, but develop

resistance to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof.

### Ovarian cancer

In a further aspect, the present invention relates to the treatment or prevention of ovarian cancer. The ovarian cancer may be epithelial ovarian cancer, germ cell ovarian cancer or sex cord stromal ovarian cancer. The ovarian cancer may be primary peritoneal cancer. The ovarian cancer may be fallopian tube cancer. The ovarian cancer may be characterised by borderline ovarian tumours. The ovarian cancer may be characterised by germ cell ovarian tumours. The ovarian cancer may be clear cell ovarian cancer. The cancer may be serous ovarian cancer. The ovarian cancer may be mucinous ovarian cancer. The ovarian cancer may be endometrioid cancer.

The ovarian cancer may be an ovarian cancer that is characterised by having overexpression of GREM1. The ovarian cancer may also be recurrent ovarian cancer. In other words, the ovarian cancer to be treated by the methods of the present invention includes ovarian cancer that has returned after months or even years after earlier treatment, such as chemotherapy, radiotherapy or curative surgery. A preferred type of ovarian cancer for treatment may be resistant to one or more known anti-cancer agents (such as chemotherapeutic agents), as described further below.

The present invention further provides for treatment and prevention of ovarian cancer by administering an anti-GREM1 antagonist in combination with gemcitabine, or a derivative thereof. The ovarian cancer may be a disseminated ovarian cancer. The ovarian cancer may be a metastatic ovarian cancer. The ovarian cancer may be metastatic ovarian cancer of the lung. The ovarian cancer may be metastatic ovarian cancer of the liver. The ovarian cancer may be metastatic ovarian cancer of the bone.

In some aspects, the ovarian cancer may be an ovarian cancer that is responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof. The ovarian cancer may alternatively be an ovarian cancer that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or

deoxycytidine analogue, such as gemcitabine or a derivative thereof. The ovarian cancer may be previously considered unsuitable for treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. In some instances, the ovarian cancer may be initially responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, but develop resistance to treatment with the cytidine analogue or deoxycytidine analogue, such as gemcitabine treatment.

For example, in some aspects, the ovarian cancer may be an ovarian cancer that is responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The ovarian cancer may alternatively be an ovarian cancer that is poorly responsive, non-responsive or refractory to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The ovarian cancer may be previously considered unsuitable for treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. In some instances, the ovarian cancer may be initially responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof, but develop resistance to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof.

### Colorectal cancer

The invention relates in one aspect to prevention or treatment of colorectal cancer. By way of background, the intestinal mucosa is a complex ecosystem and the epithelium has an inter-dependent relationship with its microenvironment, particularly the underlying stroma. Mesenchymal-epithelial crosstalk is intimately involved in regulating homeostasis and is dynamically altered in intestinal regeneration and cancer. Cell-signalling networks are the effector pathways of inter-compartmental crosstalk and control epithelial cell fate determination, but can be co-opted and corrupted by the tumour microenvironment in colorectal cancer.

The current chemotherapeutic management of colorectal cancer has not substantially changed for the last 20 years and is predominantly based around the use of combination cytotoxic agents (such as FOLFOX (a combination therapy including folinic acid, fluorouracil and oxaliplatin) and FOLFIRI (a combination therapy including folinic acid, fluorouracil and irinotecan) regimens <http://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs>) against the proliferating tumour epithelium, and resistance to these epithelial targeted agents may arise. It is now more important than ever to identify new therapies for use in colorectal cancer.

A cancer or tumour for treatment is thus colorectal cancer or a colorectal tumour. An especially preferred form of colorectal cancer for treatment is colorectal cancer that is characterised by having overexpression of GREM1 in stromal cells, i.e. stromal GREM1 overexpression. The stromal cells may be cancer associated fibroblasts. A colorectal cancer with stromal GREM1 overexpression may display no epithelial GREM1 overexpression. A colorectal cancer with stromal GREM1 overexpression may comprise stromal Fox11 overexpression. A particularly suitable form of colorectal cancer for treatment is colorectal cancer that is a mesenchymal subtype colorectal cancer, also described as CMS4 (Guinney et al, Nat Med 2015). Any other subtypes of colorectal cancer may also be treated including any of CMS1, CMS2 and CMS3 as described in Guinney et al supra. A colorectal cancer as described herein may be a proximal colorectal cancer (or a proximal colorectal tumour). The proximal colon is the region of the large bowel upstream of the splenic flexure, meaning the caecum, the ascending colon and the transverse colon. Cancers or tumours in this region are also referred to as right-sided cancers or tumours. The invention may concern treating right-sided colorectal cancer or a right-sided colorectal tumour.

The colorectal cancer may be distal colorectal cancer (or a distal colorectal tumour). The distal colon is the region of the large bowel downstream of the splenic flexure, meaning the descending colon, the sigmoid colon and the rectum. Cancers or tumours in this region are also referred to as left-sided cancers or tumours. The invention may concern treating left-sided colorectal cancer or a left-sided colorectal tumour. A cancer having stromal overexpression of GREM1 may preferably be a sporadic cancer.

The sporadic cancer may be caused by a somatic mutation. The sporadic cancer may be caused by a carcinogenic agent. A sporadic cancer is not due to an inherited genetic mutation. The sporadic cancer may cause the stromal overexpression of GREM1. Proliferation of the sporadic cancer may be dependent on the stromal overexpression of GREM1 in the cancer.

At least three single nucleotide polymorphisms (SNPs) close to GREM1 are independently associated with risk of colorectal cancer (CRC) in white northern Europeans, and probably in other ethnic groups (Tomlinson et al, PLoS Genet, 2011). There is a direct link with GREM1 expression and it is likely that the other SNPs have similar effects. In addition, two common SNPs near BMP2, two near BMP4 and one near BMP7 influence the expression of BMP ligands and affect CRC risk. Thus, the cancer may comprise one or more of the above SNPs.

A further type of cancer or tumour for treatment according to the invention is one that exhibits overexpression of GREM1 in epithelial cells. The overexpression of GREM1 in epithelial cells may cause the cancer. Proliferation of the cancer may be dependent on the epithelial overexpression of GREM1. Thus, the cancer may be of epithelial origin. The cancer may be colorectal cancer or duodenal cancer. The cancer may be GREM1-initiated. By GREM1-initiated it is meant that a mutagenic event enhancing activity or expression of GREM1 is causative of the cancer. Such a cancer may be due to an inherited genetic mutation. The cancer may thus be a familial cancer (see below).

A preferred type of colorectal cancer for treatment may be resistant to one or more known anti-cancer agents (such as chemotherapeutic agents), as described further below.

The colorectal cancer may be a disseminated colorectal cancer. The colorectal cancer may be a metastatic colorectal cancer. The colorectal cancer may be metastatic colorectal cancer of the lung. The colorectal cancer may be metastatic colorectal cancer of the liver. The colorectal cancer may be metastatic colorectal cancer of the bone.

The colorectal cancer may be characterised by stromal overexpression of the *Foxl1*. The colorectal cancer may be characterised by stromal overexpression of one or more *Wnt* ligand. For example, the colorectal cancer may be characterised by stromal overexpression of *Wnt5A* and/or *Wnt2B*. A colorectal cancer may be particularly suitable



for prevention or treatment using a GREM1 antagonist if said colorectal cancer has stromal overexpression of *Foxl1* and/or a *Wnt* ligand e.g. *Wnt5A* or *Wnt2B*.

In some aspects, the colorectal cancer may be a colorectal cancer that is responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof. The colorectal cancer may alternatively be a colorectal cancer that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. The colorectal cancer may be previously considered unsuitable for treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. In some instances, the colorectal cancer may be initially responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, but develop resistance to treatment with the cytidine analogue or deoxycytidine analogue, such as gemcitabine treatment.

For example, in some aspects, the colorectal cancer may be a colorectal cancer that is responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The colorectal cancer may alternatively be a colorectal cancer that is poorly responsive, non-responsive or refractory to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The colorectal cancer may be previously considered unsuitable for treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. In some instances, the colorectal cancer may be initially responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof, but develop resistance to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof.

### *Familial cancer*

Familial cancers include cancers resulting from a mutation or mutations in the GREM1 encoding gene, or any other mutation affecting expression of the GREM1 gene. The autosomal dominant condition Hereditary Mixed Polyposis Syndrome (HMPS) is

caused by a 40kb duplication upstream of GREM1 that results in a pathological compartment expression switch from a restricted mesenchymal gradient to ectopic GREM1 gene expression throughout the epithelium.

The subject to be treated with anti-GREM1 antagonist may have been previously determined as being at risk of developing a familial cancer. For example, the subject may have been determined as being at risk on the basis of their family history and/or because the subject carries a mutation in a gene known to give rise to, or increase the risk of developing, the familial cancer.

The familial cancer may be Lynch syndrome, which is also referred to as hereditary nonpolyposis colorectal cancer (HNPCC). The familial cancer may be familial adenomatous polyposis (FAP).

Patients or subjects suffering with familial adenomatous polyposis (FAP) may be particularly suitable for treatment with the combination therapy comprising the anti-GREM1 antagonist. The familial cancer to be treated or prevented with the combination therapy comprising the anti-GREM1 antagonist (*e.g.* an anti-GREM1 antibody) and gemcitabine, or a derivative thereof may be FAP. A subject who has previously suffered from FAP may be preventatively administered with an anti-GREM1 antagonist in combination with gemcitabine, or a derivative thereof, *e.g.* to prevent relapse. A subject who has not previously suffered from FAP but has been previously determined to be at risk of developing FAP may be preventatively administered with an anti-GREM1 antagonist in combination with gemcitabine. A subject may have been determined as being at risk of developing FAP because it has been found that the subject carries a deleterious mutation in their *Apc* gene.

In some aspects, the familial cancer may be a familial cancer that is responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof. The familial cancer may alternatively be a familial cancer that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. The familial cancer may be previously considered unsuitable for treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. In some instances,

the familial cancer may be initially responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, but develop resistance to treatment with the cytidine analogue or deoxycytidine analogue, such as gemcitabine treatment.

For example, in some aspects, the familial cancer may be a familial cancer that is responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The familial cancer may alternatively be a familial cancer that is poorly responsive, non-responsive or refractory to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The familial cancer may be previously considered unsuitable for treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. In some instances, the familial cancer may be initially responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof, but develop resistance to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof.

### Multiple myeloma

The invention relates in another aspect to treatment or prevention of multiple myeloma. Multiple Myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of plasma cells (PCs) within the bone marrow (BM). It is well known that the BM supports tumour growth in MM, with bi-directional signalling between the tumour cells and the BM critical for the continued growth, spread and survival of the MM PCs. Cellular and non-cellular BM components exert different effects upon the growth and spread of MM PC. While recent studies have identified components of the BM that play a role in disease progression, and therapies targeting these have been developed, the standard-of-care treatments in MM still rely primarily on targeting the tumour cells themselves. While such therapies are effective in prolonging patient survival, due to the large role the BM plays in the growth, spread, survival and drug resistance of MM cells, more effective therapies

that target this important aspect of disease are needed. Indeed, MM is a largely incurable disease, with disease relapse a key issue faced in effectively treating this disease.

The invention accordingly is also directed to treatment or prevention of multiple myeloma. Multiple myeloma typically comprises the presence of more than one mass of plasma cells within the bone marrow. Multiple myeloma is thus typically associated with aberrant proliferation of plasma cells in the bone marrow. An especially preferred form of multiple myeloma for treatment is characterised by having overexpression of GREM1 in the bone marrow. The multiple myeloma may therefore comprise stromal GREM1 overexpression. The stromal GREM1 overexpression may be present in the compact bone compartment of the bone. The stromal GREM1 overexpression may reflect an increased number of stromal cells, or an increase in the expression levels of GREM1 within existing GREM1-expressing stromal cells. The bone marrow may comprise osteochondroreticular (OCR) stem cells. The stromal cells overexpressing GREM1 may comprise OCR stem cells. A preferred type of multiple myeloma for treatment may be resistant to one or more known anti-cancer agents (such as chemotherapeutic agents), as described further below.

In some aspects, the multiple myeloma may be a multiple myeloma that is responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof. The multiple myeloma may alternatively be a multiple myeloma that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. The multiple myeloma may be previously considered unsuitable for treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. In some instances, the multiple myeloma may be initially responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, but develop resistance to treatment with the cytidine analogue or deoxycytidine analogue, such as gemcitabine treatment.

For example, in some aspects, the multiple myeloma may be a multiple myeloma that is responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The multiple myeloma may alternatively be a multiple myeloma that is poorly responsive, non-responsive or refractory to treatment with

gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The multiple myeloma may be previously considered unsuitable for treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. In some instances, the multiple myeloma may be initially responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof, but develop resistance to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof.

### Breast cancer

The invention relates in another aspect to treatment or prevention of breast cancer. The breast cancer may be invasive breast cancer, such as invasive lobular breast cancer. The breast cancer may be triple negative breast cancer. The breast cancer may be inflammatory breast cancer. The breast cancer may be angiosarcoma of the breast. The breast cancer may be ductal carcinoma in situ or lobular carcinoma in situ.

The invention provides for treatment and prevention of breast cancer by administering an anti-GREM1 antagonist in combination with gemcitabine, or a derivative thereof. The breast cancer may comprise stromal GREM1 overexpression. The stromal breast cells overexpressing GREM1 may comprise stromal fibroblasts, also described herein as cancer-associated fibroblasts. The breast cancer may also be recurrent breast cancer. In other words, the breast cancer to be treated by the methods of the present invention includes breast cancer that has returned after months or even years after earlier treatment, such as chemotherapy, radiotherapy or curative surgery. A preferred type of breast cancer for treatment may be resistant to one or more known anti-cancer agents (such as chemotherapeutic agents), as described further below. The breast cancer may be a disseminated breast cancer. The breast cancer may be a metastatic breast cancer. The breast cancer may be metastatic breast cancer of the lung. The breast cancer may be metastatic breast cancer of the liver. The breast cancer may be metastatic breast cancer of the bone.

In some aspects, the breast cancer may be a breast cancer that is responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof. The breast cancer may alternatively be a breast cancer that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. The breast cancer may be previously considered unsuitable for treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. In some instances, the breast cancer may be initially responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, but develop resistance to treatment with the cytidine analogue or deoxycytidine analogue, such as gemcitabine treatment.

For example, in some aspects, the breast cancer may be a breast cancer that is responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The breast cancer may alternatively be a breast cancer that is poorly responsive, non-responsive or refractory to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The breast cancer may be previously considered unsuitable for treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. In some instances, the breast cancer may be initially responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof, but develop resistance to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof.

#### Prostate cancer

In a further aspect, the present invention relates to the treatment or prevention of prostate cancer. The prostate cancer may be prostatic adenocarcinoma. The prostate cancer may be a transitional cell carcinoma or urothelial cancer that has spread to the prostate.

The prostate cancer may be a prostate cancer that is characterised by having overexpression of GREM1. The prostate cancer may also be recurrent prostate cancer. In other words, the prostate cancer to be treated by the methods of the present invention includes prostate cancer that has returned after months or even years after earlier treatment, such as chemotherapy, radiotherapy or curative surgery. A preferred type of prostate cancer for treatment may be resistant to one or more known anti-cancer agents (such as chemotherapeutic agents), as described further below.

The present invention further provides for treatment and prevention of prostate cancer by administering an anti-GREM1 antagonist in combination with gemcitabine, or a derivative thereof. The prostate cancer may be a disseminated prostate cancer. The prostate cancer may be a metastatic prostate cancer. The prostate cancer may be metastatic prostate cancer of the lung. The prostate cancer may be metastatic prostate cancer of the liver. The prostate cancer may be metastatic prostate cancer of the bone.

In some aspects, the prostate cancer may be a prostate cancer that is responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine, or a derivative thereof. The prostate cancer may alternatively be a prostate cancer that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. The prostate cancer may be previously considered unsuitable for treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof. In some instances, the prostate cancer may be initially responsive to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, but develop resistance to treatment with a cytidine analogue or deoxycytidine analogue, such as gemcitabine treatment.

For example, in some aspects, the prostate cancer may be a prostate cancer that is responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The prostate cancer may alternatively be a prostate cancer that is poorly responsive, non-responsive or refractory to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. The prostate cancer may be previously considered unsuitable for treatment with gemcitabine,

azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof. In some instances, the prostate cancer may be initially responsive to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof, but develop resistance to treatment with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine or any derivatives thereof.

### Stroma and epithelium

The cancers described for prevention or treatment herein using a GREM1 antagonist in combination with gemcitabine may comprise stromal and/or epithelial GREM1 overexpression.

The terms “stromal cell(s)” or “stroma” as used herein refers to structural and/or connective portions of a tissue or organ.

Stromal tissue is primarily made of extracellular matrix containing connective tissue cells. Extracellular matrix is primarily composed of ground substance - a porous, hydrated gel, made mainly from proteoglycan aggregates - and connective tissue fibers. There are three types of fibers commonly found within the stroma: collagen type I, elastic, and reticular (collagen type III) fibres. Fibroblasts and pericytes are among the most common types of stromal cells.

In the context of a cancer or tumour (e.g. initiating in the epithelium of a tissue or organ), the stroma of the tissue or organ may assist cancer growth and progression. The stroma associated with the cancer or tumour may be a desmoplastic stroma caused by growth of fibrous or connective tissue around the cancer or tumour.

The overexpression of GREM1 may be observed in any part of the stroma/any stromal cells. The stromal cells may be fibroblasts or fibroblast-like support cell. The stromal cells may be fibroblasts or fibroblast-like support cell isolated from a desmoplastic stroma of any cancer or tumour described above, such as from the pancreas, colon or rectum in a colorectal cancer, or the bone marrow in multiple myeloma. The stromal cells may be cancer-associated fibroblasts.



The term “epithelial” as used herein refers to a cell derived from the outer or inner linings of a tissue or organ. In relation to the colon, the intestinal epithelium is the layer of cells that form the luminal surface or lining of both the small and large intestine of the gastrointestinal tract. It is composed of simple columnar epithelium. The “upper barrier” is the intestinal epithelial single layer of columnar cells consisting of four intestinal epithelial cell types: the absorbent enterocytes, the goblet cells, the Paneth cells and the enteroendocrine cells. Upper barrier features are similar in small and large bowel. The main difference is constituted by the presence of elevations and projections (circular folds, villi and microvilli) in duodenum, jejunum and ileum that allows the increase of the absorption surface. This is not observed in the colon, which instead shows a flat surface. Amongst the mucous membrane protrusions termed villi, there are inflexions called crypts of Lieberkühn, which are distinct glandular invaginations. The cell in which epithelial GREM1 overexpression is observed may be any epithelial cell, such as any intestinal epithelial cell.

While not being bound by theory, the inventors hypothesise that stromal targeting using an anti-GREM1 antagonist is able to enhance the efficacy of chemotherapy treatment for pancreatic cancer since the stroma itself is able to confer chemoresistance on tumour cells. The present inventors also postulate that overexpression of GREM1 in the epithelium and/or stroma may promote a stem/progenitor cell phenotype (increasing the number of stem/progenitor cells), promoting epithelial stem cell behaviour and driving cancer progression and/or resistance to chemotherapeutic agents. Thus, a combination therapy comprising a GREM1 antagonist and a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof used according to the invention may prevent induction of an aberrant cancer stem/progenitor cell phenotype, reduce epithelial stem cell behaviour and/or decrease the number of stem/progenitor cells, in the epithelium of a tissue or organ of a subject in which cancer is to be prevented or treated. The ability of a GREM1 antagonist to affect stem cell behaviour may be assayed clinically by the assessment of known epithelial and cancer stem cell markers.

The overexpression of GREM1 in the stroma and/or epithelium may be determined by any means. The overexpression of GREM1 is typically determined by comparison to

the level of the marker in normal cells of the same tissue type, i.e. basal expression level. The expression is typically normalized against the expression level of other genes, preferably comprising one or more housekeeping genes. GREM1 may also be classified as showing an overexpression or underexpression in a threshold percentage of a population of cancer patients. The overexpression in each patient in the population may be higher than 2 from the geometric mean. At least 10%, more preferably at least 15% or more of the patients in the population may display such an overexpression.

GREM1 stromal overexpression refers to stromal GREM1 levels being higher than that of a matched normal tissue. For example, stromal GREM1 levels may be at least two fold higher than that of matched normal tissue.

Where GREM1 is overexpressed, its amount may be increased by any amount relative to basal. For example, GREM1-initiated cancers such as HMPS may comprise a several thousand-fold upregulation of epithelial GREM1, whereas no GREM1 expression is observed in normal epithelium. Sporadic cancers comprising stromal GREM1 overexpression may comprise any level of stromal overexpression over the physiological GREM1 expression level in normal stroma of the organ. The skilled person is able to evaluate the existence of an overexpression in stroma or epithelium compared with the level of GREM1 in normal cells of the same type.

The amount determined may be the amount of mRNA. The cancer may thus comprise an overexpression of GREM1 mRNA. The cancer may comprise an increased amount of GREM1 mRNA compared with normal cells of the same tissue type. The mRNA may be increased by any amount. The amount of mRNA can be measured using a quantitative reverse transcription polymerase chain reaction (qRT-PCR), such as real time qRT-PCR, quantigene assay (Affymetrix/Thermo Fisher), by northern blotting or using microarrays, RNA sequencing. mRNA expression is preferably determined by comparing the gene expression of a sample to the distribution of expression levels of the specific gene across a reference sample composed of tumours that are diploid for that gene. A z-score may be derived using RNAseq by expectation maximisation (RSEM) algorithm (cBioportal for Cancer Genomics, [www.cbioportal.org](http://www.cbioportal.org); Gao et al, 2013 and Serami et al

2012). A z-score of 2 SD higher or lower than the mean of the reference set is preferably considered as overexpression or underexpression respectively.

The amount determined may be the amount of protein. The cancer may comprise an overexpression of GREM1 protein, such as compared with normal cells of the same tissue type. The protein may be increased by any amount. The amount of protein can be measured using immunohistochemistry, western blotting, mass spectrometry or fluorescence-activated cell sorting (FACS), including by use of an anti-GREM1 antibody of the invention. The thresholds for determining expression may vary between techniques used, and may be validated against immunohistochemistry scores.

The uses of GREM1 antagonists in combination with cytidine analogues or deoxycytidine analogues for treating or preventing cancer in a patient as described herein may thus comprise (a) measuring the amount of GREM1 in the cancer and (b) if the cancer comprises an overexpression of GREM1, administering to the patient the GREM1 antagonist in combination with a cytidine analogue or deoxycytidine analogue as described herein and thereby treating or preventing the cancer. The amount of GREM1 may be the mRNA or protein amount, and the overexpression any overexpression discussed above. The GREM1 antagonist may be any GREM1 antagonist as described herein.

The uses of GREM1 antagonists in combination with Gemcitabine or a derivative thereof for treating or preventing cancer in a patient as described herein may thus comprise (a) measuring the amount of GREM1 in the cancer and (b) if the cancer comprises an overexpression of GREM1, administering to the patient the GREM1 antagonist in combination with Gemcitabine, or a derivative thereof and thereby treating or preventing the cancer. The amount of GREM1 may be the mRNA or protein amount, and the overexpression any overexpression discussed above. The GREM1 antagonist may be any GREM1 antagonist as described herein.

The above measurements may be carried out in any suitable sample from the patient. The measurements may be carried out in a cancer or tumour biopsy obtained from the patient. The stroma and/or epithelium (stromal and/or epithelial cells) may be isolated from the biopsy. The biopsy tissue may be formalin fixed paraffin embedded (FFPE) tissue or fresh tissue. The tissue may be pancreatic tissue, bladder tissue, lung tissue,

endometrial tissue, breast tissue, stomach tissue, duodenal tissue, oesophageal tissue, bone marrow or colorectal tissue. Any of the methods discussed above may be carried out on the cancer biopsy. Such methods may also be carried out on cancer cells circulating in the blood of the patient. The RNA methods may be carried out on urinary or blood exosomes.

*Combination therapies using an anti-GREM1 antagonist in combination with a proliferation-dependent cytotoxic agent*

In a further embodiment of the invention, there is provided an anti-GREM1 antagonist in combination with a proliferation-dependent cytotoxic agent for use in a method for the treatment or prevention of pancreatic cancer. The method may comprise separate, sequential or simultaneous administration of the proliferation-dependent cytotoxic agent.

The invention also provides a proliferation-dependent cytotoxic agent for use in a method for the treatment or prevention of pancreatic cancer, wherein the method comprises separate, sequential or simultaneous administration of an anti-GREM1 antagonist.

In one embodiment, the pancreatic cancer is a pancreatic cancer that is characterised by having overexpression of GREM1. In another embodiment, the pancreatic cancer may be characterised as having exocrine tumours or neuroendocrine tumours. Pancreatic neuroendocrine cancers (also known as islet cell tumours) develop in the endocrine gland of the pancreas. An especially preferred form of pancreatic cancer is an exocrine pancreatic cancer, such as pancreatic ductal adenocarcinoma. Other exocrine pancreatic cancers include squamous cell carcinomas, which form in pancreatic ducts; adenosquamous carcinomas; signet ring cell carcinomas; and colloid carcinomas, which typically develop from intraductal papillary mucinous neoplasms.

A preferred type of pancreatic cancer for treatment may be resistant to one or more known anti-cancer agents (such as chemotherapeutic agents). The pancreatic cancer may be a disseminated pancreatic cancer. The pancreatic cancer may be metastatic pancreatic cancer. Metastatic cancer should be understood as one that has spread from its initial site

of origin within the body. Thus, metastatic pancreatic cancer refers to a cancer that starts in the pancreas and spreads to other organs, such as the lungs, liver, bones and brain. The pancreatic cancer may also be recurrent pancreatic cancer. In other words, the pancreatic cancer to be treated by the methods of the present invention includes pancreatic cancer that has returned after months or even years after earlier treatment, such as chemotherapy, radiotherapy or curative surgery.

In some aspects, the pancreatic cancer may be a pancreatic cancer that is responsive to treatment with a proliferation-dependent cytotoxic agent. The pancreatic cancer may be a pancreatic cancer that is poorly responsive, non-responsive or refractory to treatment with a proliferation-dependent cytotoxic agent. The pancreatic cancer may be unsuitable for treatment with a proliferation-dependent cytotoxic agent. In some instances, the pancreatic cancer may be initially responsive to treatment with a proliferation-dependent cytotoxic agent, but develop resistance to treatment with a proliferation-dependent cytotoxic agent.

The uses of GREM1 antagonists in combination with proliferation-dependent cytotoxic agents for treating or preventing pancreatic cancer in a patient as described herein may comprise (a) measuring the amount of GREM1 in the cancer and (b) if the pancreatic cancer comprises an overexpression of GREM1, administering to the patient the GREM1 antagonist in combination with proliferation-dependent cytotoxic agent and thereby treating or preventing the pancreatic cancer. The amount of GREM1 may be the mRNA or protein amount, and the overexpression any overexpression discussed above. The GREM1 antagonist may be any GREM1 antagonist as described herein. The proliferation-dependent cytotoxic agent may be any proliferation-dependent cytotoxic agent as described herein.

#### *Proliferation-dependent cytotoxic agent*

The term proliferation-dependent cytotoxic agent as used in the present invention in the context of treating or preventing pancreatic cancer describes any cytotoxic agent that targets proliferating cells. In other words, highly proliferative cell populations including

rapidly dividing cancer cells exhibit increased sensitivity to such agents. Without being bound by theory, the inventors' postulate that anti-GREM1 antagonists are able to drive dormant stem-like cancer cells into a more proliferative state, making them more susceptible to treatment with proliferation-dependent cytotoxic agents. Thus, in one aspect, the proliferation-dependent cytotoxic agent for use in the methods of the present invention is cytotoxic to proliferating stem-like cancer cells.

In one embodiment, the proliferation-dependent cytotoxic agent is a nucleoside inhibitor or an antimetabolite. Nucleoside inhibitors or antimetabolites exert cytotoxic activity by mimicking endogenous nucleosides and interfering with the synthesis of nucleic acids. For example, nucleoside inhibitors or antimetabolites include analogues of physiological pyrimidine and purine nucleobases and nucleosides. Such compounds may also interfere with DNA methylation or modify the metabolism of physiological nucleosides. Nucleoside inhibitors or antimetabolites may also mediate enzyme inhibition and perturb the synthesis of nucleic acids. Accordingly, nucleoside inhibitors or antimetabolites are typically described as being cell-cycle specific.

Examples of nucleoside inhibitors or antimetabolites include folic acid antagonists, such as methotrexate and pemetrexed; pyrimidine antagonists, such as 5-Fluorouracil, Foxuridine, Capecitabine, Cytarabine and Gemcitabine; purine antagonists, such as 6-Mercaptopurine and 6-Thioguanine; and adenosine deaminase inhibitors, such as cladribine, fludarabine and pentostatin. In a preferred embodiment in the context of pancreatic cancer, the proliferation-dependent cytotoxic agent is selected from Gemcitabine and Capecitabine.

In a preferred embodiment the nucleoside inhibitor or antimetabolite is a cytidine analogue or deoxycytidine analogue. As described above, cytidine analogues or deoxycytidine analogues mimic endogenous cytidine or deoxycytidine. Such compounds may also interfere with DNA methylation or modify the metabolism of physiological nucleosides. As a result, cytidine analogues and deoxycytidine analogues are widely used in anticancer therapies.

Exemplary cytidine analogues or deoxycytidine analogues for use in the treatment of pancreatic cancer include gemcitabine (2'-deoxy-2',2'-difluorocytidine), or a derivative

thereof; azacitidine (5-azacytidine), or a derivative thereof; cytarabine (Ara-C/ cytosine 1-[beta]-D-arabinofuranoside), or a derivative thereof; decitabine (5-aza-2'-deoxycytidine/5-azadeoxycytidine), or a derivative thereof; and troxacitabine (Troxyt/ 4-amino-1-[(2S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one), or a derivative thereof. In a preferred embodiment, the deoxycytidine analogue is gemcitabine.

In some embodiments, the combination therapy provides an anti-GREM1 antagonist together with one or more cytidine analogues or deoxycytidine analogues. In a preferred embodiment, the present invention provides an anti-GREM1 antagonist for use in a method for the treatment or prevention of a pancreatic cancer, wherein the method further comprises administering gemcitabine. In one exemplary embodiment, the present invention provides an anti-GREM1 antagonist for use in a method for the treatment or prevention of a pancreatic cancer, wherein the method further comprises administering gemcitabine in combination with troxacitabine. One exemplary pancreatic cancer is an exocrine pancreatic cancer, such as a pancreatic ductal adenocarcinoma.

In another embodiment, the proliferation-dependent cytotoxic agent is a mitotic inhibitor. The term mitotic inhibitor as used herein refers to inhibitors that prevent cell division by inhibiting mitosis through the disruption of microtubules. For example, mitotic inhibitors may target tubulin and thus impair the normal function of mitotic spindles, leading to the disruption of microtubule polymerization. In one embodiment of the present invention, the mitotic inhibitor is a microtubule-stabilizing drug. Such drugs may inhibit cell division by disrupting microtubule-dependent signalling events, stimulating tubulin formation and/or increasing the density of cellular microtubules.

Examples of mitotic inhibitors and/or microtubule-stabilizing drugs include Cabazitaxel, Docetaxel, Paclitaxel, Vinblastine, Vincristine, Vinorelbine and Abraxane. In a preferred embodiment in the context of pancreatic cancer, the mitotic inhibitor and/or microtubule-stabilizing drug is selected from abraxane and paclitaxel.

In yet a further embodiment of the present invention, the proliferation-dependent cytotoxic agent may comprise one or more of oxaliplatin, folinic acid, irinotecan and fluorouracil. In the context of pancreatic cancer, the proliferation-dependent cytotoxic agent may be FOLFIRINOX or FOLFOX.

In a preferred embodiment of the invention, the proliferation-dependent cytotoxic agent is gemcitabine and the cancer is pancreatic cancer.

### GREM1

The terms GREM1 or Gremlin-1 as used in the present invention in the context of a protein refer to a protein that typically has the amino acid sequence as set out in the UniProt entry O60565 (SEQ ID NO: 1), human GREM1. The terms GREM1 and Gremlin-1 may also refer to a Gremlin-1 polypeptide which:

(a) comprises or consists of the amino acid sequence of SEQ ID NO: 1 with or without the N-terminal signal peptide, i.e. may comprise or consist of the mature peptide sequence as shown in SEQ ID NO: 21; or

(b) is a derivative having one or more amino acid substitutions, modifications, deletions or insertions relative to the amino acid sequence of SEQ ID NO: 1 with or without the N-terminal signal peptide (as shown in SEQ ID NO: 21), which retains the activity of Gremlin-1, such as the amino acid sequence of SEQ ID NO: 20.

(c) a variant thereof, such variants typically retain at least about 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94% or 95% identity to SEQ ID NO: 1 (or SEQ ID NO: 20 or 21) (or even about 96%, 97%, 98% or 99% identity). In other words, such variants may retain about 60% - about 99% identity to SEQ ID NO: 1, suitably about 80% - about 99% identity to SEQ ID NO: 1, more suitably about 90% - about 99% identity to SEQ ID NO: 1 and most suitably about 95% - about 99% identity to SEQ ID NO: 1. Variants are described further below.

As discussed further below, residue numbers are typically quoted based on the sequence of SEQ ID NO: 1. However, residue numbering could readily be extrapolated by the skilled person to a derivative or variant sequence as discussed above. Where residue numbers are quoted, the invention also encompasses these residues on a variant or derivative sequence.

A GREM1 or Gremlin-1 nucleic acid sequence may comprise or consist of the sequence of SEQ ID NO: 36 or SEQ ID NO: 37 or a variant thereof. Variant nucleic acid sequences are described further below. A GREM1 or Gremlin-1 nucleic sequence may



comprise or consist of any GREM1 transcript variant. Examples of GREM1 transcripts variants are Transcript 1 (NCBI: NM\_013372.6; ENSEMBL: ENST00000560677.5); Transcript 2: NCBI: NM\_001191323.1; ENSEMBL: ENST00000560830.1); Transcript 3: NCBI: NM\_001191322.1; ENSEMBL: ENST00000622074.1. The sequences available at the above accession numbers as of 18 June 2018 are incorporated by reference herein.

### Antagonist

An anti-GREM1 antagonist is any molecule that reduces the function or activity of GREM1. The anti-GREM1 antagonist may reduce function or activity of GREM1 by any amount. The anti-GREM1 antagonist may reduce GREM1 function or activity by at least 10%, at least 20%, at least 30% at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95%, or may prevent any GREM1 function or activity. The extent to which an anti-GREM1 antagonist reduces GREM1 function or activity may be determined by measuring GREM1 function or activity in cells in the presence and absence of the anti-GREM1 antagonist. The cells may be normal cells or cancer cells. The cells may be cancer cells as described above. They may be pancreatic cancer cells. The pancreatic cancer cells may be present in KPC mouse models as described in the Examples. Thus, an *in vivo* assay for activity of a GREM1 antagonist in a combination therapy in pancreatic cancer may be performed in a mouse model. More generally, a GREM1 antagonist shown to reduce function or activity of GREM1 by any means may then be assayed *in vitro* or *in vivo* for its ability to prevent or reduce proliferation of cancer cells, such as pancreatic cancer cells, or to prevent, reduce or eliminate a cancer or tumour.

The antagonist may decrease GREM1 function by any means. It may increase or decrease the activity or amount of any molecule affecting GREM1 function directly or indirectly. It may decrease the amount of GREM1 at the mRNA or protein level. It may increase degradation of GREM1. It may decrease the function of GREM1 by inhibitory modification. It may decrease the transcription of a molecule enhancing GREM1 function. It may disrupt DNA encoding GREM1 or a molecule enhancing GREM1 function, using an agent such as a zinc finger nuclease.

The antagonist may be an agent interacting with Gremlin-1. An agent that interacts with Gremlin-1 is typically an agent which binds Gremlin-1. Agents that interact with Gremlin-1 may modulate Gremlin-1. An inhibitory modulating agent may have an effect on any of the functions of Gremlin-1, but typically reduces binding of Gremlin-1 to BMP (BMP 2/4/7). The antagonist may be a BMP-7 mimetic molecule Gremlin-1 is a negative regulator of BMP, so reduced binding increases signalling through BMP. An activating modulating agent may increase binding of Gremlin-1 to BMP.

BMP binding and signalling may be detected by any method known in the art.

The antagonist may act by binding the active site of GREM1 or act allosterically by binding at a different site. The antagonist may act by binding a regulator or ligand for GREM1, to thereby reduce activation of GREM1. The antagonist may be reversible or irreversible.

A GREM1 antagonist may be a small molecule inhibitor, a peptide, a protein, an antibody, a polynucleotide, an oligonucleotide, an antisense RNA, small interfering RNA (siRNA) or small hairpin RNA (shRNA).

An antagonist of GREM1 may be an oligonucleotide which specifically hybridises to an mRNA encoding GREM1 or an mRNA encoding a molecule which enhances GREM1 activity. An antagonist of GREM1 may be a polynucleotide encoding any molecule that decreases GREM1 function. For example, the GREM1 antagonist may be a polynucleotide encoding an anti-GREM1 antibody described herein.

An antagonist of GREM1 may be an antibody which specifically binds to any target molecule (typically a protein) so as to decrease GREM1 function directly or indirectly. The antagonist may be an antibody specifically binding GREM1. In this aspect, the antibody may decrease GREM1 function by allosteric inactivation or by blocking interaction between its target and a ligand required for activity.

Interaction of an antagonist agent with protein residues may be determined by any appropriate method known in the art, such as distances between the residue and agent as determined by x-ray crystallography (typically less than 6 Å, or less than 4 Å). The region of Gremlin-1 which may be targeted by a therapeutic may include amino acids Asp92-

Leu99, Arg116-His130, Ser137-Ser142, Cys176-Cys178. These are within 6 Å of those mutated on the surface of Gremlin-1.

### Antibody antagonists

The term “antibody” as referred to herein includes whole antibodies and any antigen binding fragment (*i.e.*, “antigen-binding portion”) or single chains thereof. An antibody refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, or an antigen-binding portion thereof. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or V<sub>H</sub>) and a heavy chain constant region. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or V<sub>L</sub>) and a light chain constant region. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The V<sub>H</sub> and V<sub>L</sub> regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).

The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (*e.g.*, effector cells) and the first component (C1q) of the classical complement system.

An antibody used according to the invention may be a monoclonal antibody or a polyclonal antibody, and will typically be a monoclonal antibody. An antibody used according to the invention may be a chimeric antibody, a CDR-grafted antibody, a nanobody, a human or humanised antibody or an antigen-binding portion of any thereof. For the production of both monoclonal and polyclonal antibodies, the experimental animal is typically a non-human mammal such as a goat, rabbit, rat or mouse but the antibody may also be raised in other species.

Polyclonal antibodies may be produced by routine methods such as immunisation of a suitable animal, with the antigen of interest. Blood may be subsequently removed from the animal and the IgG fraction purified.

Antibodies against Gremlin-1 may be obtained, where immunisation of an animal is necessary, by administering the polypeptides to an animal, e.g. a non-human animal, using well-known and routine protocols, see for example Handbook of Experimental Immunology, D. M. Weir (ed.), Vol 4, Blackwell Scientific Publishers, Oxford, England, 1986). Many warm-blooded animals, such as rabbits, mice, rats, sheep, cows, camels or pigs may be immunized. However, mice, rabbits, pigs and rats are generally most suitable.

Monoclonal antibodies may be prepared by any method known in the art such as the hybridoma technique (Kohler & Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, 1983, Immunology Today, 4:72) and the EBV-hybridoma technique (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, pp77-96, Alan R Liss, Inc., 1985).

Antibodies used according to the invention may also be generated using single lymphocyte antibody methods by cloning and expressing immunoglobulin variable region cDNAs generated from single lymphocytes selected for the production of specific antibodies by for example the methods described by Babcook, J. *et al.*, 1996, Proc. Natl. Acad. Sci. USA 93(15): 7843-78481; WO92/02551; WO2004/051268 and WO2004/106377.

The antibodies can also be generated using various phage display methods known in the art and include those disclosed by Brinkman *et al.* (in J. Immunol. Methods, 1995, 182: 41-50), Ames *et al.* (J. Immunol. Methods, 1995, 184:177-186), Kettleborough *et al.* (Eur. J. Immunol. 1994, 24:952-958), Persic *et al.* (Gene, 1997 187 9-18), Burton *et al.* (Advances in Immunology, 1994, 57:191-280) and WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and US 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108.

Fully human antibodies are those antibodies in which the variable regions and the constant regions (where present) of both the heavy and the light chains are all of human origin, or substantially identical to sequences of human origin, but not necessarily from the same antibody. Examples of fully human antibodies may include antibodies produced, for example by the phage display methods described above and antibodies produced by mice

in which the murine immunoglobulin variable and optionally the constant region genes have been replaced by their human counterparts e.g. as described in general terms in EP 0546073, U5,545,806, US 5,569,825, US 5,625,126, US 5,633,425, US 5,661,016, US 5,770,429, EP 0438474 and EP 0463151.

Alternatively, an antibody used according to the invention may be produced by a method comprising immunising a non-human mammal with a Gremlin-1 immunogen; obtaining an antibody preparation from said mammal; deriving therefrom monoclonal antibodies that recognise Gremlin-1.

The antibody molecules used according the present invention may comprise a complete antibody molecule having full length heavy and light chains or a fragment or antigen-binding portion thereof. The term "antigen-binding portion" of an antibody refers to one or more fragments of an antibody that retain the ability to selectively bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. The antibodies and fragments and antigen binding portions thereof may be, but are not limited to Fab, modified Fab, Fab', modified Fab', F(ab')<sub>2</sub>, Fv, single domain antibodies (e.g. VH or VL or VHH), scFv, bi, tri or tetra-valent antibodies, Bis-scFv, diabodies, triabodies, tetrabodies and epitope-binding fragments of any of the above (see for example Holliger and Hudson, 2005, Nature Biotech. 23(9):1126-1136; Adair and Lawson, 2005, Drug Design Reviews - Online 2(3), 209-217). The methods for creating and manufacturing these antibody fragments are well known in the art (see for example Verma et al., 1998, Journal of Immunological Methods, 216, 165-181). Other antibody fragments for use in the present invention include the Fab and Fab' fragments described in International patent applications WO 2005/003169, WO 2005/003170 and WO 2005/003171 and Fab-dAb fragments described in International patent application WO2009/040562. Multi-valent antibodies may comprise multiple specificities or may be monospecific (see for example WO 92/22853 and WO 05/113605). These antibody fragments may be obtained using conventional techniques known to those of skill in the art, and the fragments may be screened for utility in the same manner as intact antibodies.

The constant region domains of the antibody molecule, if present, may be selected having regard to the proposed function of the antibody molecule, and in particular the effector functions which may be required. For example, the constant region domains may be human IgA, IgD, IgE, IgG or IgM domains. In particular, human IgG constant region domains may be used, especially of the IgG1 and IgG3 isotypes when the antibody molecule is intended for therapeutic uses and antibody effector functions are required. Alternatively, IgG2 and IgG4 isotypes may be used when the antibody molecule is intended for therapeutic purposes and antibody effector functions are not required.

An antibody used according to the invention may be prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from an animal (*e.g.*, a mouse) that is transgenic or transchromosomal for the immunoglobulin genes of interest or a hybridoma prepared therefrom, (b) antibodies isolated from a host cell transformed to express the antibody of interest, *e.g.*, from a transfectoma, (c) antibodies isolated from a recombinant, combinatorial antibody library, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of immunoglobulin gene sequences to other DNA sequences.

An antibody used according to the invention may be a human antibody or a humanised antibody. The term "human antibody", as used herein, is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region also is derived from human germline immunoglobulin sequences. The human antibodies described herein may include amino acid residues not encoded by human germline immunoglobulin sequences (*e.g.*, mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*). However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

Such a human antibody may be a human monoclonal antibody. Such a human monoclonal antibody may be produced by a hybridoma that includes a B cell obtained from a transgenic nonhuman animal, *e.g.*, a transgenic mouse, having a genome

comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.

Human antibodies may be prepared by *in vitro* immunisation of human lymphocytes followed by transformation of the lymphocytes with Epstein-Barr virus.

The term “human antibody derivatives” refers to any modified form of the human antibody, e.g., a conjugate of the antibody and another agent or antibody.

The term “humanized antibody” is intended to refer to CDR-grafted antibody molecules in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. Additional framework region modifications may be made within the human framework sequences.

As used herein, the term ‘CDR-grafted antibody molecule’ refers to an antibody molecule wherein the heavy and/or light chain contains one or more CDRs (including, if desired, one or more modified CDRs) from a donor antibody (e.g. a murine or rat monoclonal antibody) grafted into a heavy and/or light chain variable region framework of an acceptor antibody (e.g. a human antibody). For a review, see Vaughan *et al*, Nature Biotechnology, 16, 535-539, 1998. In one embodiment rather than the entire CDR being transferred, only one or more of the specificity determining residues from any one of the CDRs described herein above are transferred to the human antibody framework (see for example, Kashmiri *et al.*, 2005, Methods, 36, 25-34). In one embodiment only the specificity determining residues from one or more of the CDRs described herein above are transferred to the human antibody framework. In another embodiment only the specificity determining residues from each of the CDRs described herein above are transferred to the human antibody framework.

When the CDRs or specificity determining residues are grafted, any appropriate acceptor variable region framework sequence may be used having regard to the class/type of the donor antibody from which the CDRs are derived, including mouse, primate and human framework regions. Suitably, the CDR-grafted antibody according to the present invention has a variable domain comprising human acceptor framework regions as well as one or more of the CDRs or specificity determining residues described above. Thus,

provided in one embodiment is a neutralising CDR-grafted antibody wherein the variable domain comprises human acceptor framework regions and non-human donor CDRs.

Examples of human frameworks which can be used in the present invention are KOL, NEWM, REI, EU, TUR, TEI, LAY and POM (Kabat *et al.*, *supra*). For example, KOL and NEWM can be used for the heavy chain, REI can be used for the light chain and EU, LAY and POM can be used for both the heavy chain and the light chain.

Alternatively, human germline sequences may be used; these are available for example at: <http://www.vbase2.org/> (see Retter *et al.*, Nucl. Acids Res. (2005) 33 (supplement 1), D671-D674).

In a CDR-grafted antibody described herein, the acceptor heavy and light chains do not necessarily need to be derived from the same antibody and may, if desired, comprise composite chains having framework regions derived from different chains.

Also, in a CDR-grafted antibody described herein, the framework regions need not have exactly the same sequence as those of the acceptor antibody. For instance, unusual residues may be changed to more frequently occurring residues for that acceptor chain class or type. Alternatively, selected residues in the acceptor framework regions may be changed so that they correspond to the residue found at the same position in the donor antibody (see Reichmann *et al.*, 1998, Nature, 332, 323-324). Such changes should be kept to the minimum necessary to recover the affinity of the donor antibody. A protocol for selecting residues in the acceptor framework regions which may need to be changed is set forth in WO 91/09967.

It will also be understood by one skilled in the art that antibodies may undergo a variety of posttranslational modifications. The type and extent of these modifications often depends on the host cell line used to express the antibody as well as the culture conditions. Such modifications may include variations in glycosylation, methionine oxidation, diketopiperazine formation, aspartate isomerization and asparagine deamidation. A frequent modification is the loss of a carboxy-terminal basic residue (such as lysine or arginine) due to the action of carboxypeptidases (as described in Harris, R.J. *Journal of Chromatography* 705:129-134, 1995).



In one embodiment the antibody heavy chain comprises a CH1 domain and the antibody light chain comprises a CL domain, either kappa or lambda.

Biological molecules, such as antibodies or fragments, contain acidic and/or basic functional groups, thereby giving the molecule a net positive or negative charge. The amount of overall “observed” charge will depend on the absolute amino acid sequence of the entity, the local environment of the charged groups in the 3D structure and the environmental conditions of the molecule. The isoelectric point (pI) is the pH at which a particular molecule or surface carries no net electrical charge. In one embodiment the antibody or fragment according to the present disclosure has an isoelectric point (pI) of at least 7. In one embodiment the antibody or fragment has an isoelectric point of at least 8, such as 8.5, 8.6, 8.7, 8.8 or 9. In one embodiment the pI of the antibody is 8. Programs such as \*\* ExPASy [http://www.expasy.ch/tools/pi\\_tool.html](http://www.expasy.ch/tools/pi_tool.html) (see Walker, The Proteomics Protocols Handbook, Humana Press (2005), 571-607) may be used to predict the isoelectric point of the antibody or fragment.

In order to characterise preferred Gremlin-1 epitopes, the inventors have crystallised human Gremlin-1 alone, and in complex with an antibody termed Ab 7326 (Fab fragments). Crystallisation of Gremlin-1 has allowed putative residues in the BMP binding site to be determined. Furthermore, crystallisation with Ab 7326, which is an allosteric inhibitory antibody, has allowed residues in the antibody epitope to be determined. Antibodies binding this epitope have particular potential as therapeutic agents in the treatment of diseases associated with Gremlin-1.

The preferred Ab 7326 antibody described herein has been identified to bind the following residues of Gremlin-1: Ile110 (131), Lys126 (147), Lys127 (148), Phe128 (149), Thr129 (150), Thr130 (151), Arg148 (169), Lys153 (174) and Gln154 (175), where Lys126 (147), Lys127 (148), Phe128 (149), Thr129 (150), Thr130 (151), Arg148 (169), Lys153 (174) and Gln154 (175) are present on one Gremlin-1 monomer and Ile110 (131) is present on the second Gremlin-1 monomer. Numbering not in brackets is based on the structural file and (which matches the numbering of mouse Gremlin-2 based on structural alignment). The numbers in brackets represent the residues based on the UniProt entry

O60565 of SEQ ID NO: 1. These epitope residues were identified using NCONT analysis at 4 Å from the Gremlin-1-Ab 7326 Fab complex.

Antibodies described herein may therefore bind to an epitope which comprises at least one residue selected from Ile131, Lys147, Lys148, Phe149, Thr150, Thr151, Arg169, Lys174 and Gln175 (with residue numbering based on SEQ ID NO: 1). Antibodies described herein may bind an epitope which comprises 2, 3, 4, 5, 6, 7, 8 or all 9 of these residues (preferably at least 5 residues).

Antibodies described herein may also recognise an epitope where Ile131 is present on a different Gremlin-1 monomer to the other residues.

Although these residues are provided for a particular sequence of human Gremlin-1, the skilled person could readily extrapolate the positions of these residues to other corresponding Gremlin sequences (e.g. mouse) using routine techniques. Antibodies binding to epitopes comprising the corresponding residues within these other Gremlin sequences are therefore also provided by the invention.

To screen for antibodies that bind to a particular epitope, a routine cross-blocking assay such as that described in Antibodies, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harb., NY) can be performed. Other methods include alanine scanning mutants, peptide blots (Reineke (2004) *Methods Mol Biol* 248:443-63), or peptide cleavage analysis. In addition, methods such as epitope excision, epitope extraction and chemical modification of antigens can be employed (Tomer (2000) *Protein Science* 9: 487-496). Such methods are well known in the art.

Antibody epitopes may also be determined by x-ray crystallography analysis. Antibodies of the present disclosure may therefore be assessed through x-ray crystallography analysis of the antibody bound to Gremlin-1. Epitopes may, in particular, be identified in this way by determining residues on Gremlin-1 within 4Å of an antibody paratope residue.

An antibody as described herein may thus bind to an epitope on Gremlin-1 comprising at least one residue selected from Trp93, Phe117, Tyr119, Phe125, Tyr126 and Phe138, wherein the residue numbering is according to SEQ ID NO: 1. Further described herein is an antibody which binds an epitope comprising all of Trp93, Phe117, Tyr119, Phe125, Tyr126 and Phe138. Additionally described is an antibody which binds an epitope

which comprises the following residues: Ile131, Lys147, Lys148, Phe149, Thr150, Thr151, Arg169, Lys174 and Gln175. Preferably, Lys147, Lys148, Phe149, Thr150, Thr151, Arg169, Lys174 and Gln175 are located on one monomer of Gremlin-1 and Ile131 is located on the other monomer of Gremlin-1 (Gremlin-1 dimers bind to BMP dimers).

An antibody may bind an above Gremlin-1 residue if the antibody paratope is within 4 Å of the Gremlin-1 residue as determined by x-ray crystallography.

Antibodies which bind to an epitope disclosed herein may comprise at least one, at least two or all three heavy chain CDR sequences of SEQ ID NOS: 4 to 6 (HCDR1/HCDR2/HCDR3 respectively). These are the HCDR1/HCDR2/HCDR3 sequences of the Ab 7326 antibody of the Examples as determined using Kabat methodology.

The Kabat and Chothia methods for determining CDR sequences are well known in the art (as well as other techniques). CDR sequences may be determined using any appropriate method and in the present invention, whilst Kabat is typically employed, other techniques could be used as well. In the present instance, SEQ ID NO: 3 presents the Ab 7326 HCDR1 sequence as determined using a combined Chothia & Kabat definition.

Antibodies used according to the invention may comprise at least one, at least two or all three light chain CDR sequences of SEQ ID NOS: 7 to 9 (LCDR1/LCDR2/LCDR3 respectively). These are the LCDR1/LCDR2/LCDR3 sequences of Ab 7326 using Kabat methodology.

The antibody preferably comprises at least a HCDR3 sequence of SEQ ID NO: 6.

Typically, the antibody comprises at least one heavy chain CDR sequence selected from SEQ ID NOS: 4 to 6 and at least one light chain CDR sequence selected from SEQ ID NOS 7 to 9. The antibody may comprise at least two heavy chain CDR sequences selected from SEQ ID NOS: 4 to 6 and at least two light chain CDR sequences selected from SEQ ID NOS: 7 to 9. The antibody typically comprises all three heavy chain CDR sequences of SEQ ID NOS: 4 to 6 (HCDR1/HCDR2/HCDR3 respectively) and all three light chain CDR sequences SEQ ID NOS: 7 to 9 (LCDR1/LCDR2/LCDR3 respectively). The antibodies may be chimeric, human or humanised antibodies.

The antibody may comprise a heavy chain variable region (HCVR) sequence of SEQ ID NO: 10 or 12 (the HCVR of Ab 7326 variants 1 and 2). The antibody may comprise a light chain variable region (LCVR) sequence of SEQ ID NO: 11 or 13 (the LCVR of Ab 7326 variants 1 and 2). The antibody preferably comprises the heavy chain variable region sequence of SEQ ID NO: 10 or 12 and the light chain variable region sequence of SEQ ID NO: 11 or 13 (especially HCVR/LVCR pairs of SEQ ID NOs: 10/11 or 12/13).

The antibody may comprise a heavy chain (H-chain) sequence of SEQ ID NO: 14 mouse full length IgG1 heavy chain variant 1, or SEQ ID NO: 28 mouse full length IgG1 heavy chain variant 2, or SEQ ID NO: 30 human full length IgG1 heavy chain variant 1, or SEQ ID NO: 16 human full length IgG1 heavy chain variant 2, or SEQ ID NO: 22 human full length IgG4P heavy chain variant 1, or SEQ ID NO: 34 human full-length IgG4P heavy chain variant 2, or SEQ ID NO: 18 Fab heavy chain variant 1, or SEQ ID NO: 32 Fab heavy chain variant 2.

The antibody may comprise a light chain (L-chain) sequence of SEQ ID NO: 15 mouse full length IgG1 light chain variant 1, or SEQ ID NO: 29 mouse full length IgG1 light chain variant 2, or SEQ ID NO: 31 human full length IgG1 light chain variant 1, or SEQ ID NO: 17 human full length IgG1 light chain variant 2, or SEQ ID NO: 23 human full length IgG4P light chain variant 1, or SEQ ID NO: 35 human full-length IgG4P light chain variant 2, or SEQ ID NO: 19 Fab light chain variant 1, or SEQ ID NO: 33 Fab light chain variant 2.

In one example, the antibody comprises a heavy chain / light chain sequence pair of SEQ ID NOs: 14/15 mouse full length IgG1 variant 1, or SEQ ID NOs: 28/29 mouse full length IgG1 variant 2, or SEQ ID NOs: 30/31 human full length IgG1 variant 1, or SEQ ID NOs: 16/17 human full length IgG1 variant 2, or SEQ ID NOs: 22/23 human full length IgG4P variant 1, or

SEQ ID NOs: 34/35 human full-length IgG4P variant 2, or

SEQ ID NOs: 18/19 Fab light chain variant 1, or

SEQ ID NOs: 32/33 Fab light chain variant 2.

The variant forms of corresponding sequences may be interchanged. For example, the antibody may comprise a heavy chain / light chain sequence pair of

SEQ ID NOs: 14/29 mouse full length IgG1 heavy chain variant 1/light chain variant 2, or

SEQ ID NOs: 28/15 mouse full length IgG1 heavy chain variant 2/light chain variant 1, or

SEQ ID NOs: 30/17 human full length IgG1 heavy chain variant 1/light chain variant 2, or

SEQ ID NOs: 16/31 human full length IgG1 heavy chain variant 2/light chain variant 1, or

SEQ ID NOs: 22/35 human full length IgG4P heavy chain variant 1/light chain variant 2,

or

SEQ ID NOs: 34/23 human full-length IgG4P heavy chain variant 2/light chain variant 1,

or

SEQ ID NOs: 18/33 Fab heavy chain variant 1/light chain variant 2, or

SEQ ID NOs: 32/19 Fab heavy chain variant 2/light chain variant 1.

The antibodies may be chimeric, human or humanised antibodies.

The antibody may alternatively be or may comprise a variant of one of the specific sequences recited above. The following description of antibody variants is also applicable to selection of GREM1 polypeptide variants as described above.

For example, a variant may be a substitution, deletion or addition variant of any of the above amino acid sequences.

A variant antibody may comprise 1, 2, 3, 4, 5, up to 10, up to 20 or more (typically up to a maximum of 50) amino acid substitutions and/or deletions from the specific sequences discussed above. "Deletion" variants may comprise the deletion of individual amino acids, deletion of small groups of amino acids such as 2, 3, 4 or 5 amino acids, or deletion of larger amino acid regions, such as the deletion of specific amino acid domains or other features. "Substitution" variants typically involve the replacement of one or more amino acids with the same number of amino acids and making conservative amino acid substitutions. For example, an amino acid may be substituted with an alternative amino acid having similar properties, for example, another basic amino acid, another acidic

amino acid, another neutral amino acid, another charged amino acid, another hydrophilic amino acid, another hydrophobic amino acid, another polar amino acid, another aromatic amino acid or another aliphatic amino acid. Some properties of the 20 main amino acids which can be used to select suitable substituents are as follows:

Ala	aliphatic, hydrophobic, neutral	Met	hydrophobic, neutral
Cys	polar, hydrophobic, neutral	Asn	polar, hydrophilic, neutral
Asp	polar, hydrophilic, charged (-)	Pro	hydrophobic, neutral
Glu	polar, hydrophilic, charged (-)	Gln	polar, hydrophilic, neutral
Phe	aromatic, hydrophobic, neutral	Arg	polar, hydrophilic, charged (+)
Gly	aliphatic, neutral	Ser	polar, hydrophilic, neutral
His	aromatic, polar, hydrophilic, charged (+)	Thr	polar, hydrophilic, neutral
Ile	aliphatic, hydrophobic, neutral	Val	aliphatic, hydrophobic, neutral
Lys	polar, hydrophilic, charged(+)	Trp	aromatic, hydrophobic, neutral
Leu	aliphatic, hydrophobic, neutral	Tyr	aromatic, polar, hydrophobic

"Derivatives" or "variants" generally include those in which instead of the naturally occurring amino acid the amino acid which appears in the sequence is a structural analog thereof. Amino acids used in the sequences may also be derivatized or modified, e.g. labelled, providing the function of the antibody is not significantly adversely affected.

Derivatives and variants as described above may be prepared during synthesis of the antibody or by post- production modification, or when the antibody is in recombinant form using the known techniques of site- directed mutagenesis, random mutagenesis, or enzymatic cleavage and/or ligation of nucleic acids.

Variant antibodies may have an amino acid sequence which has more than about 60%, or more than about 70%, e.g. 75 or 80%, typically more than about 85%, e.g. more than about 90 or 95% amino acid identity to the amino acid sequences disclosed herein (particularly the HCVR/LCVR sequences and the H- and L-chain sequences). Furthermore, the antibody may be a variant which has more than about 60%, or more than about 70%, e.g. 75 or 80%, typically more than about 85%, e.g. more than about 90 or

95% amino acid identity to the HCVR/LCVR sequences and the H- and L-chain sequences disclosed herein, whilst retaining the exact CDRs disclosed for these sequences. Variants may retain at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the HCVR/LCVR sequences and to the H- and L-chain sequences disclosed herein (in some circumstances whilst retaining the exact CDRs).

Variants typically retain about 60% - about 99% identity, about 80% - about 99% identity, about 90% - about 99% identity or about 95% - about 99% identity. This level of amino acid identity may be seen across the full length of the relevant SEQ ID NO sequence or over a part of the sequence, such as across about 20, 30, 50, 75, 100, 150, 200 or more amino acids, depending on the size of the full length polypeptide.

In connection with amino acid sequences, "sequence identity" refers to sequences which have the stated value when assessed using ClustalW (Thompson *et al.*, 1994, *supra*) with the following parameters:

Pairwise alignment parameters -Method: accurate, Matrix: PAM, Gap open penalty: 10.00, Gap extension penalty: 0.10;

Multiple alignment parameters -Matrix: PAM, Gap open penalty: 10.00, % identity for delay: 30, Penalize end gaps: on, Gap separation distance: 0, Negative matrix: no, Gap extension penalty: 0.20, Residue-specific gap penalties: on, Hydrophilic gap penalties: on, Hydrophilic residues: GPSNDQEKR. Sequence identity at a particular residue is intended to include identical residues which have simply been derivatized.

Antibodies having specific sequences and variants which maintain the function or activity of these chains are therefore provided.

Antibodies may compete for binding to Gremlin-1 with, or bind to the same epitope as, those defined above in terms of H-chain/L-chain, HCVR/LCVR or CDR sequences. In particular, an antibody may compete for binding to Gremlin-1 with, or bind to the same epitope as, an antibody which comprises a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 4/5/6/7/8/9. An antibody may compete for binding to Gremlin-1 with, or bind to the same epitope as, an antibody which comprises a HCVR and LCVR sequence pair of SEQ ID NOs: 10/11 or 12/13 or full length chains of SEQ ID Nos: 14/15 or 16/17.

The term “epitope” is a region of an antigen that is bound by an antibody. Epitopes may be defined as structural or functional. Functional epitopes are generally a subset of the structural epitopes and have those residues that directly contribute to the affinity of the interaction. Epitopes may also be conformational, that is, composed of non-linear amino acids. In certain embodiments, epitopes may include determinants that are chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and, in certain embodiments, may have specific three-dimensional structural characteristics, and/or specific charge characteristics.

One can easily determine whether an antibody binds to the same epitope as, or competes for binding with, a reference antibody by using routine methods known in the art. For example, to determine if a test antibody binds to the same epitope as a reference antibody of the invention, the reference antibody is allowed to bind to a protein or peptide under saturating conditions. Next, the ability of a test antibody to bind to the protein or peptide is assessed. If the test antibody is able to bind to the protein or peptide following saturation binding with the reference antibody, it can be concluded that the test antibody binds to a different epitope than the reference antibody. On the other hand, if the test antibody is not able to bind to protein or peptide following saturation binding with the reference antibody, then the test antibody may bind to the same epitope as the epitope bound by the reference antibody of the invention.

To determine if an antibody competes for binding with a reference antibody, the above-described binding methodology is performed in two orientations. In a first orientation, the reference antibody is allowed to bind to a protein/peptide under saturating conditions followed by assessment of binding of the test antibody to the protein/peptide molecule. In a second orientation, the test antibody is allowed to bind to the protein/peptide under saturating conditions followed by assessment of binding of the reference antibody to the protein/peptide. If, in both orientations, only the first (saturating) antibody is capable of binding to the protein/peptide, then it is concluded that the test antibody and the reference antibody compete for binding to the protein/peptide. As will be appreciated by the skilled person, an antibody that competes for binding with a reference antibody may not necessarily bind to the identical epitope as the reference antibody, but



may sterically block binding of the reference antibody by binding an overlapping or adjacent epitope.

Two antibodies bind to the same or overlapping epitope if each competitively inhibits (blocks) binding of the other to the antigen. That is, a 1-, 5-, 10-, 20- or 100-fold excess of one antibody inhibits binding of the other by at least 50%, 75%, 90% or even 99% as measured in a competitive binding assay (see, e.g., Junghans et al., *Cancer Res*, 1990:50:1495-1502). Alternatively, two antibodies have the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other. Two antibodies have overlapping epitopes if some amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.

Additional routine experimentation (e.g., peptide mutation and binding analyses) can then be carried out to confirm whether the observed lack of binding of the test antibody is in fact due to binding to the same epitope as the reference antibody or if steric blocking (or another phenomenon) is responsible for the lack of observed binding. Experiments of this sort can be performed using ELISA, RIA, surface plasmon resonance, flow cytometry or any other quantitative or qualitative antibody-binding assay available in the art.

Antibodies can be tested for binding to Gremlin-1 by, for example, standard ELISA or Western blotting. An ELISA assay can also be used to screen for hybridomas that show positive reactivity with the target protein. The binding selectivity of an antibody may also be determined by monitoring binding of the antibody to cells expressing the target protein, for example by flow cytometry. Thus, a screening method may comprise the step of identifying an antibody that is capable of binding Gremlin-1 by carrying out an ELISA or Western blot or by flow cytometry.

Antibodies may selectively (or specifically) recognise Gremlin-1. An antibody, or other compound, “selectively binds” or “selectively recognises” a protein when it binds with preferential or high affinity to the protein for which it is selective but does not substantially bind, or binds with low affinity, to other proteins. The selectivity of an antibody may be further studied by determining whether or not the antibody binds to other

related proteins as discussed above or whether it discriminates between them. Antibodies used according to the invention typically recognise human Gremlin-1.

Antibodies may also have cross-reactivity for related proteins, or for human Gremlin-1 and for Gremlin-1 from other species.

By specific (or selective), it will be understood that the antibody binds to the protein of interest with no significant cross-reactivity to any other molecule. Cross-reactivity may be assessed by any suitable method described herein. Cross-reactivity of an antibody may be considered significant if the antibody binds to the other molecule at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 100% as strongly as it binds to the protein of interest. An antibody that is specific (or selective) may bind to another molecule at less than about 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25% or 20% the strength that it binds to the protein of interest. The antibody may bind to the other molecule at less than about 20%, less than about 15%, less than about 10% or less than about 5%, less than about 2% or less than about 1% the strength that it binds to the protein of interest.

Anti-gremlin antibodies have been previously described, for example WO2014/159010A1 (Regeneron) describes anti-gremlin antibodies that inhibit Gremlin-1 activity, with binding affinity  $K_D$  values ranging from 625pM to 270nM at 25°C. Ciucan et al (2013) describe an anti-Gremlin-1 monoclonal antibody with a binding affinity  $K_D$   $5.6 \times 10^{-10}$  M.

The anti-Gremlin-1 antibodies described herein (and also in WO/2018/115017 filed 19 December 2017 and WO 2019/243801 filed 18 June 2019, both of which are incorporated herein by reference in their entirety) are allosteric inhibitors of Gremlin-1 activity, and bind to a novel epitope as described above, distal from the BMP binding site. The antibodies bind to Gremlin-1 with exceptionally high affinity with  $K_d$  values <100pM. The antibodies therefore represent a significant improvement over currently available antibodies and are expected to be particularly useful for the treatment of Gremlin-1 mediated diseases.

Thus, antibodies suitable for use with the present invention may have a high

affinity binding for (human) Gremlin-1. The antibody may have a dissociation constant ( $K_D$ ) of less than  $<1$  nM, and preferably  $<500$  pM. In one example, the antibody has a dissociation constant ( $K_D$ ) of less than 200pM. In one example, the antibody has a dissociation constant ( $K_D$ ) of less than 100pM. A variety of methods can be used to determine the binding affinity of an antibody for its target antigen such as surface plasmon resonance assays, saturation assays, or immunoassays such as ELISA or RIA, as are well known to persons of skill in the art. An exemplary method for determining binding affinity is by surface plasmon resonance analysis on a BIAcore™ 2000 instrument (Biacore AB, Freiburg, Germany) using CM5 sensor chips, as described by Krinner et al., (2007) Mol. Immunol. February; 44 (5):916-25. (Epub 2006 May 11)).

Antibodies used according to the invention are typically inhibitory antibodies. Gremlin-1 negatively regulates BMP-2, 4 and 7, so inhibition of Gremlin-1 results in increased signalling through BMP.

Particular functional assays that may be used for screening whether an antibody is capable of inhibiting Gremlin 1 include the SMAD phosphorylation assay and the Hek Id1 reporter gene assay. Typically, an inhibitory antibody restores SMAD phosphorylation and/or restores signalling of BMP in the Hek Id1 reporter gene assay. SMAD phosphorylation may be restored to at least 80 %, 90 % or 100 % when compared with a BMP control. In the Hek Id1 reporter gene assay, an inhibitory antibody may have an  $IC_{50}$  of less than 10 nM, preferably less than 5 nM.

Once a suitable antibody has been identified and selected, the amino acid sequence of the antibody may be identified by methods known in the art. The genes encoding the antibody can be cloned using degenerate primers. The antibody may be recombinantly produced by routine methods.

The present disclosure also provides an isolated DNA sequence encoding the heavy and/or light chain variable regions(s) (or the full length H- and L-chains) of an antibody molecule newly described herein.

A variant polynucleotide may comprise 1, 2, 3, 4, 5, up to 10, up to 20, up to 30, up to 40, up to 50, up to 75 or more nucleic acid substitutions and/or deletions from any of the nucleic acid sequences (including GREM1 and anti-GREM1 antibody nucleic acid

sequences) given in the sequence listing. Generally, a variant has 1-20, 1-50, 1-75 or 1-100 substitutions and/or deletions.

Suitable variants may be at least about 70% homologous to a polynucleotide of any one of nucleic acid sequences disclosed herein, typically at least about 80 or 90% and more suitably at least about 95%, 97% or 99% homologous thereto. Variants may retain at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity. Variants typically retain about 60% - about 99% identity, about 80% - about 99% identity, about 90% - about 99% identity or about 95% - about 99% identity. Homology and identity at these levels is generally present at least with respect to the coding regions of the polynucleotides. Methods of measuring homology are well known in the art and it will be understood by those of skill in the art that in the present context, homology is calculated on the basis of nucleic acid identity. Such homology may exist over a region of at least about 15, at least about 30, for instance at least about 40, 60, 100, 200 or more contiguous nucleotides (depending on the length). Such homology may exist over the entire length of the unmodified polynucleotide sequence.

Methods of measuring polynucleotide homology or identity are known in the art. For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (e.g. used on its default settings) (Devereux *et al* (1984) *Nucleic Acids Research* 12, p387-395).

The PILEUP and BLAST algorithms can also be used to calculate homology or line up sequences (typically on their default settings), for example as described in Altschul S.F. (1993) *J Mol Evol* 36:290-300; Altschul, S, F *et al* (1990) *J Mol Biol* 215:403-10.

Software for performing BLAST analysis is publicly available through the National Centre for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul *et al*, *supra*). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the

cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89:10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, typically less than about 0.1, suitably less than about 0.01, and most suitably less than about 0.001. For example, the smallest sum probability may be in the range of about 1 - about 0.001, often about 0.01 - about 0.001.

The homologue may differ from a sequence in the relevant polynucleotide by less than about 3, 5, 10, 15, 20 or more mutations (each of which may be a substitution, deletion or insertion). For example, the homologue may differ by 3-50 mutations, often 3-20 mutations. These mutations may be measured over a region of at least 30, for instance at least about 40, 60 or 100 or more contiguous nucleotides of the homologue.

In one embodiment, a variant sequence may vary from the specific sequences given in the sequence listing by virtue of the redundancy in the genetic code. The DNA code has 4 primary nucleic acid residues (A, T, C and G) and uses these to “spell” three letter codons which represent the amino acids the proteins encoded in an organism’s genes. The linear sequence of codons along the DNA molecule is translated into the linear sequence of amino acids in the protein(s) encoded by those genes. The code is highly degenerate, with 61 codons coding for the 20 natural amino acids and 3 codons representing “stop” signals.

Thus, most amino acids are coded for by more than one codon - in fact several are coded for by four or more different codons. A variant polynucleotide of the invention may therefore encode the same polypeptide sequence as another polynucleotide of the invention, but may have a different nucleic acid sequence due to the use of different codons to encode the same amino acids.

The DNA sequence may comprise synthetic DNA, for instance produced by chemical processing, cDNA, genomic DNA or any combination thereof.

DNA sequences which encode an antibody molecule described herein can be obtained by methods well known to those skilled in the art. For example, DNA sequences coding for part or all of the antibody heavy and light chains may be synthesised as desired from the determined DNA sequences or on the basis of the corresponding amino acid sequences.

General methods by which the vectors may be constructed, transfection methods and culture methods are well known to those skilled in the art. In this respect, reference is made to "Current Protocols in Molecular Biology", 1999, F. M. Ausubel (ed), Wiley Interscience, New York and the Maniatis Manual produced by Cold Spring Harbor Publishing.

### *Nucleic acid antagonists*

A polynucleotide, such as a nucleic acid, is a polymer comprising two or more nucleotides. The nucleotides can be naturally occurring or artificial. A nucleotide typically contains a nucleobase, a sugar and at least one linking group, such as a phosphate, 2'O-methyl, 2' methoxy-ethyl, phosphoramidate, methylphosphonate or phosphorothioate group. The nucleobase is typically heterocyclic. Nucleobases include, but are not limited to, purines and pyrimidines and more specifically adenine (A), guanine (G), thymine (T), uracil (U) and cytosine (C). The sugar is typically a pentose sugar. Nucleotide sugars include, but are not limited to, ribose and deoxyribose. The nucleotide is typically a ribonucleotide or deoxyribonucleotide. The nucleotide typically contains a

monophosphate, diphosphate or triphosphate. Phosphates may be attached on the 5' or 3' side of a nucleotide.

Nucleotides include, but are not limited to, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP), thymidine monophosphate (TMP), thymidine diphosphate (TDP), thymidine triphosphate (TTP), uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), 5-methylcytidine monophosphate, 5-methylcytidine diphosphate, 5-methylcytidine triphosphate, 5-hydroxymethylcytidine monophosphate, 5-hydroxymethylcytidine diphosphate, 5-hydroxymethylcytidine triphosphate, cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), deoxyadenosine monophosphate (dAMP), deoxyadenosine diphosphate (dADP), deoxyadenosine triphosphate (dATP), deoxyguanosine monophosphate (dGMP), deoxyguanosine diphosphate (dGDP), deoxyguanosine triphosphate (dGTP), deoxythymidine monophosphate (dTMP), deoxythymidine diphosphate (dTDP), deoxythymidine triphosphate (dTTP), deoxyuridine monophosphate (dUMP), deoxyuridine diphosphate (dUDP), deoxyuridine triphosphate (dUTP), deoxycytidine monophosphate (dCMP), deoxycytidine diphosphate (dCDP) and deoxycytidine triphosphate (dCTP), 5-methyl-2'-deoxycytidine monophosphate, 5-methyl-2'-deoxycytidine diphosphate, 5-methyl-2'-deoxycytidine triphosphate, 5-hydroxymethyl-2'-deoxycytidine monophosphate, 5-hydroxymethyl-2'-deoxycytidine diphosphate and 5-hydroxymethyl-2'-deoxycytidine triphosphate. The nucleotides are preferably selected from AMP, TMP, GMP, UMP, dAMP, dTMP, dGMP or dCMP.

The nucleotides may contain additional modifications. In particular, suitable modified nucleotides include, but are not limited to, 2'-amino pyrimidines (such as 2'-amino cytidine and 2'-amino uridine), 2'-hydroxyl purines (such as , 2'-fluoro pyrimidines (such as 2'-fluorocytidine and 2'fluoro uridine), hydroxyl pyrimidines (such as 5'- $\alpha$ -P-borano uridine), 2'-O-methyl nucleotides (such as 2'-O-methyl adenosine, 2'-O-methyl guanosine, 2'-O-methyl cytidine and 2'-O-methyl uridine), 4'-thio pyrimidines (such as 4'-thio uridine and 4'-thio cytidine) and nucleotides have modifications of the

nucleobase (such as 5-pentynyl-2'-deoxy uridine, 5-(3-aminopropyl)-uridine and 1,6-diaminohexyl-N-5-carbamoylmethyl uridine).

The nucleotides in the polynucleotide may be attached to each other in any manner. The nucleotides may be linked by phosphate, 2'O-methyl, 2' methoxy-ethyl, phosphoramidate, methylphosphonate or phosphorothioate linkages. The nucleotides are typically attached by their sugar and phosphate groups as in nucleic acids. The nucleotides may be connected via their nucleobases as in pyrimidine dimers.

The GREM1 antagonist may be a polynucleotide encoding an anti-GREM1 antibody described herein.

The polynucleotide can be a nucleic acid, such as deoxyribonucleic acid (DNA) or a ribonucleic acid (RNA). The polynucleotide may be any synthetic nucleic acid known in the art, such as peptide nucleic acid (PNA), glycerol nucleic acid (GNA), threose nucleic acid (TNA), locked nucleic acid (LNA), morpholino nucleic acid or other synthetic polymers with nucleotide side chains. The polynucleotide may be single stranded or double stranded.

The polynucleotide sequence may be cloned into any suitable expression vector. In an expression vector, the polynucleotide sequence encoding a construct is typically operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell. Such expression vectors can be used to express a construct.

In one embodiment, the anti-GREM1 antagonist is a polynucleotide encoding an anti-GREM1 antibody described herein. The polynucleotide may be provided for use in gene therapy. The polynucleotide may be provided in any suitable vector capable of providing for expression of the anti-GREM1 antibody *in vivo*.

The polynucleotide encoding the anti-GREM1 antibody may be a DNA sequence. The DNA sequence may be provided in any suitable vector, *e.g.* an expression vector, for administration to a subject in need thereof. For example, the DNA sequence may be administered to the subject in an expression vector capable of providing for expression of the anti-GREM1 antibody *in vivo*. The expression vector may be a viral expression vector, such as an adeno-associated virus (AAV) vector. In one embodiment, the anti-GREM1



antagonist is a DNA sequence which encodes an anti-GREM1 antibody described herein. In one embodiment, the anti-GREM1 antagonist is a DNA sequence for use in gene therapy, wherein the DNA sequence encodes an anti-GREM1 antibody described herein. In one embodiment, the anti-GREM1 antagonist is an AAV comprising a DNA sequence which encodes an anti-GREM1 antibody described herein. In one embodiment, the anti-GREM1 antagonist is an AAV for use in gene therapy, wherein the AAV comprises a DNA sequence which encodes an anti-GREM1 antibody described herein.

The polynucleotide encoding the anti-GREM1 antibody may be an RNA sequence. The RNA sequence may be administered to a subject in need thereof in any suitable vector. The RNA sequence may be a messenger RNA (mRNA) sequence. The mRNA sequence may be administered to a subject in need thereof in a stabilised form. For example the mRNA sequence may be provided in a lipid nanoparticle (LNP) composition. The LNP composition may comprise any suitable LNPs capable of encapsulating the mRNA sequence to provide for increased stability of said mRNA sequence. Thus, in one embodiment, the anti-GREM1 antagonist is a stabilised mRNA sequence encoding an anti-GREM1 antibody described herein. In one embodiment, the anti-GREM1 antagonist is a stabilised mRNA sequence for use in gene therapy, wherein the mRNA sequence encodes an anti-GREM1 antibody described herein. In one embodiment, the anti-GREM1 antagonist is a LNP composition which comprises an mRNA encoding an anti-GREM1 antibody described herein. In one embodiment, the anti-GREM1 antagonist is an LNP composition for use in gene therapy, wherein the LNP composition comprises an mRNA encoding an anti-GREM1 antibody described herein.

The term “*operably linked*” refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence “*operably linked*” to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. Multiple copies of the same or different polynucleotide may be introduced into the vector.

The expression vector may then be introduced into a suitable host cell. Thus, a construct can be produced by inserting a polynucleotide sequence encoding a construct

into an expression vector, introducing the vector into a compatible bacterial host cell, and growing the host cell under conditions which bring about expression of the polynucleotide sequence.

A GREM1 antagonist which is nucleic acid-based may reduce expression of GREM1. Antisense and RNA interference (RNAi) technology for knocking down protein expression are well known in the art and standard methods can be employed to knock down expression of a molecule of interest. Both antisense and siRNA technology interfere with mRNA. Antisense oligonucleotides interfere with mRNA by binding to (hybridising with) a section of the mRNA. The antisense oligonucleotide is therefore designed to be complementary to the mRNA (although the oligonucleotide does not have to be 100% complementary as discussed below). In other words, the antisense oligonucleotide may be a section of the cDNA. Again, the oligonucleotide sequence may not be 100% identical to the cDNA sequence. This is also discussed below. RNAi involves the use of double-stranded RNA, such small interfering RNA (siRNA) or small hairpin RNA (shRNA), which can bind to the mRNA and inhibit protein expression.

Accordingly, the antagonist may be a oligonucleotide which specifically hybridises to an mRNA encoding GREM1, such as the encoding sequence of SEQ ID NO: 36 or SEQ ID NO: 37 or a variant thereof. An oligonucleotide “*specifically hybridises*” to a target sequence when it hybridises with preferential or high affinity to the target sequence but does not substantially hybridise, does not hybridise or hybridises with only low affinity to other sequences. More preferably, the oligonucleotide hybridises to the target sequence with a  $T_m$  that is at least 5 °C, at least at least 10 °C, at least 20 °C, at least 30 °C or at least 40 °C, greater than its  $T_m$  for other nucleic acids. Conditions that permit the hybridisation are well-known in the art (for example, Sambrook et al., 2001, Molecular Cloning: a laboratory manual, 3rd edition, Cold Spring Harbour Laboratory Press; and Current Protocols in Molecular Biology, Chapter 2, Ausubel et al., Eds., Greene Publishing and Wiley-Interscience, New York (1995)). The hybridisation conditions may be stringent conditions as described in the art.

Oligonucleotides are short nucleotide polymers which typically have 50 or fewer nucleotides, such 40 or fewer, 30 or fewer, 22 or fewer, 21 or fewer, 20 or fewer, 10 or

fewer or 5 or fewer nucleotides. The oligonucleotide used may be 20 to 25 nucleotides in length, more preferably 21 or 22 nucleotides in length. The nucleotides can be naturally occurring or artificial. The nucleotides can be any of those described above.

The GREM1 antagonist may be an antibody that binds to GREM1, typically specifically binding GREM1. An antibody “specifically binds” to a protein when it binds with preferential or high affinity to that protein but does not substantially bind, does not bind or binds with only low affinity to other proteins. For instance, an antibody “specifically binds” a target molecule when it binds with preferential or high affinity to that target but does not substantially bind, does not bind or binds with only low affinity to other human proteins.

An antibody binds with preferential or high affinity if it binds with a  $K_d$  of  $1 \times 10^{-7}$  M or less, more preferably  $5 \times 10^{-8}$  M or less, more preferably  $1 \times 10^{-8}$  M or less or more preferably  $5 \times 10^{-9}$  M or less. An antibody binds with low affinity if it binds with a  $K_d$  of  $1 \times 10^{-6}$  M or more, more preferably  $1 \times 10^{-5}$  M or more, more preferably  $1 \times 10^{-4}$  M or more, more preferably  $1 \times 10^{-3}$  M or more, even more preferably  $1 \times 10^{-2}$  M or more.

The antibody may be, for example, a monoclonal antibody, a polyclonal antibody, a single chain antibody, a chimeric antibody, a bispecific antibody, a CDR-grafted antibody or a humanized antibody. The antibody may be an intact immunoglobulin molecule or a fragment thereof such as a Fab,  $F(ab')_2$  or Fv fragment.

### Patient

Any patient may be treated in accordance with the invention. The patient is typically human. However, the patient may be another mammalian animal, such as a commercially farmed animal, such as a horse, a cow, a sheep, a fish, a chicken or a pig, a laboratory animal, such as a mouse or a rat, or a pet, such as a guinea pig, a hamster, a rabbit, a cat or a dog.

### Pharmaceutical Compositions, Dosages and Dosage Regimes

A GREM1 antagonist of the invention may be provided in a pharmaceutical composition. A cytidine analogue or deoxycytidine analogue may be provided as part of the same pharmaceutical composition or in a separate pharmaceutical composition. For example, gemcitabine or a derivative thereof may be provided as part of the same pharmaceutical composition or in a separate pharmaceutical composition. For example, azacitidine, cytarabine, decitabine, troxacitabine, or derivatives thereof may be provided as part of the same pharmaceutical composition or in a separate pharmaceutical composition. The proliferation dependent cytotoxic agent may also be provided as part of the same pharmaceutical composition or in a separate pharmaceutical composition. The pharmaceutical composition will normally be sterile and will typically include a pharmaceutically acceptable carrier and/or adjuvant. These compositions may comprise, in addition to the therapeutically active ingredient(s), a pharmaceutically acceptable excipient, carrier, diluent, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The pharmaceutical carrier or diluent may be, for example, an isotonic solution.

As used herein, "*pharmaceutically acceptable carrier*" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The precise nature of the carrier or other material may depend on the route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular and intraperitoneal routes.

The carrier may be suitable for parenteral, e.g. intravenous, intramuscular, intradermal, intraocular, intraperitoneal, subcutaneous, spinal or other parenteral routes of administration, for example by injection or infusion. Alternatively, the carrier may be suitable for non-parenteral administration, such as a topical, epidermal or mucosal route of administration. The carrier may be suitable for oral administration. Depending on the route of administration, the modulator may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound. For example, solid oral forms may contain, together with the active substance, diluents,

e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescent mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

Other oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10% to 95% of active ingredient, preferably 25% to 70%. Where the pharmaceutical composition is lyophilised, the lyophilised material may be reconstituted prior to administration, e.g. a suspension. Reconstitution is preferably effected in buffer.

Capsules, tablets and pills for oral administration to an individual may be provided with an enteric coating comprising, for example, Eudragit "S", Eudragit "L", cellulose acetate, cellulose acetate phthalate or hydroxypropylmethyl cellulose.

Liquid dispersions for oral administration may be syrups, emulsions or suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active substance, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

Solutions for intravenous administration or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1% to 2%.

Polynucleotide or oligonucleotide inhibitors may be naked nucleotide sequences or be in combination with cationic lipids, polymers or targeting systems. They may be delivered by any available technique. For example, the polynucleotide or oligonucleotide may be introduced by needle injection, preferably intradermally, subcutaneously or intramuscularly. Alternatively, the polynucleotide or oligonucleotide may be delivered directly across the skin using a delivery device such as particle-mediated gene delivery. The polynucleotide or oligonucleotide may be administered topically to the skin, or to mucosal surfaces for example by intranasal, oral, or intrarectal administration.

Uptake of polynucleotide or oligonucleotide constructs may be enhanced by several known transfection techniques, for example those including the use of transfection agents. Examples of these agents include cationic agents, for example, calcium phosphate and DEAE-Dextran and lipofectants, for example, lipofectam and transfectam. The dosage of the polynucleotide or oligonucleotide to be administered can be altered.

The pharmaceutical compositions of the invention may include one or more pharmaceutically acceptable salts. A "*pharmaceutically acceptable salt*" refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects. Examples of such salts include acid addition salts and base addition salts.

Pharmaceutically acceptable carriers comprise aqueous carriers or diluents. Examples of suitable aqueous carriers that may be employed in the pharmaceutical compositions of the invention include water, buffered water and saline. Examples of other carriers include ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. In many cases, it will be desirable to include isotonic

agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.

Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration.

Pharmaceutical compositions of the invention may comprise additional active ingredients.

Also within the scope of the present disclosure are kits comprising the combination therapies described herein and instructions for use. The kit may further contain one or more additional reagents, such as an additional therapeutic or prophylactic agent as discussed herein.

The antagonists described herein or formulations or compositions thereof may be administered for prophylactic and/or therapeutic treatments.

In therapeutic applications, compounds are administered to a subject already suffering from a disorder or condition as described above, in an amount sufficient to cure, alleviate or partially arrest the condition or one or more of its symptoms. Such therapeutic treatment may result in a decrease in severity of disease symptoms, or an increase in frequency or duration of symptom-free periods. An amount adequate to accomplish this is defined as a "*therapeutically effective amount*".

In prophylactic applications, formulations are administered to a subject at risk of a disorder or condition as described above, in an amount sufficient to prevent or reduce the subsequent effects of the condition or one or more of its symptoms. An amount adequate to accomplish this is defined as a "*prophylactically effective amount*". Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject.

A subject for administration may be a human or non-human animal. The term "*non-human animal*" includes all vertebrates, *e.g.*, mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc. Administration to humans is typical.

An antagonist, proliferation-dependent cytotoxic agent, such as gemcitabine, cytidine analogue or deoxycytidine analogue, or pharmaceutical composition of the invention may be administered via one or more routes of administration using one or more of a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. Examples of routes of administration for compounds or pharmaceutical compositions of the invention include intravenous, intramuscular, intradermal, intraocular, intraperitoneal, subcutaneous, spinal or other parenteral routes of administration, for example by injection or infusion. The phrase "*parenteral administration*" as used herein means modes of administration other than enteral and topical administration, usually by injection. Alternatively, antibody/modulatory agent or pharmaceutical composition of the invention can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration. The antibody/modulatory agent or pharmaceutical composition of the invention may be for oral administration.

A suitable dosage of an antibody/modulatory agent or pharmaceutical composition of the invention may be determined by a skilled medical practitioner. Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

A suitable dose may be, for example, in the range of from about 0.01 $\mu$ g/kg to about 1000mg/kg body weight, typically from about 0.1 $\mu$ g/kg to about 100mg/kg body weight, of the patient to be treated dependent on the conditions mentioned above. For example, a



suitable dosage may be from about 1 $\mu$ g/kg to about 10mg/kg body weight per day or from about 10  $\mu$ g/kg to about 5 mg/kg body weight per day.

Dosage regimens may be adjusted to provide the optimum desired response (*e.g.*, a therapeutic response). For example, a single dose may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. The dose may be provided as multiple doses, for example taken at regular intervals, for example 2, 3 or 4 doses administered hourly. Multiple doses may be administered via the same or different routes and to the same or different locations. Alternatively, doses can be via a sustained release formulation, in which case less frequent administration is required. Dosage and frequency may vary depending on the half-life of the antagonist in the patient and the duration of treatment desired.

Typically polynucleotide or oligonucleotide inhibitors are administered in the range of 1 pg to 1 mg, preferably to 1 pg to 10  $\mu$ g nucleic acid for particle mediated delivery and 10  $\mu$ g to 1 mg for other routes.

Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

As mentioned above, modulators/antibodies or pharmaceutical compositions of the invention may be co-administered with one or other more other therapeutic agents.

Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins.

Combined administration of two or more agents may be achieved in a number of different ways. Both may be administered together in a single composition, or they may be administered in separate compositions as part of a combined therapy. For example, the one may be administered before or separately, after or sequential, or concurrently or simultaneously with the other. The anti-GREM1 antagonist may be administered before or separately, after or sequential, or concurrently or simultaneously with the cytidine

analogue or deoxycytidine analogue as described herein. For example, the anti-GREM1 antagonist may be administered before or separately, after or sequential, or concurrently or simultaneously with gemcitabine or a derivative thereof. The anti-GREM1 antagonist may be administered before or separately, after or sequential, or concurrently or simultaneously with gemcitabine, azacitidine, cytarabine, decitabine, troxacitabine, or derivatives thereof. Alternatively, in the context of pancreatic cancer, the anti-GREM1 antagonist may be administered before or separately, after or sequential, or concurrently or simultaneously with the proliferation-dependent cytotoxic agent.

#### Additional therapeutic combinations

A combination therapy of the invention as described above may be used/administered in combination with a further therapeutic composition of treatment, for example as adjunct therapy. The other therapeutic compositions or treatments may for example be one or more of those discussed herein, and may be administered either simultaneously or sequentially with the composition of the invention.

As discussed above, GREM1 antagonists have particular utility in combination treatments, since they may be used to sensitise a cancer or tumour to a further anti-cancer agent, such as radiotherapy or surgery. The cancer may be resistant to the other anti-cancer agent or cancer therapy in the absence of the GREM1 antagonist.

Thus, an anti-GREM1 antagonist in combination with gemcitabine or a derivative thereof may further be used in combination with any other cancer therapy or any other therapeutic agent for a cancer. In addition, an anti-GREM1 antagonist in combination with a proliferation-dependent cytotoxic agent may further be used in combination with any other cancer therapy or any other therapeutic agent for treatment of a pancreatic cancer. The other cancer therapy may be selected from any known therapy for the relevant cancer, such as any known therapy for pancreatic cancer. The other cancer therapy may be a radiotherapy. Suitable radiotherapy treatments are described for example in Van Cutsem (and others) *Annals of Oncology*, 2014. Vol 25, Issue 3. The radiotherapy may be carried out before surgery on a cancer or after surgery on a cancer. The radiotherapy may be

adjuvant radiotherapy. The radiotherapy may be carried out in combination with a chemotherapy, such as in combination with gemcitabine or a proliferation-dependent cytotoxic agent as described herein. For example, a combination therapy comprising a GREM1 antagonist and gemcitabine or a derivative thereof may be used in combination with radiotherapy. In addition, in the context of pancreatic cancer, a combination therapy comprising a GREM1 antagonist and a proliferation-dependent cytotoxic agent may be used in combination with radiotherapy.

The further therapeutic agent for a cancer, such as a further chemotherapeutic agent may be selected from any known therapeutic agent for the relevant cancer, including any known chemotherapeutic agent or combination of chemotherapeutic agents for the relevant cancer. For example, a combination therapy comprising a GREM1 antagonist and gemcitabine may be used in combination with one or more of abraxane, paclitaxel, oxaliplatin, folinic acid, irinotecan, fluorouracil, FOLFIRINOX or FOLFOX, particularly in treatments of pancreatic cancer. For example, an anti-GREM1 antagonist for use according to the present invention may be administered in combination with gemcitabine and a further cytidine analogue or deoxycytidine analogue.

In addition, a combination therapy comprising a GREM1 antagonist and a proliferation-dependent cytotoxic agent may be used in combination with a further chemotherapeutic agent, such as gemcitabine, abraxane, paclitaxel, oxaliplatin, folinic acid, irinotecan, fluorouracil, FOLFIRINOX or FOLFOX. Any of the combinations described herein are contemplated in the context of compositions and kits for treatment of a cancer or a pancreatic cancer. In a preferred embodiment, an anti-GREM1 antagonist for use according to the present invention may be administered in combination with gemcitabine and troxacitabine. In a particularly preferred embodiment, an anti-GREM1 antagonist for use in a method of treating pancreatic cancer may be administered in combination with gemcitabine and troxacitabine. The cancer may be resistant to radiotherapy or one or more chemotherapeutic agents (such as one of the above chemotherapeutic agents) when not administered together with a combination therapy comprising a GREM1 antagonist as described herein.

As part of the above aspects, the invention provides an anti-GREM1 antagonist in combination with gemcitabine or a derivative thereof, or a proliferation –dependent cytotoxic agent for use in a method of treatment and/or prevention of cancer, such as pancreatic cancer, according to the invention, wherein the method further comprises separate, sequential or simultaneous administration of an additional anti-cancer agent.

### Compositions and kits

Additionally provided is a composition or kit comprising an anti-GREM1 antagonist and a cytidine analogue or deoxycytidine analogue. The cytidine analogue or deoxycytidine analogue as described herein may be one or more of gemcitabine, azacitidine, cytarabine, decitabine or troxacitabine. In one embodiment, there is provided a composition or kit comprising an anti-GREM1 antagonist and gemcitabine or a derivative thereof. Also encompassed within the invention is a composition or kit comprising an anti-GREM1 antagonist and Capecitabine or a derivative thereof. A derivative of gemcitabine may be any derivative as described above. An anti-GREM1 antagonist may be any anti-GREM1 antagonist as described herein. The composition or kit may be suitable for the treatment of pancreatic cancer.

A composition of kit comprising an anti-GREM1 antagonist and a mitotic inhibitor is also provided. The composition or kit may comprise an anti-GREM1 antagonist and one or more mitotic inhibitors selected from: Cabazitaxel, Docetaxel, Paclitaxel, Vinblastine, Vincristine, Vinorelbine and Abraxane. In a preferred embodiment in the context of pancreatic cancer, the mitotic inhibitor and/or microtubule-stabilizing drug is selected from abraxane and paclitaxel, particularly as part of a composition or kit for treatment of pancreatic cancer. A preferred combination comprises an anti-GREM1 antagonist and Paclitaxel or Abraxane.

A bispecific antibody combining an anti-GREM1 specificity and one of the other above specificities may be provided in a composition or kit as described herein. The anti-GREM1 antagonist in any of the above compositions and kits may preferably be an anti-GREM1 antibody.

### Detection and diagnosis

Based on the correlation between stromal GREM1 and cancer, the present invention also provides for additional means for the prediction of responsiveness of a cancer to a treatment.

The invention provides a method for determining whether or not a patient having or suspected of having or being at risk of developing cancer is likely to respond to a combination treatment with a GREM1 antagonist and a cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, which method comprises measuring stromal and/or epithelial expression of GREM1 in the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the combination.

The invention additionally provides a method for determining whether or not a patient having or suspected of having or being at risk of developing pancreatic cancer is likely to respond to a combination treatment with a GREM1 antagonist and a proliferation-dependent cytotoxic agent, which method comprises measuring stromal and/or epithelial expression of GREM1 in the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the combination.

Predicted responsiveness in an individual to a given therapy means that the individual is expected to derive benefit, or a sufficient extent of benefit, from receiving the therapy. Predicted non-responsiveness in an individual to a therapy means that the individual is not expected to derive benefit, or a sufficient extent of benefit, from receiving the therapy. The method for predicting the response may be carried out before administration of the combination treatment with a GREM1 antagonist and the cytidine analogue or deoxycytidine analogue, such as gemcitabine or a derivative thereof, or a GREM1 antagonist and a proliferation-dependent cytotoxic agent. The prediction may then be taken into account when selecting or recommending a suitable treatment for the individual. Alternatively, the method may be carried out after treatment with the therapy and used to monitor and predict the individual's response to treatment. Typically the method is for predicting whether or not the individual will have a primary response to

treatment with the therapy, i.e. whether or not the individual will respond when first receiving the treatment. In some cases the method is for predicting secondary non-responsiveness, i.e. whether or not an individual who initially responds to treatment will later stop responding to treatment or will respond less well to the treatment.

In some cases, an overexpression of GREM1, as compared with a reference sample or reference level, indicates that the individual will respond to therapy with a combination treatment as described herein. A combination therapy comprising a GREM1 antagonist in combination with a cytidine analogue or deoxycytidine analogue as described herein may then be selected or recommended, and may then further be administered to the individual. A combination therapy comprising a GREM1 antagonist in combination with gemcitabine, or a derivative thereof may then be selected or recommended, and may then further be administered to the individual. Similarly, in the context of pancreatic cancer, a therapy comprising use of a or a GREM1 antagonist in combination with a proliferation-dependent cytotoxic agent may be selected based on the overexpression of GREM1.

In other cases, a decreased or normal level of GREM1, as compared with a reference sample or reference level, indicates that the individual will not respond to therapy with a GREM1 antagonist. A combination therapy comprising a GREM1 antagonist and gemcitabine (or a derivative thereof) or a GREM1 antagonist and a proliferation-dependent cytotoxic agent is then not administered to the individual. Further, a therapeutic treatment other than a combination therapy described herein may be selected or recommended for treatment of the individual, and may then further be administered to the individual.

In all aspects of the invention, an individual having cancer (e.g. pancreatic cancer) or an individual suspected of having the disease or condition and/or an individual at risk of developing the disease or condition may be selected for treatment or identified. For example, the individual may not have been formally diagnosed but may be suspected of having the disease or condition because of the presence of one or more symptoms. The individual may be considered at risk of developing cancer if they have one or more risk factors associated with cancer and/or one or more predispositions which increase their susceptibility to cancer. Risk factors in relation to pancreatic cancer can include familial

pancreatitis caused by mutations in the *PRSS1* gene and inherited genetic mutations such as mutation or mutations in the GREM1 encoding gene, or any other mutation affecting expression of the GREM1 gene.

The following Examples illustrate the invention.

### Examples

#### **Materials and methods**

Test antibody and drug Anti-gremlin-1 antibody - Ab7326 mIgG1 - APP.4405.IgG.mFc - Lot number - PB 4682

Vehicle - Phosphate Buffered Saline pH 7.4 (provided by the Beatson Institute)

Gemcitabine - (provided by the Beatson Institute, purchased from LC Labs, Woburn, MA, USA) in Phosphate Buffered Saline pH 7.4.

#### *Genetically Modified Mice*

LSL-Kras<sup>G12D</sup>/+; Trp53<sup>R172H</sup>/+; Pdx1-Cre (KPC) mice have been described previously (Hingorani et al., 2005). Mice were generated by crossing mice bearing Pdx1-Cre, and conditional LSL-KrasG12D or LSL-Trp53R172H alleles (strains 01XJ6 and 01XL9, Mouse Models of Human Cancer Consortium [MMHCC], NCI-Frederick, Frederick, MD, USA). Mice on a mixed background were bred in-house at the CRUK Beatson Institute and maintained in conventional caging with environmental enrichment, access to standard chow and water *ad libitum*. Genotyping was performed by Transnetyx (Cordoba, TN, USA). Mice of both sexes were recruited onto study. All animal experiments were performed under a UK Home Office licence and approved by the University of Glasgow Animal Welfare and Ethical Review Board.

#### *Treatments*

Mice were monitored 3 times weekly until a diagnosis of pancreatic cancer was made by abdominal palpation and confirmed by ultrasound imaging. Mice were randomised onto treatment arms and dosed with: 30mg/kg Ab7326 mIgG1 s.c. twice weekly; 100 mg/kg gemcitabine i.p., twice weekly; 30mg/kg Ab7326 mIgG1 s.c. twice weekly and 100 mg/kg gemcitabine i.p., twice weekly; or PBS vehicle control twice weekly. There were  $\geq 5$  mice per group. Mice were monitored daily and sacrificed when reaching ethical endpoint (symptoms include abdominal distension, cachexia, intermittent hunching or reduced mobility, piloerection, mild diarrhoea, anaemia). Statistical assessment of survival from start of treatment was carried out by Kaplan-Meier and Log-Rank analysis.

#### *Ultrasound Imaging*

The VisualSonics Vevo 3100 preclinical imaging platform (FUJIFILM VisualSonics, Toronto, Canada) was used for high-resolution ultrasound imaging to confirm tumour diagnosis and for weekly monitoring of tumour progression. Anaesthesia was induced and maintained with a mixture of isoflurane and medical air. Tumour volume was calculated weekly for each mouse and plotted longitudinally.

#### *Sampling*

Mice were culled by Schedule 1 method, as per Institutional guidelines. Post-mortem tumour burden was assessed by gross pathology and histology. Organs were removed and fixed in 10% buffered formalin. Terminal blood was sampled where possible. The majority of the tumour was fixed in 10% buffered formalin for FFPE processing, and any remainder harvested into RNAlater® (Sigma-Aldrich) for RNA prep and/or flash frozen. Fixed tissues were paraffin embedded and 5  $\mu\text{m}$  sections placed on poly-L-lysine slides for IHC analysis.

#### *Histology and Immunohistochemistry*

H&E and Picrosirius red staining was carried out on formalin-fixed, paraffin-embedded tissues as described previously. Immunohistochemistry was performed using standard protocols. Briefly, formalin-fixed paraffin-embedded sections were deparaffinized and rehydrated by passage through Xylene and a graded alcohol series. Endogenous peroxidase



activity was inactivated by treatment with hydrogen peroxide, after which citrate buffer antigen retrieval was performed. Sections were blocked in serum, and then incubated with primary antibody. Sections were incubated in secondary antibody for 30 minutes and staining visualized with 3,3'-diaminobenzidine tetrahydrochloride. Primary antibodies used were anti-Ki67 (SP6, ThermoFisher) 1:200, anti-cleaved caspase 3 (ASP175, Cell Signaling) 1:50, and anti-alpha-SMA (1A4, Sigma-Aldrich) 1:20,000).

### Example 1: Confirmation of *Grem1* mRNA expression in pancreatic cancer

In order to investigate whether gremlin-1 might play a role in pancreatic cancer, *Grem1* mRNA expression, as determined by RNAseq analysis, was determined in a cohort of human pancreatic ductal adenocarcinoma (PDAC) patients. This confirmed that *Grem1* mRNA was expressed in human PDAC, and that high expression was significantly associated with poor prognosis (Figure 1). The results were consistent with a published study reporting a link between *Grem1* expression and poor outcome in pancreatic cancer (Yu et al., 2018).

To determine whether *grem1* mRNA was expressed in the KPC genetically engineered mouse model of pancreatic cancer, gene expression was examined in KPC tumours (and other autochthonous pancreatic cancer models) and compared to control KrasG12D-expressing normal pancreatic duct epithelium. The results indicate that *grem1* mRNA expression was elevated in KPC tumours (and other murine pancreatic tumours) compared with control (Table 1).

**Table 1**

Gene Symbol	Gene Title	KPC tumour vs. pancreatic duct cells (fold change)	p-value	All mouse PDAC vs. pancreatic duct cells (fold change)	p-value
<i>grem1</i>	gremlin 1	5.5	$4.0 \times 10^{-3}$	6.4	$4.1 \times 10^{-3}$

**Example 2: Treatment with a combination of Ab7326 mIgG1 and gemcitabine results in improved survival in a KPC mouse model compared to treatment with vehicle controls or Ab7326 mIgG1 and gemcitabine as single agents**

A pilot experiment in healthy littermate mice was performed, in line with local requirements, to ensure tolerability of the dose and schedule provided. No adverse effects were observed.

Next, the efficacy of gremlin-1 inhibition as a potential therapeutic approach for pancreatic cancer was tested in the KPC model. KPC mice develop tumours that are similar to human pancreatic tumours in terms of both histology and pathology. In addition, the tumours are extremely aggressive, often metastatic and highly chemo-resistant, again mimicking human pancreatic cancer. A cohort of KPC mice was established and mice were monitored until they developed pancreatic cancer detectable by palpation. The breeding strategy required to generate these mice, and the experimental design is shown in Figure 2.

Mice were monitored at least weekly by palpation until pancreatic tumours were detectable. At this time, high resolution ultrasound imaging was used to confirm the presence of pancreatic cancer, and mice were enrolled into cohorts for treatment with the anti-Gremlin1 antibody Ab7326 mIgG1, standard of care chemotherapy Gemcitabine, Ab7326 mIgG1 + Gemcitabine in combination, or vehicle control (detailed in Table 2). High resolution ultrasound imaging was performed weekly over the treatment period in order to monitor the tumour burden of each individual mouse on treatment. Mice remained on study and were closely monitored until ethical endpoint was reached, at which time they were sacrificed as per institutional guidelines. Clinical features displayed included abdominal distension, loss of body conditioning indicative of cachexia, reduced mobility and occasionally jaundice.

**Table 2**

TREATMENT	Dose	Schedule	n = (censored)	Median (days)
<b>Ab7326 mIgG1</b>	30mg/kg s.c.	twice weekly	7 (2)	26
<b>Vehicle (PBS)</b>	na	twice weekly	7 (1)	20
<b>Gemcitabine</b>	100mg/kg i.p.	twice weekly	5	24
<b>Ab7326 mIgG1 + Gemcitabine</b>	30mg/kg s.c. 100mg/kg i.p.	twice weekly twice weekly	6 (1)	37

Analysis of 3D tumour imaging by ultrasound revealed that there was no tumour shrinkage or stasis in any treatment arm (Figure 3). However, mice treated with the combination of Ab7326 mIgG1 and gemcitabine showed a significant increase in median survival (37 days) compared with vehicle controls (20 days, Log Rank,  $p=0.037$ , see Figure 4, Table 2, and data for individual mice in Table 3). Mice treated with the combination of Ab7326 mIgG1 and gemcitabine also exhibited increased survival compared with those treated with either Ab7326 mIgG1 (median survival 26 days, n.s.), or gemcitabine (median survival 24 days, n.s.) as single agents. The negligible benefit from gemcitabine monotherapy is in line with recent studies. (Olive et al., 2009; Frese et al., 2012; Provenzano et al., 2012).

**Table 3**

Mouse ID	Days on Rx	Censored (= 0)			
		Ab7326	Vehicle	Gemcitabine	Ab7326 + Gemcitabine
<b>NKD141.9e</b>	26	1			
<b>NKD158.3i *</b>	85	0			
<b>NKD142.9f</b>	12	1			
<b>NKD168.2l</b>	33	1			
<b>NKD154.4b</b>	24	0			
<b>NKD154.4g</b>	13	1			
<b>NKD154.5b</b>	9	1			
<b>NKD169.1c</b>	3		1		
<b>NKD159.3b</b>	16		1		
<b>NKD167.2e</b>	29		1		
<b>NKD142.9c</b>	27		1		
<b>NKD167.3e</b>	20		1		

<b>NKD161.4b</b>	16		1		
<b>NKAG81.9d</b>	23		0		
<b>NKD140.10e</b>	3			1	
<b>NKD169.1d</b>	34			1	
<b>NKD164.2f</b>	24			1	
<b>NKD165.2d</b>	44			1	
<b>NKD148.5d</b>	17			1	
<b>NKD134.9c</b>	23				1
<b>NKD157.3d</b>	20				1
<b>NKD162.2d</b>	38				1
<b>NKD164.2c *</b>	93				0
<b>NKD143.8d</b>	35				1
<b>NKD154.4h</b>	57				1

Following sacrifice of experimental mice, examination of gross pathology did not reveal any differences in tumour burden or phenotype between different experimental conditions. Immunohistochemical (IHC) analysis was performed on formalin-fixed paraffin-embedded tumour tissue to assess tumour cell proliferation (Ki67) and apoptosis (cleaved caspase 3). We also performed IHC- based analysis of the tumour microenvironment to assess any changes in the number of alpha-SMA-positive tumour-associated fibroblasts or in the quality or quantity of collagen I and III (as measured by picrosirius red staining). The staining did not reveal any obvious impact on any of these parameters in any of the regimens tested (data not shown).

## **Results**

In summary, Gremlin-1 represents a valid target for the treatment of pancreatic cancer and the results presented herein demonstrate that Ab7326 mIgG1 can be given safely to KPC mice, as a single agent, and in combination with gemcitabine. A significant improvement in survival was observed when mice were treated with a combination of Ab7326 mIgG1 and gemcitabine compared to vehicle control (Figure 4, 9 Table 2, and data for individual mice in Table 3).

**Aspects of the invention**

1. An anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer, wherein the method further comprises administering a cytidine analogue or deoxycytidine analogue.
2. The anti-GREM1 antagonist for use according to aspect 1, wherein the cancer is a solid cancer.
3. The anti-GREM1 antagonist for use according to aspect 1 or aspect 2, wherein the cancer has stromal GREM1 overexpression
4. The anti-GREM1 antagonist for use according to any one of the preceding aspects, wherein the cancer is a metastatic cancer.
5. The anti-GREM1 antagonist for use according to any one of the preceding aspects, wherein the cancer comprises dormant cancer cells, optionally dormant stem-like cancer cells.
6. The anti-GREM1 antagonist for use according to any one of the preceding aspects, wherein the cancer is a recurring cancer and/or wherein said method is for preventing relapse of a cancer.
7. The anti-GREM1 antagonist for use according to any one of the preceding aspects, wherein the cancer is a cancer that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or deoxycytidine analogue.
8. The anti-GREM1 antagonist for use according to aspect 7, wherein the cancer is a cancer that is poorly responsive, non-responsive or refractory to treatment with gemcitabine, or a derivative thereof.
9. The anti-GREM1 antagonist for use according to any one of the preceding aspects, wherein the cancer is selected from colorectal cancer, multiple myeloma, pancreatic cancer, bladder cancer, breast cancer, lung cancer, stomach cancer,

duodenal cancer, oesophageal cancer, head and neck cancer, prostate cancer, glioma, endometrial cancer, ovarian cancer, liver cancer, spleen cancer, bone-resident cancer, and osteosarcoma.

10. The anti-GREM1 antagonist for use according to aspect 9, wherein the cancer is pancreatic cancer.

11. The anti-GREM1 antagonist for use according to aspect 10, wherein the pancreatic cancer is an exocrine pancreatic cancer.

12. The anti-GREM1 antagonist for use according to aspect 10 or aspect 11, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC).

13. The anti-GREM1 antagonist for use according to aspect 9, wherein the cancer is lung cancer.

14. The anti-GREM1 antagonist for use according to aspect 13, wherein the cancer is non-small cell lung cancer.

15. The anti-GREM1 antagonist for use according to aspect 9, wherein the cancer is bladder cancer.

16. The anti-GREM1 antagonist for use according to aspect 9, wherein the cancer is breast cancer.

17. The anti-GREM1 antagonist for use according to aspect 9, wherein the cancer is ovarian cancer.

18. The anti-GREM1 antagonist for use according to any one of the preceding aspects, wherein the cancer has epithelial GREM1 overexpression.

19. The anti-GREM1 antagonist for use according to aspect 18, wherein the cancer is a GREM1-initiated cancer.

20. The anti-GREM1 antagonist for use according to any one of the preceding aspects, wherein the cancer is a disseminated cancer.
21. The anti-GREM1 antagonist for use according to any one of the preceding aspects, wherein the cancer is an established cancer.
22. The anti-GREM1 antagonist for use according to any one of aspects 1 to 21, wherein the cytidine analogue or deoxycytidine analogue is gemcitabine, or a derivative thereof.
23. The anti-GREM1 antagonist for use according to any one of aspects 1 to 21, wherein the cytidine analogue or deoxycytidine analogue is azacitidine, or a derivative thereof.
24. The anti-GREM1 antagonist for use according to any one of aspects 1 to 21, wherein the cytidine analogue or deoxycytidine analogue is cytarabine, or a derivative thereof.
25. The anti-GREM1 antagonist for use according to any one of aspects 1 to 21, wherein the cytidine analogue or deoxycytidine analogue is decitabine, or a derivative thereof.
26. The anti-GREM1 antagonist for use according to any one of aspects 1 to 21, wherein the cytidine analogue or deoxycytidine analogue is troxacitabine, or a derivative thereof.
27. An anti-GREM1 antagonist for use in a method for the treatment or prevention of pancreatic cancer, wherein the method further comprises administering a proliferation-dependent cytotoxic agent.
28. The anti-GREM1 antagonist for use according to aspect 27, wherein the pancreatic cancer is an exocrine pancreatic cancer.
29. The anti-GREM1 antagonist for use according to aspect 27 or aspect 28, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC).
30. The anti-GREM1 antagonist for use according to any one of aspects 27 to 29, wherein the pancreatic cancer is metastatic pancreatic cancer.

31. The anti-GREM1 antagonist for use according to any one of aspects 27 to 30, wherein the pancreatic cancer is recurrent pancreatic cancer.

32. The anti-GREM1 antagonist for use according to any one of aspects 27 to 31, wherein the pancreatic cancer is a pancreatic cancer that is poorly responsive, non-responsive or refractory to treatment with a proliferation-dependent cytotoxic agent

33. The anti-GREM1 antagonist for use according to any one of aspects 27 to 32, wherein the proliferation-dependent cytotoxic agent is a nucleoside inhibitor or an antimetabolite.

34. The anti-GREM1 antagonist for use according to any one of aspects 27 to 32, wherein the proliferation-dependent cytotoxic agent is a cytidine analogue or deoxycytidine analogue.

35. The anti-GREM1 antagonist for use according to any one of aspects 27 to 32, wherein the proliferation-dependent cytotoxic agent is a mitotic inhibitor.

36. The anti-GREM1 antagonist for use according to aspect 35, wherein the mitotic inhibitor is a microtubule-stabilizing drug.

37. The anti-GREM1 antagonist for use according to aspect 35 or 36, wherein the mitotic inhibitor and/or microtubule stabilizing drug is selected from abraxane and paclitaxel.

38. The anti-GREM1 antagonist for use according to any one of aspects 27 to 33, wherein the proliferation-dependent cytotoxic agent comprises one or more of oxaliplatin, folinic acid, irinotecan and fluorouracil; optionally wherein the proliferation-dependent cytotoxic agent is FOLFIRINOX or FOLFOX.

39. The anti-GREM1 antagonist for use according to any one of aspects 27 to 32, wherein the proliferation-dependent cytotoxic agent is:

(a) gemcitabine or a derivative thereof;



- (b) azacitidine or a derivative thereof;
- (c) cytarabine or a derivative thereof;
- (d) decitabine or a derivative thereof;
- (e) troxacitabine or a derivative thereof; or
- (f) capecitabine.

40. The anti-GREM1 antagonist for use according to any one of the preceding aspects, wherein the antagonist is a peptide, a protein, an antibody, a polynucleotide, an oligonucleotide, an antisense RNA, a small interfering RNA (siRNA), a small molecule inhibitor or a small hairpin RNA (shRNA).

41. The anti-GREM1 antagonist for use according to aspect 40, wherein the antagonist is an antibody which binds to an epitope on Gremlin-1 comprising at least one residue selected from Ile131, Lys147, Lys148, Phe149, Thr150, Thr151, Arg169, Lys174 and Gln175, wherein the residue numbering is according to SEQ ID NO: 1.

42. The anti-GREM1 antagonist for use according to aspect 41, wherein the antibody binds an epitope comprising all of Ile131, Lys147, Lys148, Phe149, Thr150, Thr151, Arg169, Lys174 and Gln175.

43. The anti-GREM1 antagonist for use according to aspect 41 or 42, wherein Lys147, Lys148, Phe149, Thr150, Thr151, Arg169, Lys174 and Gln175 are located on the same Gremlin-1 monomer and Ile131 is located on the second Gremlin-1 monomer.

44. The anti-GREM1 antagonist for use according to aspect 40, wherein the antagonist is an anti-Gremlin-1 antibody which comprises heavy chain complementarity determining region (HCDR) sequences contained within a heavy chain variable region (HCVR) of SEQ ID NO: 10 or 12 and/or light chain

complementarity determining region (LCDR) sequences contained within a light chain variable region (LCVR) of SEQ ID NO: 11 or 13.

45. The anti-GREM1 antagonist for use according to aspect 40, wherein the antagonist is an anti-Gremlin-1 antibody which comprises at least one HCDR sequence selected from SEQ ID NOs: 3, 4, 5 and 6 and/or at least one LCDR sequence selected from SEQ ID NOs: 7, 8 and 9.

46. The anti-GREM1 antagonist for use according to aspect 45, wherein the anti-Gremlin-1 antibody comprises a HCDR3 sequence of SEQ ID NO: 6.

47. The anti-GREM1 antagonist for use according to aspect 45 or 46, wherein the anti-Gremlin-1 antibody comprises an HCDR1/HCDR2/HCDR3 sequence combination selected from SEQ ID NOs: 4/5/6 or from SEQ ID NOs: 3/5/6 and/or an LCDR1/LCDR2/LCDR3 sequence combination selected from SEQ ID NOs: 7/8/9.

48. The anti-GREM1 antagonist for use according to any one of aspects 45 to 47, wherein the anti-Gremlin-1 antibody comprises a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9.

49. The anti-GREM1 antagonist for use according to any one of aspects 45 to 48, wherein the anti-Gremlin-1 antibody comprises a heavy chain variable region (HCVR) sequence of SEQ ID NO: 10 or 12 and/or a light chain variable region (LCVR) sequence of SEQ ID NO: 11 or 13, or sequences which are at least 95% identical thereto.

50. The anti-GREM1 antagonist for use according to aspect 49, wherein the anti-Gremlin-1 antibody comprises a HCVR and LCVR sequence pair of SEQ ID NOs: 10/11 or 12/13 or sequences which are at least 95% identical thereto.

51. The anti-GREM1 antagonist for use according to aspect 50, wherein the anti-Gremlin-1 antibody comprises HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequences consisting of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9 and the remainder of the HCVR and LCVR comprise at least 95% identity to SEQ ID NOs: 10, 11, 12 and/or 13 respectively.

52. The anti-GREM1 antagonist for use according to aspects 49-51, wherein the anti-Gremlin-1 antibody comprises a heavy chain of SEQ ID NO: 14, 16, 18, 22, 28, 30, 32 or 34 and/or a light chain of SEQ ID NO: 15, 17, 19, 23, 29, 31, 33 or 35, or sequences which are at least 95% identical thereto.

53. The anti-GREM1 antagonist for use according to aspect 52, wherein the anti-Gremlin-1 antibody comprises a heavy and light chain pair of SEQ ID NOs: 14/15, 16/17, 18/19, 22/23, 28/29 or 30/31, 32/33, 34/35, or sequences which are at least 95% identical thereto.

54. The anti-GREM1 antagonist for use according to aspect 53, wherein the HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequences of the antibody consist of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9 and the remainder of the heavy and light chains comprise at least 95% identity to SEQ ID NOs: 14, 15, 16 and/or 17 respectively.

55. The anti-GREM1 antagonist for use according to aspect 40, wherein the antagonist is an antibody which competes for binding to Gremlin-1 with an antibody as defined in any one of aspects 42-52.

56. The anti-GREM1 antagonist for use according to aspect 40, wherein the antagonist is an antibody which binds the same epitope on Gremlin-1 as an antibody defined in any one of aspects 42-52.

57. The anti-GREM1 antagonist for use according to any one of aspects 40-56, wherein the antagonist antibody is a chimeric, human or humanised antibody.

58. The anti-GREM1 antagonist for use according to any one of aspects 40-57, wherein the antagonist antibody is a Fab, modified Fab, Fab', modified Fab', F(ab')<sub>2</sub>, Fv, single domain antibody or an scFv.

59. The anti-GREM1 antagonist for use according to aspect 40, wherein the antagonist is a polynucleotide encoding an antibody as defined in any one of aspects 41-58, or an expression vector carrying said polynucleotide.

60. The anti-GREM1 antagonist for use according to any one of aspects 40-58, wherein the antagonist antibody is comprised in pharmaceutical composition further comprising a pharmaceutically acceptable adjuvant and/or carrier.

61. The anti-GREM1 antagonist for use according to any one of the preceding aspects, wherein the method further comprises administering an additional anti-cancer agent.

62. The anti-GREM1 antagonist for use according to aspect 61, wherein the method comprises administering gemcitabine in combination with a further cytidine analogue or deoxycytidine analogue.

63. The anti-GREM1 antagonist for use according to aspect 61 or 62, wherein the method comprises administering gemcitabine in combination with troxacitabine.

64. A cytidine analogue or deoxycytidine analogue for use in a method for the treatment or prevention of cancer wherein the method further comprises administering an anti-GREM1 antagonist.

65. The cytidine analogue or deoxycytidine analogue for use according to aspect 64, wherein said cancer, said antagonist, said cytidine analogue or deoxycytidine analogue and/or said method are as defined in any one of aspects 1-26 and 40 to 63.

66. A method of treating cancer comprising administering a therapeutically effective amount of an anti-GREM1 antagonist in combination with a therapeutically effective amount of a cytidine analogue or deoxycytidine analogue to a subject in need thereof.

67. The method according to aspect 66, wherein said cancer, said antagonist, said cytidine analogue or deoxycytidine analogue and/or said method are as defined in any one of aspects 1-26 and 40 to 63.

68. A proliferation-dependent cytotoxic agent for use in a method for the treatment or prevention of pancreatic cancer, wherein the method further comprises administering an anti-GREM1 antagonist.

69. The proliferation-dependent cytotoxic agent for use according to aspect 68, wherein said proliferation-dependent cytotoxic agent, said pancreatic cancer, said antagonist and/or said method are as defined in any one of aspects 27 to 63.

70. A method of treating pancreatic cancer comprising administering a therapeutically effective amount of an anti-GREM1 antagonist in combination with a therapeutically effective amount of a proliferation-dependent cytotoxic agent.

71. The method according to aspect 70, wherein said proliferation-dependent cytotoxic agent, said pancreatic cancer, said antagonist and/or said method are as defined in any one of aspects 27 to 63.

72. A composition or kit comprising an anti-GREM1 antagonist and a cytidine analogue or deoxycytidine analogue.

73. The composition or kit according to aspect 72, wherein the cytidine analogue or deoxycytidine analogue is as defined in any one of aspects 22 to 26.

74. A composition or kit comprising:  
an anti-GREM1 antagonist and a mitotic inhibitor.

75. The composition or kit according to aspect 74, wherein the mitotic inhibitor is as defined in any one of aspects 36 or 37.

76. The composition or kit according to any one of aspects 72 to 75, wherein the anti-GREM1 antagonist is as defined in any one of aspects 40 to 59.

77. A method for determining whether or not a patient having or suspected of having or being at risk of developing cancer is likely to respond to a combination treatment with a GREM1 antagonist and a cytidine analogue or deoxycytidine analogue, which method comprises measuring stromal and/or epithelial expression of GREM1 in the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the combination.

78. A method for determining whether or not a patient having or suspected of having or being at risk of developing pancreatic cancer is likely to respond to a combination treatment with a GREM1 antagonist and a proliferation-dependent cytotoxic agent, which method comprises measuring stromal and/or epithelial expression of GREM1 in the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the combination.

**SEQUENCE LISTING****SEQ ID NO: 1 (Human Gremlin-1; Uniprot ID: O60565)**

MSRTAYTVGALLLLGTLPAEAGKKKGSQGAIPPPDKAQHNDSEQTQSPQQPGRNRGRGQGRGTAMPGEEV  
 LESSQEALHVTERKYLKRDWCKTQPLKQTIHEEGNSRTIINRFQYGCNSFYIPRHIRKEEGSFQSCSFCKP  
 KKFTTMMVTLNCPQLPPTKKKRVTRVKQCRCSIDL

**SEQ ID NO: 2 (Human truncated Gremlin-1 used in crystallography with N-terminal tag)**

MGSSHHHHHSSGENLYFQGSAMPGEEVLESSQEALHVTERKYLKRDWCKTQPLKQTIHEEGNSRTIINRFQ  
 YGCNSFYIPRHIRKEEGSFQSCSFCKPCKFTTMMVTLNCPQLPPTKKKRVTRVKQCRCSIDL

**SEQ ID NO: 3 (Ab7326 HCDR1 combined Kabat & Chothia)**

GYTFTDYMH

**SEQ ID NO: 4 (Ab7326 HCDR1 Kabat)**

DYYMH

**SEQ ID NO: 5 (Ab7326 HCDR2 Kabat)**

LVDPEDGETIYAEKFQG

**SEQ ID NO: 6 (Ab7326 HCDR3 Kabat)**

DARGSGSYYPNHFDY

**SEQ ID NO: 7 (Ab7326 LCDR1 Kabat)**

KSSQSVLYSSNNKNYLA

**SEQ ID NO: 8 (Ab7326 LCDR2 Kabat)**

WASTRES

**SEQ ID NO: 9 (Ab7326 LCDR3 Kabat)**

QQYYDTPT

**SEQ ID NO: 10 (Ab7326 Heavy chain variable region variant 1)**

QVQLVESGAEVKKPGATVKISCKVSGYTFDYMHVWQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITAD  
 TSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGTLLVTVSS

**SEQ ID NO: 11 (Ab7326 Light chain variable region variant 1)**

DIVMTQSPDLSAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGS  
 GTDFTLTINSLQAEDVAVYFCQQYYDTPTFGQGTTRLEIK

**SEQ ID NO: 12 (Ab7326 Heavy chain variable region variant 2)**

QVQLVQSGAEVKKPGATVKISCKVSGYTFDYMHVWQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITAD  
 TSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGTLLVTVSS

**SEQ ID NO: 13 (Ab7326 Light chain variable region variant 2)**

DIVMTQTPDLSAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGS  
 GTDFTLTINSLQAEDVAVYFCQQYYDTPTFGQGTTRLEIK

**SEQ ID NO: 14 (Mouse full length IgG1 heavy chain variant 1)**

QVQLVESGAEVKKPGATVKISCKVSGYTFDYMHVWQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITAD  
 TSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGTLLVTVSSAKTTPPSVYPLAPGSAQTNSM  
 VTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSSETVTCNVAHPASSTKVDK  
 KIVPRDCGCKPCICTVPEVSSVFIFFPKPKDVLTIITLTPKVTICVVDISKDDPEVQFSWFVDDVEVHTAQTQP  
 REEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVS

LTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLVNQKSNWEAGNTFTCSVLHEGLHNHHT  
EKSLSHSPGK

**SEQ ID NO: 15 (Mouse full length IgG1 light chain variant 1)**

DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGS  
GTDFTLTINSLQAEDVAVYFCQQYYDTPFTFGQGRLEIKRTDAAPTVISIFPPSSEQLTSGGASVVCFLNNFYF  
KDINVKWKIDGSRQNGVLNSWTDQDSKDYSTYSMSSTLTTLTKDEYERHNSYTCETHKTSTSPIVKSFNREK

**SEQ ID NO: 16 (Human full length IgG1 heavy chain variant 2)**

QVQLVQSGAEVKKPGATVKISCKVSGYTFDTYYMHVWQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITAD  
TSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGT  
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVD  
KKVEPKSCDKTHTCPPCPAPELGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH  
NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL  
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVVFSCVMHEA  
LHNHYTQKSLSLSPGK

**SEQ ID NO: 17 (Human full length IgG1 light chain variant 2)**

DIVMTQTPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGS  
GTDFTLTINSLQAEDVAVYFCQQYYDTPFTFGQGRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCFLNNFYF  
REAKVQWKVDNALQSGNSQESVTEQDSKDYSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

**SEQ ID NO: 18 (Fab heavy chain variant 1)**

QVQLVSGAEVKKPGATVKISCKVSGYTFDTYYMHVWQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITAD  
TSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGT  
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVD  
KKVEPKSC

**SEQ ID NO: 19 (Fab light chain variant 1)**

DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGS  
GTDFTLTINSLQAEDVAVYFCQQYYDTPFTFGQGRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCFLNNFYF  
REAKVQWKVDNALQSGNSQESVTEQDSKDYSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

**SEQ ID NO: 20 (Human truncated Gremlin-1 used in crystallography without N-terminal tag)**

AMPGEEVLESSQEALHVTERKYLKRDWCKTQPLKQTIHEEGNSRTIINRFYCYGQCNSFYIPRHIRKEEGSFQ  
SCSFCKPKKFTTMMVTLNCPQLQPPTKKKRVTRVKQCRCSIDL

**SEQ ID NO: 21 (Mature Gremlin-1 sequence of SEQ ID NO: 1 lacking the signal peptide of amino acids 1-21)**

KKKGSQGAIPPPDKAQHNDSEQTQSPQQPGSRNRGRGQGRGTAMPGEEVLESSQEALHVTERKYLKRDWCKTQ  
PLKQTIHEEGNSRTIINRFYCYGQCNSFYIPRHIRKEEGSFQSCSFCKPKKFTTMMVTLNCPQLQPPTKKKRV  
TRVKQCRCSIDL

**SEQ ID NO: 22 (Human IgG4P heavy chain variant 1)**

QVQLVSGAEVKKPGATVKISCKVSGYTFDTYYMHVWQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITAD  
TSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGTLLVTVSSASTKGPSVFPLAPCSRSTSEST  
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVD  
KRVESKYGPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAK  
TKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKN  
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVVFSCVMHEALHN  
HYTQKSLSLSLGK

**SEQ ID NO: 23 (Human IgG4P light chain variant 1)**

DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGS



GTDFTLTIINSLQAEDVAVYFCQQYYDTPTFGQGRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYP  
REAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

**SEQ ID NO: 24 (Human IgG1 heavy chain DNA variant 1)**

caagtgcaactggtggaatccggggccgaagtgaaaaagcccgagccactgtgaagatctcttgcaaatgtg  
ccggctacaccttcaccgactattacatgactgggtccagcaggcacctgggaagggccttgagtggatggg  
tctggatcgatcccgaggacggcgaaaactatctacgcccgagaagtccagggtcgcgtcaccatcaccgcccac  
acttccaccgacaccgctacatggagctgtccagcttgaggtccgaggacacagccgtgtactactgcccga  
cggatgctcggggaagcggcagctactaccgaaccacttcgactactggggacagggcactctcgtgactgt  
ctcgagcgcttctacaaaagggccctccgtgttcccgctcgcctccatcatcgaagtctaccagcggaggcact  
gcggtctcgggtgctcgtgaaggactacttccggagccggtgaccgtgtcgtggaacagcggagccctga  
ccagcgggggtgcacaccttccggccgtcttgactcaagcggcctttactccctgtcatcagtggtgactgt  
cccgtccagctcattgggaacccaaacctacatctgcaatgtgaatcacaacctagcaacaccaaggttgac  
aagaaagtgcagcccaaatcgtgtgacaagactcacactgtccgcccgtgcccggcaccgaaactgctgggag  
gtcccagcgtcttctgttccctccaaagccgaaagacacgctgatgatctcccgcaccccgagggtcacttg  
cgtggtcgtggacgtgtcacatgaggaccagaggtgaagttcaattggtagctggatggcgtcgaagtccac  
aatgccccaaactaagcccagagaagaacagtaacaattcgacctaccgctcgtgtccggtcctcaggtgtgc  
atcaggattggctgaaacgggaaggaatacaagtgcgaagtgtccaacaaggcgtgcccggcaccgatcgagaa  
aactatctccaaagcgaaggacagcctaggaacctcaagtctacacgctgccaccatcacgggatgaactg  
actaagaatcaagtctcactgacttgtctggtgaaggggttttaccctagcgcattgcccgtggagtgggaat  
ccaacggccagccagagaaactacaagactaccctccagtgctcgcactcggatggatcgttcttcccttta  
ctcgaagctcaccgtggataagtcccgggtggcagcagggaaactgttctcctgctcgggtgatgcatgaagcc  
ctccataaccactatacccaaaagtgcgtgtccctgtcgcgggaaag

**SEQ ID NO: 25 (Human IgG1 light chain DNA variant 1)**

gacattgtgatgacccagtcctccgattcgccttgccggtgtccctgggagaaacggggccaccattaactgcaaga  
gctcacagtcctgctcctgtattcatcgaacaacaagaattacctcgcattggtatcagcagaagcctggacagcc  
tcccgaagctgctcatctactgggctagcaccgcgcaatccgggggtgccggatagattctccggatcgggttcg  
ggcactgacttcaactctgactatcaactcactgcaagccgaggatgtcgcgggtgacttctgtcagcagact  
acgacacccccgaccttggacaaggcaccagactggagattaagcgtacgggtggccgctccctccggtgttcat  
cttcccacccctccgacgagcagctgaagtccggcaccgctccgctcgtgtgctgctgaacaacttctacccc  
cgcgaggccaaggtgcagtggaaggtggacaacgcccctgcagtcgggcaactccaggaatcgtcaccgagc  
aggactccaaggacagcactactccctgtcctccaccctgacctgtccaaggccgactacgagaagcaca  
gggtgacgcctgcgaagtgaccaccagggcctgtccagccccgtgaccaagtcttcaaccggggcgagtgc

**SEQ ID NO: 26 (Human IgG4P heavy chain DNA variant 1)**

caagtgcaactggtggaatccggggccgaagtgaaaaagcccgagccactgtgaagatctcttgcaaatgtg  
ccggctacaccttcaccgactattacatgactgggtccagcaggcacctgggaagggccttgagtggatggg  
tctggatcgatcccgaggacggcgaaaactatctacgcccgagaagtccagggtcgcgtcaccatcaccgcccac  
acttccaccgacaccgctacatggagctgtccagcttgaggtccgaggacacagccgtgtactactgcccga  
cggatgctcggggaagcggcagctactaccgaaccacttcgactactggggacagggcactctcgtgactgt  
ctcgagcgcttctacaaaagggccctccgtgttccctctggcccttgcctccgggtccacctccgagtctacc  
gccgctctgggctgctgggtcaaggactacttccccgagcccgtagcagtgctcctggaactctggcgcctga  
cctccggcgtgcacaccttccctgcccgtgctgcagtcctccggcctgtactccctgtcctccgtcgtgaccgt  
gccctcctccagcctgggacccaagacctacacctgtaacgtggaccacaagccctccaacaccaaggtggac  
aagcgggtggaatctaagtacggccctcctgccccccctgcccctgcccctgaatttctgggcccagccttccg  
tgttccctgttcccccaaaagcccaaggacacctgatgatctccggacccccgaagtgacctgctggtggt  
ggacgtgtcccaggaagatcccaggtccagttcaattggtagctggacggcgtggaagtgcacaatgccaag  
accaagcccagagaggaacagttcaactccacctaccgggtggtgtccgtgctgacctgctgaccaggact  
ggctgaacggcaagagatcaagtgcagggtgtccaacaagggcctgcccctccagcatcgaagaaagaccatctc  
caaggccaagggccagccccgcgagccccaggtgtacacctgccccctagccaggaagagatgaccaagaac  
caggtgtcctgacctgtctggtcaagggcttctacccctccgacattgcccgtggaattgggagttccaacggcc  
agccccgagaacaactacaagaccacccccctgtgctggacagcagcgtccttctcctgactctcggct  
gaccgtggacaagtcccgggtggcaggaaggcaacgtcttctcctgctccgtgatgacagggccctgcacaac

cactacacccagaagtccctgtccctgagcctgggcaag

**SEQ ID NO: 27 (Human IgG4P light chain DNA variant 1)**

gacattgtgatgaccagtcctcccgattcgccttgcgggtgcctcgggagaacggggccaccattaactgcaaga  
gctcacagtcctgcctgtattcatcgaacaacaagaattacctcgcatggatcagcagaagcctggacagcc  
tcccaagctgctcatctactgggctagcaccgcgaatccgggggtgccggatagattctccggatcgggttcg  
ggcactgacttcaactctgactatcaactcactgcaagccgaggatgtcgcgggtgacttctgtcagcagta  
acgacaccccgaccttggacaaggcaccagactggagattaagcgtacgggtggccgctccctccgtgttcat  
cttcccaccctccgacgagcagctgaagtccggcaccgctccgtcgtgtgcctgctgaacaacttctacccc  
cgcgaggccaaggtgcagtggaaggtggacaacgcccctgcagtcgggcaactcccaggaatccgtcaccgagc  
aggactccaaggacagcactactcctgtcctccaccctgacctgtccaaggccgactacgagaagcaca  
gggtgtacgcctgcgaagtgaccaccagggcctgtccagcccctgaccaagtccttcaaccggggcgagtg

**SEQ ID NO: 28 (Mouse full length IgG1 heavy chain variant 2)**

QVQLVQSGAEVKKPGATVKISCKVSGYTFDDYMHVWQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITAD  
TSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGLTVTVSSAKTTPPSVYPLAPGSAQTNSM  
VTLGCLVKGYFPEPVTVWNSGSLSSGVHTFPAVLQSDLYTLSSVTVPSSTWPSSETVTCNVAHPASSTKVDK  
KIVPRDCGCKPCICTVPEVSSVFI FPPKPKDVLTIITLTPKVT CVVVDISKDDPEVQFSWFVDDVEVHTAQTQP  
REEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTI PPPKEQMAKDKVS  
LTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLVNPKSNWEAGNTFTCSVLHEGLHNHHT  
EKSLSHSPGK

**SEQ ID NO: 29 (Mouse full length IgG1 light chain variant 2)**

DIVMTQTPDSLAVSLGERATINCKSSQSVLYSSNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGS  
GTDFTLTINSLQAEDVAVYFCQQYYDTPTFGQGRLEIKRTDAAPTVISIFPPSSEQLTSGGASVVCFLNNFYP  
KDINVKWKIDGSRQNGVLNSWTDQDSKDYSTYSMSSTLTTLTKDEYERHNSYTCETHKTSTSPIVKSFNREK

**SEQ ID NO: 30 (Human full length IgG1 heavy chain variant 1)**

QVQLVQSGAEVKKPGATVKISCKVSGYTFDDYMHVWQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITAD  
TSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGLTVTVSSASTKGPSVFLAPSSKSTSGGT  
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVD  
KKVEPKSCDKTHTCPPCPAPELGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH  
NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL  
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRWQQGNVDFCSVMHEA  
LHNHYTQKSLSLSPGK

**SEQ ID NO: 31 (Human full length IgG1 light chain variant 1)**

DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGS  
GTDFTLTINSLQAEDVAVYFCQQYYDTPTFGQGRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYP  
REAKVQWKVDNALQSGNSQESVTEQDSKDYSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

**SEQ ID NO: 32 (Fab heavy chain variant 2)**

QVQLVQSGAEVKKPGATVKISCKVSGYTFDDYMHVWQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITAD  
TSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGLTVTVSSASTKGPSVFLAPSSKSTSGGT  
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVD  
KKVEPKSC

**SEQ ID NO: 33 (Fab light chain variant 2)**

DIVMTQTPDSLAVSLGERATINCKSSQSVLYSSNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGS  
GTDFTLTINSLQAEDVAVYFCQQYYDTPTFGQGRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYP  
REAKVQWKVDNALQSGNSQESVTEQDSKDYSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

**SEQ ID NO: 34 (Human IgG4P heavy chain variant 2)**

QVQLVQSGAEVKKPGATVKISCKVSGYTFDDYMHVWQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITAD

TSTD TAYMELSSLRSEDTAVVYCATDARGSGSYYPNHFDYWGQTLVTVSSASTKGPSVFLAPCSRSTSEST  
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTCNVDHKPSNTKVD  
KRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAK  
TKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIISKAKGQPREPQVYTLPPSQEEMTKN  
QVSLTCLVKGFPYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHN  
HYTQKSLSLSLGK

**SEQ ID NO: 35 (Human IgG4P light chain variant 2)**

DI VMTQTPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGS  
GTDFTLTINSLQAEDVAVYFCQQYDTPTFGQGRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYP  
REAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLTKADYKHKVYACEVTHQGLSSPVTKSFNRGEC

**SEQ ID NO: 36 (Human Gremlin-1; full sequence)**

actcggtagcgccttccgcggaccggcgacccagtgacggccgcgcgctcactctcgggtcccgcctgaccccg  
cgccgagccccggcggctctggccgcggccgcactcagcgccacgcgctcgaaagcgcaggccccgaggacccg  
ccgcactgacaggtgagcgcggacgcacccggcagggatgtgagtgggcggagggaagagggccgcaaacc  
cccaggaccgcctcagttccacgcgcggcagccctccgtgcgcgcaggctcgggtgcgctgttcgcgggggtg  
aattgtgaagaacccatcgcggggtccttccgtgtagggcgcggacaccgtgacctcgtgctctgggtctgc  
agggaaacgtaggaaaaaaagtgtcaggagcgggcaggatgacccccacatcccgtttccacctcccggagg  
ccccgaaacgcctcctgggtgctggtagcagcgcctggcagacgcgcgccttagcaggggcgcgaagtc  
caggccgcagagcgcaggagcatccggacctgctagtgcgcgcgctgactgcgcggcgagtgcccttgagagg  
gtcccatgtgcttggggcgccgcgctgggtctgggggcgctctggggcgcccatggagtcgcgggttgag  
catccggagaatccatgatgtgtgcatttgccgatccccgaggtgagatggagactggcaagggcagagccgc  
tgtgttcagccacagcggaaaaaccgaaacgggtgggtaatccgacagctgcgggtgcggggcgcgccctggccgc  
gggggtccagcgaacccgcagtgctcacaaggcagacaccacacgcgctcgcggaccggccacgcactcgcggg  
cgctcgcttctctactccagcctcttccccgccccgcgcacgcccagctgaatggtagacgttctggcgccg  
ggcagcggccaccggctgggttcccacttccgcgcgcaccccttaaaactgtgttctagaggccccagcctcgc  
ttgcagcgcctcactagctcctgaggactagggactggcggctgaggcgggttggcggctgcaacgagctggg  
cgtcttctgcttctctcgcctgctggctggctccgctggccctccacagcttgcggagcaaggccatagca  
ggggagtgagggtatattggggctgtcacctccttgcctggcggagttattttagactacagactccggaa  
gaacagacgcgcaccgcctctcgttggcattgccttcggatcgcagctcctccttgggggtgcccagcttg  
gctttatttgcctgcgccaggctctggcgacgggtcacccggccaggcggggagggacggacggcagggtgacc  
agcctctgctgtgaagaaatcctgcgcgcggagctgtccctaatgcattcccgggtcgaatccgtctact  
gccttcccctcctcgaccgactccgaatctcggctcttatagacagaaatacagcctcagcgttaggggttaa  
aatccccctcttaaacgggtccgagggcagagaggtgaccaccgataggtaattggatcctcctgctgaaag  
caaatctgagcgggtgcgcgctctgtttatgttccccttcgagatgggtgccaggacgaactgattaaaca  
atctattgtgttaagtgggtcactagggttttaagctgtcccagggaccccagagtagtggttcccttctggc  
tgtacacacaagttaaataaatagcgtagaagaggttaagataacccattctagggtagggagtcctcttct  
atccctagggcttccccctccccttttctcttttttggaggaggggagcatgagagctcttgaggggggga  
tgtacttttcaaagcaaggagggaagatcttaagaaaactatattctcactgcccccaagccaagtcta  
taacagtaggtgatttgattactatctctggataaatggcactgtcaaattgttaataactatctcaggg  
atcttttagcagggtagtgccagatgtgtgcgctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt  
tcattgtaggaattagagctttttgtaaacctttgtaatttcacaggtttcctatctttaaagttcatttt  
tagtgaaatgttttggttaaccacgcctctgtaggaaatccaggttggctaatagcggctcttatgtgagtagt  
acacaggggaaggataaaaaaccttttatgtcctacatctctgaatgagggtgcctaccctgtctttgaaacta  
agccgaagatgccttcagctcgaatggcgaagtataaaagtgataaaatgcaagaaatctcatgccgcaga  
cacctcccccaagaactgcttggtagacagcaagctgtggaacatgtccacaacagagagtaaggacagcc  
aggaaatataaaccttttatgtaaaggaaaggcagggtgggggacagtggttaggggaggtgactgcagcctct  
aaccaaaaggcaaccatcaggcaagtgtaccagcccgtgtcttcgatctgcaaggaatcttcttttagtttta  
acatagctcttagaaattcaaagtacaacaggaatcctgggacaagagaaatctttttattcacatgtgaa  
catgaagatacaaaaatagataaattttttatagactcttcaaattgtattgcattagaaaacatatacc  
atgaccactgttaaggacagcactgggtgtcaataggacagtggttaaggacctgtgtttggggctagata  
gaattgggtttaaactgctggctgggtgggcacagtggtcacaccggtaatcccagcatttgggagcca  
aggaggacggatcacctgagggtcgggagttcgacaccagcctgaccaacatggaaaaatcccgtctctactaa

aaacacaaaattagccaggcatggtggtgcatgacctgcaatcccagctacttgggaggctgaggcaggagaat  
tgcttgaaaccgggaggcggaggttgtggtgagcccagatagcgcattgcattccagcctgggcaacacgag  
tgaaaactccgtcaaaaaaacaaaaaaaacaaaacaaaacaaaaaaatgctggctttccacttatgagctgtg  
tgacctggacaaaattccaacttttctgagtgtagattccctgattggtaaagggaagatgatattatctac  
ctcatattttgttatgaaaaataaatgataaaattgggtcagaaatcagcataatgacctggcacagtaagggc  
ttcaaaaataaaaggtagctcttattattagtaatgggttaggaaaagtagcaatggtatacagaaccaggat  
atcacagggcagttctgaaattaaatcctgaatcctggccgggtgaggtggctcacgcttgtaatcctaag  
cactttcgggagactgaggcaggcggatcacgaggtcaggagtttgagaccagcctggccaacacactgaaatc  
ccgtctctactaaaaatacaaaaattagctgggtggtggcaggcgcctataatctcagctacttgggaggc  
tgaggcaggagaatcacttgagcccaggaggcggaggttgagctgagctgatatcgtgccagtgactccagc  
ctgggtgacatctcttaaaaaaaaaaattcctgaataccacactacgagtgactaacacatctttcactacag  
aacagaacctgtaacttggccgtctctcagcagtgctgctcagtgaaactttaataatttacttttctaac  
tcgtttctgttgacctcaagaattgtacatagtcattaactttcctaagaaaatctttgacaaacatagagc  
tctgagatatttcacaaccagggtggtctcctccctgtcctatgcaatgttgggccccagcctgatttagccg  
acctggtcttcagacttgagaggctgtttagggttcttacaacacaaaaggggatgagactttatcctctacct  
gtgtgccaacaagggttcttctatctccttgggtgcaacttgcctgaaaaagaaagtcaacacaattatctt  
cttaaaagttaaagatcaaattaaaaataagctatagtttcccaaagatttagacctgagaaaaaggaatag  
atctttctaaaacctggcctgcacttagagcatttggtagtcacttccactatttcttatgctgagagaataat  
ttgatgtcatgcctattgaaatgtctttctaaagcttgattcatcaggaggaaactgaccagaagtccatgcaca  
gacatttggctttcactgtaattcctactcaaaactccctttcactgattatgagcaggttgcttagctaaaa  
tgagaaatacagcaagaagaggatggaaagagctggcttaactttcccaaagacatcatgaacactgggaa  
caggtcatacatataccatttttatttctcagtcctcagtagaataattgtgttcttagaggctttgtgaa  
aattggaatacattgccatgacctgcacaggatagagggtggttaatatggcttaccttgcttgtagatgttta  
ctcttgatccctaagggaaactggaaggaaagcatgctgtagagaggacctgctttgagagtagtgcctct  
gggacaagtggaatgaaagagaggatagaggcaagagaaaaaagggtggagatgggggtgagacttgctgggtg  
gacagttgcaaagaaaactcatgatgagaataacatcacatttcttgaagaagctgaactgcattgatgggaa  
gttgaggcagagtttgaaaaagaagataactgtctgcaaaaaagaatcaacggagatgtcaggtatcttgatg  
caccctgagctatgagatgcagcttaatttaatttaatgatagtaggacatttcataagtggtggaat  
taccataaagtgtttgcagctaatgacggcgcgatgaatgatgtcataggaacctaaagtctggatgagctatgg  
attgaaattttactatgggacacccttctacatggtgctgtggaaaagaattgtcctcaagaaatgtacatct  
tctgcatttcctctacatctctgatatttacaagtgcacattatttgggtgatactacaactgggatttcaag  
tgcacatcactactatttcttcaactgaagaatcaagagcagctgggggggggggagagcttgagtgatgac  
aaggatgtggcagagccctgggtccactatgaattatagttcttaccctgcttactgtcactcatgtagagca  
gctagtgtgctcagagcactgctgttctctgagaagctgaggtctcgattgacatttctgaaagtgggttt  
acttctctctgaataaaacaaaggttggcaactcagacatcttacaataagtaactaaagatttttgaagaatag  
gtttttaaaaaatgaaaaaacatttcaacttccatagctaaataatcttattttgaggaaaatgtacttttct  
ttaaaaaaaaaaaaaagcctgtctgtcactctagaccctttggcttagaaggtaggcacactcacatagaaaca  
gaaagtctgtccaaattaaaactgaaaaccacagttgactaattttgaaattatagctctgctgttggcttct  
gcatagtagttaatttcaatggcttcaattagaaaatgaaacccatagcattccatagagaacaggtaaaaa  
gtcaggacatttggagttttccaagaaaaagaaagacaagtcttaggaagctctctaggatggaaggaaattt  
gccacactgagagtttagacatccaagagatagcaattggctcttctgctcatgggcactgggtgaaggcattt  
aaaatgcaagaatggtacctctgtaaatcaatgaggttcataataatcatgcatttaccaaatttttataag  
cacctgccttgtgccaggcactgagggttaaggtgatgaaatagccctcatcaactgtcagactagatatttac  
tcaataacagatgtgaaaatgccaagaaggaaaagttgagtataaagaaagccttaagttgggtcagagaaat  
aaaattgcatttttccgatagatgtttatggaatcggccttatgaggtaaaccttgctcctatgcagtgaaacata  
cattcccagtttagtctcagattggcctctgtgatgacaaactcagagggtcctgggtctaggaggggtgaaattt  
gtctggaggccattttcaggaggtatggaggaagactggggcataggcctggggccatcccagtagctcctcc  
tctgaaatggggagcaactgaattgtgttttatttttagatcttctgccaacttgaataaccagaaattcgtgaa  
accttctcaaattcacactatattttgagaccaggagaaggctccttgagaaattgccacactgtcttatcct  
agtctctgaaaaaattcagtcctgtattataactgggcgtttctcataagtgctttttttttttttttctt  
ttataacttttaagttctgggatacatgtgcagaatgtgcaggtttgttacataggtataacacgtgcccctg  
gtggtttggcaccatcaacccatcatctacattagttatttctcctaagctacccttccctagcccc  
caccctcgacaggccccagtgttgatgttccctcctgtgtccatgtgttctcattgttcaactcccact  
tatgagtgagagcatgcgggtgtttggttttctgttctgtgttagtttctgagaaatgatgggttttggctt  
atccacgtccctgcaaggacatgaactcatctttttatggctgcatagtagtccatgggtgtatgtgcca

catttgctttatccagtctatcattgatgagcacttgggttggctccaagtctttgctattatgactagtagt  
gcgataaacatgtgtatattgtgtctttatattagaatgatttataatcctttagggtctataccagtaatagg  
attcctgggtcaaatgggtatttctgggtctagatccttgaggaattgccacactgtctccacaacgggtgaa  
ctaatttacactcccaccaacagtgtaaaagcattcctatctccacatcctctccaacatctgttgtttcc  
tgactctttaatgacggccatttctaactggcgtgaaatgggtatctcatttggtgttttgatttgcatctctca  
atgaccaccgatgatgagctttttctcatatgtttgctggccccataaatgtctcttttgagaaatgtctgt  
tcatatcctttgcccactttttgatgggttgggttctttttcttgtaaatttgggttgagttcctggtagat  
tctggatattagccctttgtcagatggatagactgcaaaaatcttctccattctgtagggtgacctgctcact  
ctgatggtagtttcttttgccatgcagaagctgtttagtttaattagatccaatttgtcagtttggcttttg  
ttgccattgcttttgggtgttttagtcatgaagtctttgccatgcctatgtcctgaattgtattgccctgggt  
ttcttctaggatttttatgggttttaggtcttacatttaagtctttaatccatcttgaatttaattttgtataa  
gggtgaaggaaagggtccagtttcagttttctgcgtatggctagccagttttcccacggtattttatataaata  
gggaatcctttcccattgcttgttttgtcaggtttgcacaagatcagacgggtgttagatgtgtgggtgttat  
ttctgaggcctctgttctgttccattgggtctgtatctgctttgataccagtagcctgtgttttgggttact  
gtagccttgtagtacagtttgaagttaggttagcgtgatgcttgggtctttttgcttaggattgtcttggctat  
atgggtcttttttgggttctatatgaaatttaagtagtttttctatagacatctatagaactctccacccca  
aatcaacagaaatatacattcttctcagatctcactcacacttattctaaaatgaccacataattagaagtaa  
acactcctcagcaaatgcaaaaaacagaaatcctaacagctctgtcagacccagtgcaatcaaattagaactc  
aggattaagaaaacttactgaaaaaccacacaactgcatggaaactgaacaacctgctcctgaatgactactggg  
taataacaaaaattaaggcagaaataaatagggtctttgaaagaaatgagaacaaagacacaatataccagaa  
tctctgggacacagctaaagcagtgtttagagggaaattgatagcactaaatgccacaggagaaagcgggac  
agatctaaaatcgacaccctaatacacaaataaaagaactagagaaacaagagcaaaacaaattcaaaagcta  
gcagaagacaagaaataactaagatcagagcagaactgaaggagatagagacacaaaaaaccttcaaaaaat  
caatgaatccaggagctgttttttttttttggaaaagattaatgaaatagactgctagccaaactaataaagg  
agaaaagagagaagaatacaatagacaatagacacaataaaaagtataaaggggatataccactgatcca  
cagaaatacaaaactaccatcagagaatactataaacacctctacgcaataaactagaaaattgggaagaat  
ggatacattcctgaacgcatacaccctccaagactaaaccaggaagaagttgaatccctgaatagaccaata  
gcaagttctgaaattgaggcagtaattagttagcctaccaacaaaaaagcccaggaccagacagattcacag  
ccgaagtctaccagaggtacaaagaggagctagtaccattccttctgaaactattccaacaatagaaaaaga  
aggactcctccctaactcattttatgaggccagcatcatcctgataccaaaacctggcagagacacaacataa  
aggaaattcaggccaatatacctgatgaacattgatgtgaaaatcctcaataaaaactggcagcacatcaaa  
acgtaataatcacatacacagaaaccaatgacaaaaccacatgattatctcaatagatgcagaaaaggcctt  
cgataaaaattcaacacccccttcaatgctaagaactctcaataaactaggatttgatgaaacatctcaaaat  
aataagagttatttatgacaaaaccacagccagctatcatactgaatgggcaaaagctggaagcattcctttg  
aaaaccgccacaaggatgacttctctcaccactcctattcaacatactattggaagttctggccagggcaagc  
aggcaagacaaaataaataaagggtattcaaataggaagagaggaagtcaaatgtctctgtttgcagatgaca  
tgattgtatatttagaaaaccccatcatctcagcccaaatctccttaagctgataagcaacttcagcaaggt  
ctcaggatacaaaaatcaatgtgcaaaaaatcacaagcattcctatacaccaataatagacaaacagccaaatca  
tgagtgaactccattcacaagtgtacaaagaataaaaatccttaggaatccaacttacaagggatgtgaagg  
acctcttcaaggagaactacagaccactgctcaaggtataaagagaggacacaaacaaatggaaaaacattcc  
atgctcatggataggaagaatacaatattatgaaaatggccatactgccccaaaacaatttatagattcaatgcc  
atccccatcaagctaccactgacttcttccagaaattagaaaaaaactactttaatttcatatggaactga  
aaaaagagccggtatagccaagacgatcctaaagcaaaaagaaaaagctggaagcatcatgctacctgacttc  
aaactatactacaaggctacagtaacaaaaacagcatggtatagtataagtgttttttttaaaagacaaagt  
aaagtaatttttttgttgttgggtgtaaaacaaaagctctgcataaagagcagggatgttgtaacatacactga  
ccaaaggtgggaaaacctacagttggagcagaagctgaatgtcacattatcagctccgaacttataatgggtcta  
aaagtaactaggttaatgttggaaaagatgggtgccatttaagatatacttaattcaatatttaattttta  
ttgacattatcctagagttgaaatgggtgttacttaccatgtgctgttcttagaaaatctagatcctacactg  
cctttgcgcaaggtagtgtctcaataatacaaacctgtccagttttgggtgggagaaataatgttactgttaa  
gttgcacttagtgggttattatgtgtaatactgggtattccaaagagagaaggaaaatgtttgctacacagctgt  
gttcttaggtcagaaaaccacaggagtgggacaggagaacccctcaggattcaggattcaggttgtgtgagcgc  
cgcaggagggagactgtgaatttgaactgcatcctatgaaaagaaaaatcctccacactttaataattctct  
ccgtgccccatggcagcaagtgcttataggccttgcactcaagcttaataaaaaggcagacctgctgaatc  
ataatctgcatcttaacaatatcccagatattgtctgcactttcttttttttttttttttttttttttttttt

ttttttgagacagagtctcgctcagtcacccaggctggagtgcagtggecgatctcggctcactgcaagct  
ctgactcccgggttcacgccattctcctgccttagactcccagtagctggcactacaggcggccgactac  
gccccgctaattttttgtattttagtagagatgggtttcacctggttagccaggatggctcgcattcct  
gacctcgtgatccgcccctctggcctcccaaagtgcgggattacaggcgtgagccactgcccggcc  
aattgtctgcactttcaagtctaagaagcactgtcccaggaggaaaatcttttagtctgaggcttctctct  
gactctccttttaaaaatagctgctccttctccaccttccctctctctccgcttttctgtctgccttt  
actacctccctgaacattcaactgtagaagagttcccttctctgaattgcattcttcacttcattcatt  
cttttctctctctgtctatgggttctctatttttgtcgggttctccctcacctcacctccttggttat  
cattgttcacatatcactgcccttccagacctatctagcttctgacctccactaatccattgccactaa  
tttattcagcatgcccattgccatttataatgtaaatatttgcacatacttgttctatcatgcccattttct  
accttttaaatgtatatacacagacacatgtgaatgacatatttcaactttaaaaggtagaaaaatgata  
tcgtggtacaaaagtatacattgagtatctgtgcccagtttcaagatgagaataagtgagaggatgaagcctca  
tgagtacgtcacctacacgctactgtcttccattccatctgcagtagtccacacatttggttagttctcca  
attgctgtcacattgacatcgagttggatctgaacagcgtacctggggagacgaagatttggtatctttgctt  
aaatggagtgatttactgagagacaaagtacatctttaagatcagatagcaagttactgcaccaggagcgcg  
accttctctgtttgtgttttccctctgtcaaatgccttctgggtccatgaatctctcctccacatatga  
taaaaatgcaaagtctcataagcattcacagctcaggaagcctcaggctagttggggagaaaagactgggag  
tttccgggaggaatgaagtcctctgagcagagaggttaattcatcttgctgtaaaacaaaatagaaaataagtt  
cccctcaataagtgaaactaatacaaaagacaaatgtggttggtgcccagaggccaggaagaagttcttgtgaga  
ataggtgcagagaagagctaggccctggctgagtttaaccttgacttagtcactgtgggactctgggtgagt  
tactccatggattgatggctgggtcatggagataatagtaactaattcatacaggtagtgcagaaatg  
gaatatttcacgttaagtgtttaacgggtgcgtttaaatgctaggtgctattattattaattttaactaact  
ttgccaatgtttgtgtcttccctctctgtgcttcttctttagtagtagccgcacagcctacacgggtggga  
gccctgcttctcctcttggggaccctgctgcccggctgctgaagggaaaagaaaggggtcccagggtgccatcc  
ccccgccagacaaggcccagcacaatgactcagagcagactcagtcgccccagcagcctggctccaggaaccg  
ggggcggggccaagggcggggcactgccatgcccggggaggaggtgctggagtccagccaagaggccctgcat  
gtgacgggagcgaataacctgaagcagagactggtgcaaacccagccgcttaagcagacctccacgaggaag  
gctgcaacagtcgcacctcatcaaccgcttctgttacggccagtgcaactcttctacatcccaggcacat  
ccggaaggaggaaggttcttctcagtcctgctccttctgcaagcccaagaatcactaccatgatggtcaca  
ctcaactgccctgaactacagccacctaccaagaagaagagagtcacacgtgtgaagcagtgctcgttgcata  
ccatcgatttgattaaagccaaatccagggtgcacccagcatgtcctaggaatgcagccccaggaagtcccaga  
cctaaaacaaccagattcttacttggcttaaacctagaggccagaagaacccccagctgctcctggcaggag  
cctgctgtgctgagttcgtgtgcatgagtggtgaggggtgctgctggtgttttagacaccagagaaaaca  
cagctctgctagagagcactcctattttgttaaacatctgctttaaaggggatgtaccagaaaccacct  
caccctcggctcacatctaaagggcggggcgtggtctggttctgactttgtgtttttgtgccctcctgggga  
ccagaatctccttccggaatgaatgttcatggaagaggtcctctgagggcaagagacctgttttagtgctgc  
attcgacatggaaaagtcttttaacctgtgcttgcactcctcctcctcctcctcacaatccatctctt  
cttaagttgatagtgcactatgtcagtcctctctgtttgccaaggttccctaaatcacttaaccatg  
atgcaaatgtttttcattttgtgaagacctccagactctgggagaggctgggtgtgggcaaggacaagcagga  
tagtggagtgcagaaagggagggtggagggtgaggccaaatcagggtccagcaaaagtgcagtagggacattgcag  
aagcttgaaaggccaataccagaacacaggctgatgcttctgagaaagtcttttctagtagtttaacagaacc  
caagtgaacagaggagaaatgagattgcccagaaagtgattaactttggccgttgcaatctgctcaaacctaac  
accaaactgaaaacataaatactgacctcctatgttcggacctcaagcaagttagctaaaccaaaccaactc  
ctctgctttgtccctcagggtggaaaagagaggtagtttagaactctctgcataggggtgggaattaatcaaaa  
accgcagagggtgaaatcctaataaccttcttctatcgtgggttatagtcagctcatttccattccactattt  
cccataatgcttctgagagccactaacttgattgataaagatcctgctctgctgagtgactgacagtagt  
ctaagatgagagagtttagggactactctgttttagcaagagatattttgggggtctttttgttttaactatt  
gtcaggagattgggctaaagagaagacgacgagagtaaggaaataaagggaaatgctctggctagagagtag  
ttagggttaataacctggtagagatgtaaggatatagacctccttcttctttagtgctcactgaggatctgag  
gggacctgttaggagagcatagcatcatgatgtattagctgttccatctgctactgggtggatggacataact  
attgtaactattcagtagttactggtaggcactgtcctctgataaaacttggcctactggcctggcctactta  
ggattgatctaagggccaagtgacgggtgggtgaactttatgtactttggatttgggttaacctgttttctt  
caagcctgaggtttatatacaaaactcctgtaactctttttgcttctgctctctcagcctcctagccaag  
tcctatgtaatatggaaaacaaactgcagacttgagattcagttgcegatcaaggctctggcattcagaga  
acccttgcaactcgagaagctgtttttatctgtttttgttttgatccagtgctctcccatcacaactaaa

caggagccatttcaagcgaggagatattttaaacacccaaaatggtgggtctgattttcaaacttttaaac  
actactgatgattctcacgctagggcgaatttgtccaaacacatagtggtgtgtgtttgtatacactgtatgac  
cccccccaaatctttgtattgtccacattctccaacaataaagcacagagtggatttaattaagcacacaaa  
tgctaaggcagaattttgaggggtgggagagaagaaaagggaaagaagctgaaaatgtaaaccacaccagggg  
ggaaaaatgacattcagaaccagcaaacactgaatttctcttgttgttttaactctgccacaagaatgcaatt  
tcgttaacggagatgacttaagttggcagcagtaattctcttttaggagcttgtaccacagtcttgcacataa  
gtgcagatttggctcaagtaaagagaatttctcaacactaacttctactgggataatcagcagcgtactacc  
ctaaaagcatatcactagccaaagagggaaatatctgttcttcttactgtgcctatattaagactagtacaaa  
tgtggtgtgtctccaactttcattgaaaatgccatctataccatattttattcagagtcactgatgatgta  
atgatataatttttctattatagtagaatatttttatggcaagatatttgggtcttgatcatacctatta  
aaataatgccaaacaccaaataatgaattttatgatgtacactttgtgcttggcattaaaagaaaaaacacac  
atcctggaagtctgtaagttgtttttgttactgttaggtcttcaaagttaagagtgtgaagtgaanaatctgga  
ggagaggataatttccactgtgtggaatgtgaatagttaaatgaaaagttatggttatattaatgtaattatta  
cttcaaactctttggctactgtgatttcaagcatgttttcttttctctttatagactttctctgagttgg  
gcaaagaagaagctgacacaccgtatgtttagagtcttttctggtcaggggaaacaaaatcttgacca  
gctgaacatgtcttctgagtcagtcgctgaatctttttaaattgaatgttcttaagggttaacatt  
tctaaagcaatattaagaaagactttaaatgttattttggaagacttacgatgcatatacaaacgaatagc  
agataatgatgactagttcacacataaagtcttttaaggagaaaatctaaaatgaaaagtgataaacagaa  
catttataagtgatcagttaatgcctaagagtgaagtagttctattgacattcctcaagatatttaatatca  
actgcattatgtattatgtctgcttaaatcatttaaaaacggcaaagaattatatagactatgaggtaccttg  
ctgtgtaggaggatgaaaaggggagttgatagctcataaaaactaatttggcttcaagtttcatgaatctgtaa  
ctagaatttaattttcaccccaataatgttctatatagcctttgctaaagagcaactaataaattaaacctat  
tctttctgtg

**SEQ ID NO: 37 (Human Gremlin-1; coding sequence)**

atgagccgcacagcctacacggtgggagccctgcttctctcttggggaccctgctgccggctgctgaagggg  
aaaagaaaggggtcccaaggtgccatcccccgccagacaaggcccagcacaatgactcagagcagactcagtc  
gccccagcagcctggctccaggaaccgggggccccggggcgaagggcggggcactgccatgccggggaggaggtg  
ctggagtcacgccaagagggcctgcatgtgacggagcgcaaatacctgaagcagactgggtgcaaaaccagc  
cgcttaagcagaccatccacgaggaaggctgcaacagtcgcaccatcatcaaccgcttctgttacggccagtg  
caactctttctacatccccaggcacatccggaaggaggaaggttctttcagtcctgctccttctgcaagccc  
aagaaattcactaccatgatggtcacactcaactgcctgaactacagccacctaccaagaagaagagagtc  
cacgtgtgaagcagtgctgttgcataatccatcgatttggattaa

### Claims

1. An anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer, wherein the method further comprises administering a cytidine analogue or deoxycytidine analogue.
2. The anti-GREM1 antagonist for use according to claim 1, wherein:
  - (a) the cancer is a solid cancer;
  - (b) the cancer has stromal GREM1 overexpression;
  - (c) the cancer is a metastatic cancer;
  - (d) the cancer comprises dormant cancer cells, optionally dormant stem-like cancer cells;
  - (e) the cancer is a recurring cancer and/or wherein said method is for preventing relapse of a cancer;
  - (f) the cancer is a cancer that is poorly responsive, non-responsive or refractory to treatment with a cytidine analogue or deoxycytidine analogue; optionally wherein the cancer is a cancer that is poorly responsive, non-responsive or refractory to treatment with gemcitabine, or a derivative thereof; and/or
  - (g) the cancer is selected from colorectal cancer, multiple myeloma, pancreatic cancer, bladder cancer, breast cancer, lung cancer, stomach cancer, duodenal cancer, oesophageal cancer, head and neck cancer, prostate cancer, glioma, endometrial cancer, ovarian cancer, liver cancer, spleen cancer, bone-resident cancer, and osteosarcoma.
3. The anti-GREM1 antagonist for use according to claim 2 (g), wherein:
  - (a) the cancer is pancreatic cancer; optionally wherein:
    - (i) the pancreatic cancer is an exocrine pancreatic cancer; and/or



(ii) the pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC);

(b) the cancer is lung cancer; optionally wherein the cancer is non-small cell lung cancer;

(c) the cancer is bladder cancer;

(d) the cancer is breast cancer; or

(e) the cancer is ovarian cancer.

4. The anti-GREM1 antagonist for use according to any one of the preceding claims, wherein:

(a) (i) the cancer has epithelial GREM1 overexpression; optionally wherein the cancer is a GREM1-initiated cancer;

(ii) the cancer is a disseminated cancer; and/or

(iii) the cancer is an established cancer; and/or

(b) (i) the cytidine analogue or deoxycytidine analogue is gemcitabine, or a derivative thereof;

(ii) the cytidine analogue or deoxycytidine analogue is azacitidine, or a derivative thereof;

(iii) the cytidine analogue or deoxycytidine analogue is cytarabine, or a derivative thereof;

(iv) the cytidine analogue or deoxycytidine analogue is decitabine, or a derivative thereof; or

(v) the cytidine analogue or deoxycytidine analogue is troxacitabine, or a derivative thereof.

5. An anti-GREM1 antagonist for use in a method for the treatment or prevention of pancreatic cancer, wherein the method further comprises administering a proliferation-dependent cytotoxic agent.

6. The anti-GREM1 antagonist for use according to claim 5, wherein:

- (a) the pancreatic cancer is an exocrine pancreatic cancer;
- (b) the pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC);
- (c) the pancreatic cancer is metastatic pancreatic cancer;
- (d) the pancreatic cancer is recurrent pancreatic cancer; and/or
- (e) the pancreatic cancer is a pancreatic cancer that is poorly responsive, non-responsive or refractory to treatment with a proliferation-dependent cytotoxic agent.

7. The anti-GREM1 antagonist for use according to claim 5 or claim 6, wherein:

- (a) the proliferation-dependent cytotoxic agent is a nucleoside inhibitor or an antimetabolite;
- (b) the proliferation-dependent cytotoxic agent is a cytidine analogue or deoxycytidine analogue;
- (c) the proliferation-dependent cytotoxic agent is a mitotic inhibitor; optionally wherein:
  - (i) the mitotic inhibitor is a microtubule-stabilizing drug; and/or
  - (ii) the mitotic inhibitor and/or microtubule stabilizing drug is selected from abraxane and paclitaxel;
- (d) the proliferation-dependent cytotoxic agent comprises one or more of oxaliplatin, folinic acid, irinotecan and fluorouracil; optionally wherein the proliferation-dependent cytotoxic agent is FOLFIRINOX or FOLFOX; or
- (e) the proliferation-dependent cytotoxic agent is:
  - (i) gemcitabine or a derivative thereof;

- (ii) azacitidine or a derivative thereof;
- (iii) cytarabine or a derivative thereof;
- (iv) decitabine or a derivative thereof;
- (v) troxacitabine or a derivative thereof; or
- (vi) capecitabine.

8. The anti-GREM1 antagonist for use according to any one of the preceding claims, wherein the antagonist is a peptide, a protein, an antibody, a polynucleotide, an oligonucleotide, an antisense RNA, a small interfering RNA (siRNA), a small molecule inhibitor or a small hairpin RNA (shRNA).

9. The anti-GREM1 antagonist for use according to claim 8, wherein:

(a) the antagonist is an antibody which binds to an epitope on Gremlin-1 comprising at least one residue selected from Ile131, Lys147, Lys148, Phe149, Thr150, Thr151, Arg169, Lys174 and Gln175, wherein the residue numbering is according to SEQ ID NO: 1; optionally wherein:

(i) the antibody binds an epitope comprising all of Ile131, Lys147, Lys148, Phe149, Thr150, Thr151, Arg169, Lys174 and Gln175; and/or

(ii) Lys147, Lys148, Phe149, Thr150, Thr151, Arg169, Lys174 and Gln175 are located on the same Gremlin-1 monomer and Ile131 is located on the second Gremlin-1 monomer;

(b) the antagonist is an anti-Gremlin-1 antibody which comprises heavy chain complementarity determining region (HCDR) sequences contained within a heavy chain variable region (HCVR) of SEQ ID NO: 10 or 12 and/or light chain complementarity determining region (LCDR) sequences contained within a light chain variable region (LCVR) of SEQ ID NO: 11 or 13; or

(c) the antagonist is an anti-Gremlin-1 antibody which comprises at least one HCDR sequence selected from SEQ ID NOs: 3, 4, 5 and 6 and/or at least one LCDR sequence selected from SEQ ID NOs: 7, 8 and 9; optionally wherein:

(i) the anti-Gremlin-1 antibody comprises a HCDR3 sequence of SEQ ID NO: 6;

(ii) the anti-Gremlin-1 antibody comprises an HCDR1/HCDR2/HCDR3 sequence combination selected from SEQ ID NOs: 4/5/6 or from SEQ ID NOs: 3/5/6 and/or an LCDR1/LCDR2/LCDR3 sequence combination selected from SEQ ID NOs: 7/8/9;

(iii) the anti-Gremlin-1 antibody comprises a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9; and/or

(iv) the anti-Gremlin-1 antibody comprises a heavy chain variable region (HCVR) sequence of SEQ ID NO: 10 or 12 and/or a light chain variable region (LCVR) sequence of SEQ ID NO: 11 or 13, or sequences which are at least 95% identical thereto.

10. The anti-GREM1 antagonist for use according to claim 9 (c)(iv), wherein:

(a) the anti-Gremlin-1 antibody comprises a HCVR and LCVR sequence pair of SEQ ID NOs: 10/11 or 12/13 or sequences which are at least 95% identical thereto; optionally wherein the anti-Gremlin-1 antibody comprises HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequences consisting of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9 and the remainder of the HCVR and LCVR comprise at least 95% identity to SEQ ID NOs: 10, 11, 12 and/or 13 respectively; and/or

(b) the anti-Gremlin-1 antibody comprises a heavy chain of SEQ ID NO: 14, 16, 18, 22, 28, 30, 32 or 34 and/or a light chain of SEQ ID NO: 15, 17, 19, 23, 29, 31, 33 or 35, or sequences which are at least 95% identical thereto.

11. The anti-GREM1 antagonist for use according to claim 10(b), wherein the anti-Gremlin-1 antibody comprises a heavy and light chain pair of SEQ ID NOs: 14/15, 16/17, 18/19, 22/23, 28/29 or 30/31, 32/33, 34/35, or sequences which are at least 95% identical thereto; optionally wherein the HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequences of the antibody consist of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9 and the remainder of the heavy and light chains comprise at least 95% identity to SEQ ID NOs: 14, 15, 16 and/or 17 respectively.
12. The anti-GREM1 antagonist for use according to claim 8, wherein:
  - (a) the antagonist is an antibody which competes for binding to Gremlin-1 with an antibody as defined in any one of claims 9(a)(i)-10; or
  - (b) the antagonist is an antibody which binds the same epitope on Gremlin-1 as an antibody defined in any one of claims 9(a)(i)-10.
13. The anti-GREM1 antagonist for use according to any one of claims 8-12, wherein:
  - (a) the antagonist antibody is a chimeric, human or humanised antibody; and/or
  - (b) the antagonist antibody is a Fab, modified Fab, Fab', modified Fab', F(ab')<sub>2</sub>, Fv, single domain antibody or an scFv.
14. The anti-GREM1 antagonist for use according to claim 8, wherein the antagonist is a polynucleotide encoding an antibody as defined in any one of claims 9-13, or an expression vector carrying said polynucleotide.
15. The anti-GREM1 antagonist for use according to any one of claims 8-13, wherein the antagonist antibody is comprised in pharmaceutical composition further comprising a pharmaceutically acceptable adjuvant and/or carrier.
16. The anti-GREM1 antagonist for use according to any one of the preceding claims, wherein the method further comprises administering an additional anti-cancer agent; optionally wherein:

(a) the method comprises administering gemcitabine in combination with a further cytidine analogue or deoxycytidine analogue; and/or

(b) the method comprises administering gemcitabine in combination with troxycitabine

17. A cytidine analogue or deoxycytidine analogue for use in a method for the treatment or prevention of cancer wherein the method further comprises administering an anti-GREM1 antagonist; optionally wherein said cancer, said antagonist, said cytidine analogue or deoxycytidine analogue and/or said method are as defined in any one of claims 1-4 and 8 to 16.

18. A method of treating cancer comprising administering a therapeutically effective amount of an anti-GREM1 antagonist in combination with a therapeutically effective amount of a cytidine analogue or deoxycytidine analogue to a subject in need thereof; optionally wherein said cancer, said antagonist, said cytidine analogue or deoxycytidine analogue and/or said method are as defined in any one of claims 1-4 and 8 to 16.

19. A proliferation-dependent cytotoxic agent for use in a method for the treatment or prevention of pancreatic cancer, wherein the method further comprises administering an anti-GREM1 antagonist; optionally wherein said proliferation-dependent cytotoxic agent, said pancreatic cancer, said antagonist and/or said method are as defined in any one of claims 5 to 16.

20. A method of treating pancreatic cancer comprising administering a therapeutically effective amount of an anti-GREM1 antagonist in combination with a therapeutically effective amount of a proliferation-dependent cytotoxic agent; optionally wherein said proliferation-dependent cytotoxic agent, said pancreatic cancer, said antagonist and/or said method are as defined in any one of claims 5 to 16.

21. A composition or kit comprising an anti-GREM1 antagonist and a cytidine analogue or deoxycytidine analogue; optionally wherein the cytidine analogue or deoxycytidine analogue is as defined in claim 4(b) .
22. A composition or kit comprising:
  - an anti-GREM1 antagonist and a mitotic inhibitor.
23. The composition or kit according to claim 22, wherein the mitotic inhibitor is as defined in any one of claims 7(c)(i) or 7(c)(ii).
24. The composition or kit according to any one of claims 21 to 23, wherein the anti-GREM1 antagonist is as defined in any one of claims 8 to 14.
25. A method for determining:
  - (a) whether or not a patient having or suspected of having or being at risk of developing cancer is likely to respond to a combination treatment with a GREM1 antagonist and a cytidine analogue or deoxycytidine analogue, which method comprises measuring stromal and/or epithelial expression of GREM1 in the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the combination; or
  - (b) whether or not a patient having or suspected of having or being at risk of developing pancreatic cancer is likely to respond to a combination treatment with a GREM1 antagonist and a proliferation-dependent cytotoxic agent, which method comprises measuring stromal and/or epithelial expression of GREM1 in the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the combination.

Figure 1






Figure 2





Figure 3





Figure 4



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2023/059271

## Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
  - a.  forming part of the international application as filed.
  - b.  furnished subsequent to the international filing date for the purposes of international search (Rule 13*ter*.1(a)).  
 accompanied by a statement to the effect that the sequence listing does not go beyond the disclosure in the international application as filed.
2.  With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this report has been established to the extent that a meaningful search could be carried out without a WIPO Standard ST.26 compliant sequence listing.
3. Additional comments:

**INTERNATIONAL SEARCH REPORT**

International application No  
**PCT/EP2023/059271**

**A. CLASSIFICATION OF SUBJECT MATTER**  
**INV. C07K16/22 A61K39/395 A61P35/00 A61K31/7068**  
**ADD.**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**  
 Minimum documentation searched (classification system followed by classification symbols)  
**C07K A61K A61P**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
**EPO-Internal, WPI Data, BIOSIS, EMBASE**

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<b>X</b>	<b>US 2009/041757 A1 (ZHEN HANSON [US] ET AL)</b> <b>12 February 2009 (2009-02-12)</b>	<b>5-8, 19, 20</b>
<b>Y</b>	<b>the whole document</b> <b>in particular, pages 1 and 11</b> -----	<b>9-16</b>
<b>Y</b>	<b>WO 2019/243801 A1 (UCB BIOPHARMA SRL [BE]; UNIV OXFORD INNOVATION LTD [GB] ET AL.)</b> <b>26 December 2019 (2019-12-26)</b> <b>cited in the application</b> <b>the whole document</b> <b>in particular, pages 12, 25-35, 54-56 and 58-60</b> -----	<b>9-16, 22-24</b>
<b>Y</b>	<b>EP 2 826 790 A1 (SNU R&amp;DB FOUNDATION [KR]; KIM HYUN KEE [KR])</b> <b>21 January 2015 (2015-01-21)</b> <b>the whole document</b> <b>in particular, paragraphs 34-36</b> -----	<b>22-24</b>
	-/--	

Further documents are listed in the continuation of Box C.       See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search <b>24 May 2023</b>	Date of mailing of the international search report <b>05/06/2023</b>
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer <b>Pérez-Mato, Isabel</b>
--	---

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2023/059271

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CHENG ZIQI ET AL: "A review of research progress of antitumor drugs based on tubulin targets",            TRANSLATIONAL CANCER RESEARCH,            vol. 9, no. 6, 1 June 2020 (2020-06-01),            pages 4020-4027, XP093048872,            ISSN: 2218-676X, DOI: 10.21037/tcr-20-682            the whole document            in particular, pages 4021-4023</p> <p>-----</p>	22-24
A	<p>WO 2017/158396 A1 (INSERM [FR];            UNIVERSITÉ PAUL SABATIER TOULOUSE III            [FR]) 21 September 2017 (2017-09-21)            the whole document            in particular, pages 5-6</p> <p>-----</p>	1-4, 17, 18, 21, 25
A	<p>J. B. SNEDDON ET AL: "Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation",            PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES,            vol. 103, no. 40,            3 October 2006 (2006-10-03), pages            14842-14847, XP055121828,            ISSN: 0027-8424, DOI:            10.1073/pnas.0606857103            the whole document            in particular, pages 14844-14845</p> <p>-----</p>	1-25
A	<p>MINSOO KIM ET AL: "Gremlin-1 Induces BMP-Independent Tumor Cell Proliferation, Migration, and Invasion",            PLOS ONE,            vol. 7, no. 4, 13 April 2012 (2012-04-13),            page e35100, XP055121712,            DOI: 10.1371/journal.pone.0035100            the whole document            in particular, pages 4-5</p> <p>-----</p>	1-25
A	<p>ELEMAM NOHA MOUSSAAD ET AL: "Insights into the Role of Gremlin-1, a Bone Morphogenic Protein Antagonist, in Cancer Initiation and Progression",            BIOMEDICINES,            vol. 10, no. 2,            28 January 2022 (2022-01-28), page 301,            XP093048642,            DOI: 10.3390/biomedicines10020301            the whole document            in particular, page 9</p> <p>-----</p>	1-25
	-/--	

# INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2023/059271

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2022/152290 A1 (SUZHOU TRANSCENTA THERAPEUTICS CO LTD [CN]) 21 July 2022 (2022-07-21) the whole document in particular, page 102 -----	1-4

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

**PCT/EP2023/059271**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
<b>US 2009041757</b>	<b>A1</b>	<b>12-02-2009</b>	<b>NONE</b>
<hr style="border-top: 1px dashed black;"/>			
<b>WO 2019243801</b>	<b>A1</b>	<b>26-12-2019</b>	<b>AU 2019289176 A1 24-12-2020</b>
		<b>BR 112020025661 A2 23-03-2021</b>	
		<b>CA 3102743 A1 26-12-2019</b>	
		<b>CL 2020003249 A1 09-07-2021</b>	
		<b>CN 112533632 A 19-03-2021</b>	
		<b>CO 2020015923 A2 10-05-2021</b>	
		<b>EP 3806898 A1 21-04-2021</b>	
		<b>IL 279347 A 31-01-2021</b>	
		<b>JP 2021528400 A 21-10-2021</b>	
		<b>KR 20210028191 A 11-03-2021</b>	
		<b>SG 11202012312U A 28-01-2021</b>	
		<b>US 2021253688 A1 19-08-2021</b>	
		<b>WO 2019243801 A1 26-12-2019</b>	
<hr style="border-top: 1px dashed black;"/>			
<b>EP 2826790</b>	<b>A1</b>	<b>21-01-2015</b>	<b>AU 2013232855 A1 02-10-2014</b>
			<b>CN 104321342 A 28-01-2015</b>
			<b>EP 2826790 A1 21-01-2015</b>
			<b>ES 2720617 T3 23-07-2019</b>
			<b>JP 6339063 B2 06-06-2018</b>
			<b>JP 2015512894 A 30-04-2015</b>
			<b>KR 20130105541 A 25-09-2013</b>
			<b>TR 201905395 T4 21-05-2019</b>
			<b>US 2015158938 A1 11-06-2015</b>
			<b>WO 2013137686 A1 19-09-2013</b>
<hr style="border-top: 1px dashed black;"/>			
<b>WO 2017158396</b>	<b>A1</b>	<b>21-09-2017</b>	<b>EP 3429597 A1 23-01-2019</b>
			<b>US 2019076464 A1 14-03-2019</b>
			<b>WO 2017158050 A1 21-09-2017</b>
			<b>WO 2017158396 A1 21-09-2017</b>
<hr style="border-top: 1px dashed black;"/>			
<b>WO 2022152290</b>	<b>A1</b>	<b>21-07-2022</b>	<b>TW 202241944 A 01-11-2022</b>
			<b>WO 2022152290 A1 21-07-2022</b>
<hr style="border-top: 1px dashed black;"/>			